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Summary of Thesis 
Chronic obstructive pulmonary disease (COPD) is characterised by persistent inflammation 
in the airway and the lung which results in airway obstruction. Various inflammatory cells 
and mediators have been involved in the pathogenesis of COPD, in particular TNF-α through 
NF-κB signalling pathway. Current treatments for COPD are still not satisfactory and there 
is a need to develop new therapies targeting inflammatory mechanisms of COPD. Ginseng is 
a well-known medicinal herb and has been used in the treatment of COPD. Understanding 
the anti-inflammatory mechanism of ginseng and ginseng based formulas will facilitate the 
development of novel agents for treating COPD and other inflammatory diseases. The main 
objective of this project is to study the actions and mechanisms of ginseng and ginseng 
related products on the regulation of TNF-α and NF-κB pathway in inflammatory cell 
models related to COPD. The key hypothesis is that ginseng and ginsenosides may target 
TNF-α, cAMP and NF-κB signalling pathways to exert their anti-inflammatory actions.  
In order to test this hypothesis, the inflammatory cell models were firstly set up using 
macrophage-like U937 cells induced by Lipopolysaccharide(LPS) or cigarette smoke 
extract(CSE), which then were used to evaluate the effects of ginseng and ginsenosides on 
cellular release of cytokines and activation of NF-κB and cAMP pathways. U937 cells 
treated with phorbol ester 12-O-tetradecanoylphorbol-13-acetate (PMA) were incubated with 
different concentrations of ginseng, ginseng formula extracts or ginsenosides for 2 hours, 
then treated with LPS (1 μg/ml) for different time durations to measure the level of cytokines 
in the cell media by ELISA, the expression of proteins by Western blot, the transcriptional 
activity by Dual-Glo Luciferase Reporter Assay System, the level of cAMP by EIA and the 
activity of PDE4 by scintillation counting. LPS caused a significant increase in the cellular 
release of TNF-α, IL-1β and IL-6 and the expression of the key NF-κB proteins (p-IKK, p-
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IκBα and p-p65), as well as the transcriptional activity of NF-κB. The level of cAMP, PDE4 
activity and p-CREB expression were also elevated by LPS. CSE also significantly induced 
the release of TNF-α. In LPS inducing cell model, BAY11-7082, the NF-κB pathway 
inhibitor, significantly inhibited the expression of IKK, p-IKK, IκBα, p-IκBα, p65 and p-
p65,transcriptional activity of NF-κB and the release of TNF-α; the cAMP pathway 
activator, Foskolin, increased the production of cellular cAMP and the expression of p-
CREB, but inhibited the release of TNF-α and the transcriptional activity of NF-κB, without 
affecting the expression of IKK, p-IKK, IκBα, p-IκBα, p65 and p-p65; the PDE4 inhibitor, 
Rolipram, also significantly inhibited the release of TNF-α . These results indicate that the 
cell model establishment was successful and also suggest a possible interaction between NF-
κB and cAMP pathways on the regulation of TNF-α induced by LPS.   
Using the established cell model, effects of ginseng (G115) and several ginseng formulas 
(GHMFs) as well as ginsenosides on the release of cytokines were investigated. It was found 
that the release of TNF-α was significantly inhibited by G115, GHMF-III, Rb1, Rg1, Rg3, 
CK and Rh1, but not Rh2 in LPS-induced cell model and by G115 and GHMF-III in CSE-
induced cell model. GHMF-III, G115, Rb1 and Rg1 also inhibited the release of IL-1β and 
IL-6 induced by LPS. Among the GHMFs tested, GHMF-III seemed to be the most potent. 
In addition, G115, GHMF-III, Rb1, Rg1, Rh1 and CK, but not Rh2 significantly inhibited 
the expression of IKK, p-IKK, IκBα, p-IκBα, p65 and p-p65 and decreased the 
transcriptional activity of NF-κB induced by LPS. G115, GHMF-III and Rg1, but not Rb1, 
Rh1, CK and Rh2 significantly increased the cellular level of cAMP and the expression of p-
CREB, but inhibited the activity of PDE4 induced by LPS. These findings indicate that 
ginseng and ginseng related products have a significant inhibition of cytokine release and 
activation of NF-κB pathway in LPS-induced macrophage-like U937 cells. In addition, they 
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may also act as PDE4 inhibitor to regulate cAMP pathway. Such actions of ginseng and 
ginseng related products may contribute to its therapeutic efficacy against COPD.  
A separate research objective in the present study was to evaluate the clinical efficacy of 
TNF-α inhibitors in the treatment of the progression of joint damage (JD) in active 
rheumatoid Arthritis (RA). The rational of this research is that there is a wide use TNF-α 
inhibitors in the management of JD in active RA, although it is not clear if there are 
differences between these inhibitors when used alone or in combination with Methotrexate 
(MTX), and which factors may affect their efficacy. A meta-analysis was conducted to 
compare the effects of TNF-α inhibitors on the radiological progression (RP) of active RA 
when used alone or combined with MTX, and to study the correlation between the degree of 
activity of RA and the efficacy of TNF-α inhibitors on the progression of JD.  It was found 
that TNF-α inhibitors showed a better efficacy than that of MTX, and TNF-α inhibitors in 
combination with MTX produced a better efficacy than TNF-α inhibitors used alone. Among 
different types of TNF-α inhibitors, infliximab in combination with MTX exhibited a better 
efficacy than other types of TNF-α inhibitors. CRP, ESR and DAS28 were factors affecting 
the efficacy of TNF-α inhibitors on the progression of JD in active RA. These findings may 
help to guide clinical use of TNF-α inhibitors to control the progression of JD in active RA.  
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Chapter 1. General Introduction 
1.1 Chronic Obstructive Pulmonary Disease 
1.1.1 Introduction 
Chronic obstructive pulmonary disease (COPD) is the major and growing health problem 
leading to increase in morbidity, disability, mortality and medical costs worldwide. A 
population-based prevalence study showed that the prevalence of Global Initiative for 
Chronic Obstructive Lung Disease (GOLD) stage II or higher COPD had reached 10.1% for 
man and 8.5% for women in 20071. It was the fourth death cause in 20082, and is expected to 
become the third death cause within the next decade in Europe and the United States3, and 
the fifth most common cause of disability in the world by 2020 4. In Australia, COPD affects 
almost 13% or one in seven Australians 40 or over, and Australia has one of the highest rates 
of COPD deaths in the developed world. This will result in the escalating health care costs 
worldwide5. 
COPD is a disease characterized by a progressive and non- reversible airway limitation 
which is associated with a persistent inflammatory response of the airway and lungs to 
bacteria, viruses, noxious particles and gases6-8. The pathogenesis of COPD is still not fully 
clear, although the persistent inflammatory response is a specific aspect of COPD and 
cigarette smoking(CS), as the primary risk factor9, increases the susceptibility of COPD 
patients to pathogens10,11. Currently, there are still no satisfactory therapies that can block the 
inflammatory progression of COPD including corticosteroid12. Since the inflammatory cells 
and mediators play an important role in the persistent inflammation in COPD 13, it is also 
important to understand the relevant signalling pathways in these cells. 
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1.1.2 Inflammation-Related Cells in COPD 
A variety of inflammatory cells are involved in COPD14, including neutrophils, T 
lymphocytes, macrophages, air epithelial cells (AEC), air smooth muscle cells (ASEs) and 
eosinophils. These cells play different roles in the inflammatory mechanism of COPD. 
1.1.2.1 Neutrophil 
There is evidence that the number of neutropils was significantly increased in sputum and 
bronchoalveolar lavage (BAL) fluid from patients with COPD, the increase is also correlated 
with the severity of COPD and the decline in lung function of COPD patients15-18. The 
abnormal increase of neutrophils in COPD patients was likely to relate to CS, as it has been 
showed to stimulate the release of granulocyte from the bone marrow which was mediated 
by granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony 
stimulating factor (G-CSF) released by alveolar macrophages (AM)19. Additionally, CS also 
increased the retention of neutrophils in the lung20.  
Chemokines may play a key role in the abnormal distribution of neutrophils in COPD. Many 
kinds of chemokines can recruit neutrophils to the inflammatory site, such as interleukin-8 
(IL-8), interferon gamma (IFN-γ), leukotriene B4(LTB4) and growth-related oncogene-α 
(GRO- α; CXCL1)21-24, and all of these chemokines were increased in the patients with 
COPD16,25-27. As neutrophil is a major source of IL-828, it in turn recruits neutrophil itself 
and other inflammatory cells to the site to amplify the inflammatory response. In addition, 
neutrophils also produced LTB429. These chemokines links may be a vital reason for the 
abnormal distribution of neutrophils and release of IL-8 in COPD patients.  
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Neutrophils also secrete proteases, including neutrophil elastase (NE), matrix 
metalloproteinase (MMP)-8 and MMP-930-32, as well as released oxygen radicals such as 
superoxide anion, hydrogen peroxide33,34, which may contribute to lung tissue damage and 
the decline of lung function35,36. 
1.1.2.2 T Lymphocyte 
Histopathologic studies showed that the total number of T lymphocytes was increased in 
lung parenchyma, peripheral and central airways of patients with COPD37-40, and there is a 
correlation among the number of T cells, the amount of alveolar destruction, and the severity 
of airflow obstruction40 .  It has also been shown that the extent of lymphocytes infiltrates in 
airway was correlated with the severity of COPD37.  
T cells are divided into five categories according to their functions, including helper T cells 
(CD+4), cytotoxic T cells (CD+8), memory T cells, regulatory T cells and natural killer T 
cells. Among these cells, CD+4 and CD+8 have been shown to be involved in the 
pathogenesis of COPD and CD+8 are likely to play more important roles than CD+441-44. The 
numbers of CD+8 cells was elevated in the circulation of COPD patients who did not 
smoke41,42. The number of CD+4 cells was also increased in the small airway of smokers 
with severe COPD43.  It was reported that the increase in CD+8 cells was greater than CD+4 
cells in COPD44.  T helper cells type 1 (Th1) seemed to contribute to the unbalance between 
CD+4 and CD+8, since there was an unbalance between Th1 and Th2 in COPD patients45. 
Th1 cells secret Interleukin-2 (IL-2) which is an inductor for the differentiation of CD+8 
cells46,47. 
The tissue damage mediated by CD+8 cells in COPD may involve two mechanisms. First, 
CD+8 cells may contribute to the modulation on apoptosis. It has been reported that there 
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was a correlation between the number of CD+8 and apoptosis of alveolar cells in 
emphysema40, which seemed to be related with the perforin andgranzyme-B released by 
CD+848. Secondly, CD+8 cells may modulate the release of MMPs. The study about CD+8 
cells - deficient mice exposed in CS demonstrated that CD+8 cells contributed to the lung 
destruction through the release of IFN-inducible CXC chemokine ligand (CXCL) 10 (IFN-
induced protein 10, IP-10) which induced the production of MMP-1249. 
1.1.2.3 Macrophage 
It has been shown that the number of macrophages was elevated (5–10 folds) in the airways, 
lung parenchyma, BLA fluid and sputum of smokers and patients with COPD37, and the 
increase was associated with the severity of COPD17. The increase in the number of 
macrophages in inflammatory sites of COPD patients may be related to the increased release 
of monocyte-selective chemokines and the reduced apoptosis of macrophages. Monocyte 
chemotactic protein-1(MCP-1) can recruit monocytes from the circulation to tissues50,51 , 
which is the premise of monocytes differentiation to macrophages. The level of MCP-1 was 
increased in BAL fluid of COPD patients22,52,53. In addition, the expression of the anti-
apoptotic protein Bcl-XL was increased in macrophages from smokers54.  
1.1.2.3.1 Macrophage and the Immune Response 
Macrophage plays a key role in the defence against airway pathogens55. Alveolar 
macrophage(AM) was considered as the sentinel phagocytic cell of the innate immune 
system in the lung56. AMs have a unique localization in the airway and act as the first line of 
defence against the airway pathogens, such as inhaled bacteria, viruses, noxious particles and 
gases. During this defensive process, macrophages are not only served as scavenger to clear 
the pathogens in the airway, but also as pathogen to induce the immunity response. 
 5
Macrophages play an antigenic role and induce the cellular immunity response in the 
abnormal inflammation of COPD. It has been shown that macrophages present the antigen 
characteristic of major histocompatibility complex class II molecules (MHCII) after 
digesting a pathogen to activate CD4+ T 57,58. So the antigen presentation of infected 
macrophage may be a part of pathogenesis of COPD.  
1.1.2.3.2 Macrophage and Inflammatory Mediators 
Macrophage can produce a wide array of powerful inflammatory mediators which is directly 
involved in the inflammatory response in COPD. The chemokines produced by macrophages 
include Growth-Related Oncogene-α (GRO-α; CXCL1), interferon-γ inducible protein of 10 
kDa (IP-10; CXCL10), MCP-1 and IL-822,26,52,59-61. These mediators in turn recruit different 
inflammatory cells, such as IP-10 for CD+862,  MCP-1 for monocytes, neutrophils and T 
lymphocyte63, 64,65 , Gro-α and IL-8 for neutrophils21,22. 
Macrophages also produce various cytokines. For example, TNF-α was produced by AMs 
from patients with COPD induced LPS46,47. Other cytokines associated with COPD and 
produced by macrophages included Interleukin-1 beta (IL-1β), Interleukin-6 (IL-6), 
Interleukin-10 (IL-10), granulocyte-macrophage colony-stimulating factor (G-CSF) and 
IFN-γ13,66-68. Macrophages synthesize these cytokines through activating many intracellular 
inflammatory pathways, especially nuclear factor kappa-light-chain-enhancer of activated B 
cells (NF-κB) pathway50,69. There is strong evidence that NF-κB is the key transcriptional 
factor which regulated the synthesis of inflammatory gene in macrophages from patients 
with COPD70,71. 
In addition, macrophages can regulate the cellular production of reactive oxygen species 
(ROS) in COPD. Many studies have shown that the level of oxidative stress was increased in 
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COPD34,72,73, and the increase is derived from ROS produced by activated macrophages in 
airway of patients with COPD73. 
1.1.2.3.3 Macrophage and Emphysema 
Emphysema is an important pathological stage of COPD. The elastolysis of the lung is the 
primary cause of emphysema74. Studies have shown that the number of AMs was 
significantly increased in BAL fluid of smokers with emphysema comparing with those 
healthy smoker without emphysema, and this increase was correlated to the extent of 
emphysema75. AMs also expressed cathepsins (L and S), MMP-2, MMP-9 and MMP-1276-78, 
and all of them involved in the pathogenesis mechanism of emphysems79.  Cathepsins L and 
S are elastolytic cysteine proteases. MMP-2, MMP-9 and MMP-12 are the predominant 
MMP capable of elastolysis in COPD patients80. It has been demonstrated that a MMP 
inhibitor, Marimastat decreased the elastolytic activity derived from MMPs in macrophages 
from patients with COPD80. 
1.1.2.4 Airway Epithelia Cell 
Airway epithelia cell (AEC) play an important role in the innate defence system of airway. 
AEC is the pseudostratified ciliated columnar epithelial cells (from tracheatobronchioles), 
and their ciliary movement can protect the airway against the invasion of pathogens81. The 
goblet epithelia cells, as secretary cells, can also produce mucus to trap the foreign 
substances entering in the respiratory tract82. In addition, AEC can release certain mediators 
and cationic peptides with antimicrobial effects to fight against the pathogens entering into 
the respiratory tract83. ASE also contributes to the adaptive defence, as they transported IgA 
to the airway lumen84. Studies have shown that cigarette smoke weakened the innate and 
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adaptive immune functions of airway epithelic cells, resulting in the increase of 
susceptibility of COPD patients to infection10,11. 
Similar to the role of macrophages, AEC has a capacity of recruitment of inflammatory cells, 
and regulating lung tissue damage through the release of chemokines and MMPs. For 
example, AECs increased the release of IL-8 , Pro-α, GM-CSF, CXCR3, IP-10, interferon-γ 
inducible T cell chemoattractant (I-TAC; CXCL11)26,85-88, and CXCR3 in BALF of COPD 
patients86,87. The expression of activated normal T cells expressed and secreted (RANTES; 
CCL5) and the level of another chemoattractant for eosinophils (eotaxin) were significantly 
increased in ASEs from patients with COPD89,90. The expression of MMP-9 was at a low 
level in ASEs from the non-smoking subjects, but it was significantly increased in ASEs 
from COPD patients91. 
1.1.2.5 Eosinophil 
The role of eosinophil in COPD is still uncertain. A study showed that the number of 
eosinophils increased in the induced sputum in COPD patients, but in stable COPD patients, 
the number of eosinophils remained unchanged92,93. Other studies reported that the number 
of eosinophils was elevated in sputum, BAL fluid, airway and lung in the acuate 
exacerbations of chronic bronchitis with obstruction patients15,94,95. The increased number of 
eosinophils in the inflammatory site may be related to IL-8 and RANTES51,90,96,97. It has 
been shown that RANTES was strongly expressed in ACEs from patients with chronic 
bronchitis exacerbations90. The concentration of IL-8 was significantly increased in sputum 
of patients with COPD16, and further increased during acute exacerbations98. The level of 
another chemoattractant for eosinophils (eotaxin) was also significantly increased in ASEs 
from patients with COPD89. In addition, eosinophils maybe related to therapeutic outcome of 
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certain drugs as it has been shown that the presence of eosinophils in COPD patients 
displayed a good clinical response to corticosteroids treatment99. 
1.1.2.6 Airway Smooth Muscle 
Studies have shown a significant increase of the number of airway smooth muscle (ASM) in 
small airways of COPD patients 58,100,101, especially in patients with severe COPD102, and 
this increase in the number was correlated with the FEV58.  The proliferation of ASM is the 
main feature of fibrosis in COPD patients103. ASM released many inflammatory mediators, 
including IL-8, MCP-1, GRO-a, IP-10 and GM-CSF in inflammatory conditions104-108.  
1.1.2.7 Inflammatory Cells and Fibrosis in COPD 
Three types of inflammatory cells have been shown to participate in the regulation of fibrosis 
in COPD, including macrophages, AECs and ASMs, involving two main mechanisms. The 
first mechanism is through transforming growth factor beta (TGF-β)/mothers against 
decapentaplegic homolog 3(SMAD3)/ASMs pathway to modulate the chronic fibrosis in 
small airways109. The second mechanism is through TGF-β/ET-1/collagen tissue growth 
factor (CTGF, an important downstream factor of TGF-β)/fibroblasts pathway to promote 
the activation of fibroblasts110. ASM is the main structure cell in chronic fibrosis. The 
proliferation of ASM was up-regulated by TGF-β/SMADs111. There was a self-regulation of 
ASM on the proliferation, as ASM also released the TGF-β112 , which may explain why 
ASM continuously proliferated leading to the airflow limitation in COPD. ASM also 
contributed to the regulation on TGF-β/ET-1/CTGF/fibroblasts pathway, as it released and 
expressed the CTGF to induce the activation of fibroblasts113. Similar to ASM, AEC 
expressed both TGF-β and CTGF 114, indicating it may regulate the fibrosis through both 
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mechanisms. The expression of TGF-β was increased in AMs and AECs from patients with 
COPD74,114,115, thus AMs may mainly regulate chronic fibrosis through the release of TGF-β.  
1.1.3 The Inflammatory Mediators in COPD 
The inflammatory cells release various inflammatory mediators which can be divided into 
different types according to their functions in inflammatory responses, including 
chemokines, cytokines and proteases. Table 1-1 lists all inflammatory mediators which have 
been shown to be increased in COPD patients. Among these, some mediators have been 
investigated as drug targets in experimental studies and clinical trials. 
1.1.3.1 IL-8 
IL-8 is a powerful neutrophil and lymphocyte chemoattractant. It can be secreted by 
macrophages, neutrophils, and AECs118,140. CS was a powerful inducer of the synthesis of 
IL-8 in vivo141.  It has been shown that TNF-α, LPS, IL-1β, bacterial products, certain 
viruses, oxidative stress and CSE were stimulators of IL-8 secretion in vitro142-148. Further 
studies showed the synthesis of IL-8 was related to the activation of transcription factors, 
among which NF-κB is predominant149,150, and the protein and mRNA expression of IL-8 






Table 1-1 Expression of inflammatory mediators in COPD patients 
Mediator Target Source Reference 
IL-8 
Protein Induced sputum, BAL fluid, serum  16,116,117 
mRNA Lung tissue 116,117 
Protein AMs, AEC, Neutrophils 118 
Gro-α Protein Sputum, lung tissue 
116
 
Protein AECs 26 
IP-10 Protein Lung tissue 116,119 
ENA-78 Protein BAL fluid 
21
 
mRNA AECs 120 
MCP-1 Protein Sputum, BAL fluid, lung 
52
 
mRNA Lung tissue 116,117 
CCR2 Protein Lung tissue 
117
 
mRNA Lung tissue 116 
CCL3 Protein Lung tissue 
117
 
mRNA Lung tissue 116 
CCL4 Protein BAL fluid 116 
CXCR2 Protein PBLs 
116
 
mRNA BAL fluid 121 
TNF-α 
Protein Sputum, serum, leg muscle 16,116,119 
mRNA Serum, sputum 116,119 
Protein AMs, AEC 122,123 
IL-6 Protein Sputum, BAL fluid, EBC, plasma 
124-126
 
Protein Monocytes 127 
IL-9 Protein T lymphocytes 128 
GM-CSF Protein BAL fluid 129 
IL-10 Protein Sputum, serum 130 
IFN-γ Protein Bronchial biopsies 128,131 
TGF-β Protein AECs, AMs, PBLs 
115,132 
Airway biopsies 133,134 
VEGF mRNA Pulmonary vascular smooth muscle 135 
Cathepsin L Protein BAL fluid 136 
MMP-1 Protein Bronchoalveolar lavage 137 




ENA-78=Epithelial cell-derived neutrophil-activating peptide-78 ( CXCL5) 
PBLs=Peripheral blood lynphocytes 
EBC=Exhaled breath condensate 
VEGF=Vascular-Endothelial Growth Factor 
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IL-8 has two receptors, CXCR1 and CXCR2, located on the surface of neutrophil140. 
CXCR1 is a specific receptor for IL-8 and blocking its activity leads to blocking 
inflammatory signalling from IL-8 to neutrophils. CXCR2 is non-specific receptor of IL-8, 
which binds not only to IL-8, but also to ENA-78 and Gro-α141,142. In addition, collagen 
fragment (the product of lung tissue), especially proline-glycine-proline (PGP) derived from 
the breakdown of extracellular matrix, also bound to CXCR2143. In patients with COPD, the 
levels of ENA-78 and GRO-α were significantly increased in BAL fluid 21.The concentration 
of PGP which was broken down by MMP1 and MMP9 from collagen was also increased in 
the sputum and serum of COPD patients144. CXCR2 seems to play a more important role 
than CXCR1 in neutrophils related inflammatory response in COPD, as CXCR2, but not 
CXCR1, was expressed by bronchial epithelial cells from COPD patients145. Qiuet et al. also 
found that the expression of CXCR2 was significantly increased in airway neutrophil during 
acute exacerbations of COPD, and this increase is correlated with the numbers of neutrophil 
in the airway120. Previous studies on blocking IL-8 activity had limited success in 
eliminating the neutrophil related inflammation146. It indicates that CXCR2 may be a better 
drug target than IL-8 itself.  
Various IL-8 antagonists have been developed. ABX-IL-8 is an antibody against IL-8. It has 
been evaluated in clinical trial phase II for COPD147. Although the dyspnea was improved, 
there were no improvements on the lung function, quality of life and the six minute walking 
test. So, in 2003, ABX-IL-8 was withdrawn from further studies148. As alternatives, the 
antagonists (SB656933) which prevent Gro-α& IL-8 binding to CXCR2 have also been 
evaluated in clinical trial for COPD. SB656933, as an oral CXCR2 antagonist  was reported 
to inhibit the binding of Gro-α and IL-8 to CXCR2 but not CXCR1 in human neutrophils148. 
CD11b (Mac-1, alphaMbeta(2)-integrin), as both a complement receptor (CR3) and a cell 
adhesion molecule present on the surface of cells, maybe involved in the regulation of 
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SB656933 in COPD patients. CD11b can trigger chemotaxis of neutrophils and shape 
change of lung tissue149. Neutrophils over-expressed CXCR1 and CXCR2 was reported to 
respond to IL-8 with the up-regulation of CD11b in smokers with COPD, and SB-656933 
was found to inhibit the expression of CD11b in neutrophils and shape-changes of lung 
tissue in COPD patients149. This result was also confirmed in an animal model of COPD150.  
Another type of IL-8 antagonist (SB225002 and SB265610) has been reported to interfere 
with the chemokine-binding sites116. SB265610 significantly inhibited the repair and 
neutrophil recruitment in a skin-wound healing model in mice151. Other novel CXCR2 
antagonists are also under development. Studies showed that highly selective N,N’-
diarylurea CXCR2 antagonist, significantly reduced the chemotaxis of neutrophil in vitro, 
and decreased the number of neutrophil in rabbit models for ear swelling and neutropenia152.  
1.1.3.2 TNF-α 
In 1968, Dr. Gale A Granger named a cytotoxic factor produced by lymphocytes as 
lymphotoxin (LT)153.  In 1975, Dr. Lloyd J. Old found that the mice injected with LPS after 
vaccinated by Bacillus Calmette (BCG) produced the factor which killed some tumor cells or 
induced the necrosis of tumor tissue in vivo, and named it as tumor necrosis factor (TNF)154. 
In 1985, Shalaby named TNF produced by macrophages as TNF-α，and lymphotoxin(LT) 
produced by lynphotocyes as TNF-β155. TNF-α plays a key role in the inflammatory 
response of COPD. Previous studies showed that the levels of TNF-α were increased in 
peripheral blood, sputum and BLA fluid of patients with COPD16,156. The concentration of 
TNF-α was also increased in the serum from patients with stable COPD16, as well as in the 
serum from COPD patients with acute exacerbation157,158.  The concentration of soluble 
TNF-α receptors was also increased in sputum of patients with COPD159. TNF-α can be 
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produced by various cells, such as epithelial cells, macrophages and monocytes, but mainly 
in macrophages61,160,161. CS and LPS are frequently used as inductors to stimulate the release 
of TNF-α in the experimental model of COPD162,163.  CS induced TNF-α release maybe 
dependent on MMP12, as the release of TNF-α stimulated by CS was abolished in MMP12 
knockout mice122. 
TNF-α is a maintainer of abnormal inflammation of COPD. It regulates a broad spectrum of 
inflammatory mediators through activating various inflammation-related pathways. These 
pathways include NF-κB, mitogen-activated protein kinase 1/2(ERK1/2), p38 mitogen-
activated protein kinases (P38 MAPK) and phosphatidylinositol 3-kinases (PI3Ks) 
pathways164-167. For example, TNF-α can activate these pathways to release IL-8, IL-6 and 
MMP-9168-170.  
TNF-α is related to emphysema which is the end stage of COPD progression.The previous 
study showed that a lesser degree emphysema was generated by TNF-α knockout mice 
induced by CS than wild-type animals,  and TNF-α was accounted for 70% of smoke-
induced emphysema in the mice 171.  There is also evidence for a role of TNF-α in 
emphysema in TNFR−knockout mice, which may involve MMPs171. TNF-α may also be 
involved in weight loss during late stage of COPD, as the release of TNF-α was increased in 
peripheral blood monocytes from weight-losing COPD patients123,156. The effect of TNF-α 
on muscle wasting may contribute to the weight loss in COPD patients, as studies showed 
the expression of skeletal muscle proteins was inhibited by TNF-α through activating NF-
κB172. 
It is well known that TNF-α promote the inflammatory response, which in turn causes many 
the clinical problems such as RA, Ankylosing Spondylitis, Juvenile Idiopathic Arthritis, 
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Psoriasis, Psoriatic Arthritis, Crohn's disease, Behçet's syndrome, Hidradenitis Suppurativa, 
Acute Ischemic Stroke, asthma and COPD173. In TNF-α gene knockout mouse, blocking the 
bind between TNF-α and TNF-α receptor attenuated the pulmonary inflammation induced by 
cigarette smoking174. Therefore, TNF-α is a potential drug target for COPD, and TNF-α 
inhibitors have been used in clinical trial or preclinical to adjust inflammatory disorders. 
TNF-α antagonists include non-human/chimeric antibodies (infliximab, afelimomab and 
CytoTab), humanized antibodies (adalimumab, CDP-571 and CDP-870), human soluble 
TNFR/ TNFR fusion protein (Onercept and Etanercept), small molecules (ISIS-104838), and 
inhibitors of TNF-α converting enzyme (TACE)148,175. Three TNF-α inhibitors have 
currently been approved by the Food and Drug Administration (FDA) and the European 
commission(EC) for disease-specific application, infliximab (Remicade) for RA and Crohn, 
etanercept (Enbrel) for RA and AS, adalimumab (Humira) for RA. They are also listed by 
the Pharmaceutical Benefits Scheme (PBS) for use in Australia. The application of TNF-α 
antagonist (Infliximab) in COPD is currently developing in II clinical trials, and clinical 
studies demonstrated that COPD patients treated by infliximab over 6 to 24 weeks did not 
show improvement on lung function, body weight, quality of life scores, airway 
inflammation, or cytokine levels176. Another study on TNF-α inhibitor etanercept in a non-
follow-up small clinical trial on COPD and asthma showed FEV1 and stable FEV1/forced 
vital capacity(FVC) were improved by etanercept plus withdrawal of β2-agonists in patients 
with severe asthma,177. However, the uncertain effect of TNF-α inhibitors on COPD is still 
the primary factor which limits the application of these inhibitors. In addition, the cost of 
these agents was too expensive, which directly limited their widespread use. More 
importantly, these agents are associated with some serious side effects, such as lymphoma, 
congestive heart failure, opportunistic infections, and tuberculosis178,179. New efforts are 
needed to develop novel anti- TNF-α agents who are efficient, safe and cost effective to 
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replace the current ones180,181. Another potential development in this area is the use of 
inhalation formulation of TNF-α for treating the local airway inflammation. The local 
application of TNF-α inhibitors may not affect systemic pulmonary inflammation, but can be 
more directly and effectively inhibiting tissue remodelling and mucus hyper production in 
the inflammatory sites148.  
A separate approach is via inhibition of TNF-α biosynthesis. The biosynthesis of TNF-α is 
closely related with three biological processes which occur on the different parts of cell, 
including activating the inflammation-related pathways in cytoplasm, expressing mRNA 
through activating promoter in nucleus and protein synthesis in ribosome. Current studies of 
TNF-α synthesis focus on the inhibition on biological processes in cytoplasm and nucleus, 
especially the NF-κb pathway. In this aspect, a number of natural compounds such as 
ginseng, have been used in the treatment of COPD and have been shown to inhibit the 
release of TNF-α through decreasing the activity of NF-κB pathway. G115, a standardized 
extract of ginseng, has been used for the treatment of COPD, and was shown with 
significantly improvement of the Pulmonary Function Tests (PFTs), Maximum Voluntary 
Ventilation (MVV), Maximum Inspiratory Pressure (MIP) and Maximal Oxygen 
Consumption (VO2max) in patients with moderately-severe COPD182. Further study showed 
Rb1 and Rg1, as a major active components of G115 decreased the expression of activated 
NF-κB to inhibit the release of TNF-α183,184. 
1.1.3.3 MMPs 
MMPs play an important role in the pathogenesis of emphysema. In the healthy adult lung, 
the expression of MMPs is in low quantities185 . The concentrations and expressions of 
MMP-1 and MMP-9 were increased in macrophages from patients with COPD, and MMP1 
 16
has been shown to be involved in the formation of emphysema through degrading type III 
collagen186. The MMP2 and MMP9 were also expressed in emphysematous lung tissue187, 
and their activities were inhibited by blocking the expression of ET-1 in CSE-induced 
emphysema rat188.  MMP12 may be decisive factor of CS-induced emphysema, as MMP12 
knockout mice did not develop emphysema to exposure in CS189.   
Many cells and cytokines involved in the elastolysis in COPD through regulating the release 
of MMP-9 and the modulations of these cells and cytokines on MMP-9 may be bidirectional. 
For example, both neutrophils and macrophages released MMP-9 contributing to alveolar 
destruction32,79,190.IL-10 (anti-inflammatory cytokine) inhibited the release of MMP-9 in 
monocytes from patients with COPD191. MMP-9 also contributes to the repair (fibrosis) after 
elastolysis through activating fibrosis-inducing factor(TGF-β). MMP-9 promoted the 
transformation of TGF-β192, which was achieved through activating TGF-binding protein-
1193. Thus, MMP-9 may act as a bridge between the elastolysis and fibrosis.  
MMPs have also been studied as a drug target of COPD. The existing antagonists of MMPs 
include TNF-α converting enzyme (TACE) MMP inhibitors, endogenous tissue inhibitors 
(TIMPs) and pharmacological inhibitors such as zinc chelatorsand  doxycycline175. TACE is 
a protein which inhibits the pre-TNF-α cleavage into mature TNF-α, and also the release of 
MMPs. TACE is likely to have a potentially beneficial effect to inhibit the formation of 
mucus. There is evidence that the TACE-dependent mechanism was involved in the 
production of important constituents of mucus, mucins 5AC, induced by CS and LPS in 
vitro194. 
TIMPs are the endogenous tissue inhibitors of MMPs which comprise four proteases, 
including TIMP1, TIMP2, TIMP3 and TIMP4. All MMPs are inhibited by TIMPs once 
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TIMPs are activated, but the gelatinases (MMP-2 and MMP-9) can form a complex with 
TIMPs when they are in the latent form. The complex of latent MMP-2 (pro-MMP-2) with 
TIMP-2 serves to facilitate the activation of pro-MMP-2 at the cell surface by MT1-MMP 
(MMP-14)195,196. The role of pro-MMP-9/TIMP-1 complex is still unclear. TIMPs have been 
implicated in the pathogenesis of COPD. The concentration of TIMP1 and TIMP 4 were 
elevated in serum of COPD patients compared with that of control subjects197. TIMP3 
knockout mice demonstrated a progressive airspace increase198.  A polymorphism in the 
TIMP2 gene (G853A) was also associated with COPD199. 
The inhibitors of MMPs have been evaluated in clinical trial for many diseases, such as 
cancer, autoimmune disease, and cardiovascular disease200,201. However, only doxycycline is 
currently approved by the FDA for anthrax. MMPs inhibitors have certain side effects on the 
musculoskeletal system175. Further research may help to develop novel MMPs inhibitors 
with fewer side effects for the management of COPD. 
1.1.4 Inflammation Related Pathways in COPD 
It has been proven that several inflammation pathways contribute to the pathogenesis of 
COPD through the release of various inflammatory mediators (Table  1‐2    Release  of 
inflammatory mediators through the pathways related with COPD). These pathways include 
PI3K, ERK, P38 MAPK, NF-κB and cAMP, each of them plays different roles in COPD.  
Table 1-2  Release of inflammatory mediators through the pathways related with COPD 
Pathway Mediator Compartment Inducer Reference 
PI3K  
NE Neutrophils LPS 202 




MMP9 U937 TNF-α 205 
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ERK1/2 IL-6 
HBECs CSE 206 
human ACEs, BEAS-2B CSE, NHI 207,208 
monocytes from COPD patients Acetylcholine 29 
P38 
IL-8 HBECs,BEAS-2B ESHI, CSE 
207,209 
HBECs DEEP, TRP 210 
TSLP Human SMs TNF-α,IL-1 211 
IL-6 HBECs,THP-1 DEEP 210 
COX-2 HBECs DEEP 210 
IL-1 THP-1 TRP 212 
TNF-α THP-1 TRP 212 
NF-κB 
IL-8 Human SMs, HBECs 
CSE/IL-
1β,ESHI 209,211 
Eotaxin Human SMs CSE, IL-1β 211 
VEGF-α Human SMs CSE, IL-1β 211 
MMP9 A549 TNF-α 213 
ICAM-1 Human SMs TNF-α, IL-1β 214 
IL-6 Human SMs TNF-α, IL-1β 214 
GM-CSF Human SMs TNF-α, IL-1β 214 
RANTES Human SMs TNF-α, IL-1β 214 
MCP-1 Human SMs TNF-α, IL-1β 214 
Gro-α Human SMs TNF-α, IL-1β 214 
NAP-2 Human SMs TNF-α, IL-1β 214 
ENA-78 Human SMs TNF-α, IL-1β 214 
 
HBEC= bronchial epithelial cell line 
NHI:=bronchial epithelial cell line 
ESHI:=Exacerbation strains of H. influenzae 
DEEP= Tp0751 recombinant protein 
TRP= Tp0751 recombinant protein 
TSLP:=Thymic stromal lymphopoietin 
 
1.1.4.1 Phosphatidylinositol 3-Kinases Dependent Pathway 
PI3Ks are a family of related intracellular signal transducer enzymes. PI3Ks are involved in 
the regulation of various cellular functions through PI3k dependent pathway. Akt, as a 
downstream factor of PI3K pathway, can be phosphorylated by PI3K, and plays a key role in 
multiple intracellular processes such as cell growth, proliferation, differentiation, motility, 
survival and intracellular trafficking215. In macrophages from patients with COPD, the 
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expression of phosphorylated PI3K δ and Akt was increased compared with the control 
groups of age-matched smokers and non-smokers216. In addition, PI3K was involved in the 
regulation on the release of inflammatory mediators from macrophage and neutrophils, 
which are the key players in COPD inflammation(Table1-2). 
It has been known that glucocorticoid insensitivity is the biggest problem in the treatment of 
COPD. COPD patients with glucocorticoid insensitivity often have a rapid development of 
COPD and eventually lead to the occurrence of airway limitation. There is evidence for a 
potential role of PI3K, especially PI3K δ, in the glucocorticoid insensitivity of COPD. 
Marwick et al. found that glucocorticoid insensitivity was restored in PI3K δ kinase dead 
knock-in smoke-exposed mice but not PI3K γ knockout mice, and this effect was correlated 
with the activity of histone deacetylases 2 (HDAC2)217. Knockdown of HDAC2 showed that 
HDAC2 was a prerequisite molecule for glucocorticoid-insensitivity and the over-expression 
of HDAC2 was able to restore the sensitivity of glucocorticoid218. In monocytes from COPD 
patients, the reduced sensitivity to dexamethasone was also reversed by inhibition of PI3kδ 
but not by PI3Kγ216. 
1.1.4.2 ERK1/2 Dependent Pathway 
ERK1/2 is protein kinase intracellular signalling molecule. ERK1 is similar to ERK2 (85% 
sequence identity) 219. Phosphorylation of ERK1/2 leads to the activation of their kinase 
activity. Phosphorylated ERK1/2 activates the downstream factors in its pathway, and finally 
involve in a wide variety of intracellular processes such as proliferation, differentiation, 
transcription regulation and development220.  
Activated ERK1/2 was elevated in non-smoking patients with COPD221. However, CSE 
significantly up-regulated the expression of p-ERK1/2 in human ASM cells and 
 20
macrophages222,223, while the effect of CSE on the p-ERK1/2 was also proved in vivo223.  
ERK1/2 is likely to be related to muscle atrophy in COPD, as Lemireet et al. found that the 
ratios of phosphorylated to total expression of  ERK 1/2 were significantly elevated in 
quadriceps from patients with COPD compared with healthy controls224.  This effect of 
ERK1/2 may relate to its action on IL-6(Table1-2), as IL-6 induced the skeletal muscle 
atrophy172.  Previous studies showed the concentration of IL-6 was increased in induced 
sputum, bronchoalveolar lavage, and exhaled breath condensate of COPD patients, 
particularly during exacerbations124,225,226.  In the plasma of COPD patients, IL-6 was also 
increased 125,126,227, especially during exacerbations228. 
1.1.4.3 P38 MAPK Dependent Pathway 
P38 mitogen-activated protein kinases (P38 MAPK) are a class of mitogen-activated protein 
kinase which participate in a signalling cascade controlling cellular responses to cytokines 
and stress. There was a strong induction of p38 phosphorylation in patients with COPD221. 
However, the expression of mRNA and protein of total/phosphorylated p38 MAPK was not 
up-regulated in biopsies obtained from stable out- patients with COPD229. 
Small molecule inhibitors of p38 MAPK have been used in the pre-clinical study of COPD.  
PH797804, a diarylpyridinone inhibitor of p38 MAPK, was reported to improve in dyspnea 
score(DS), aspiratory capacity(AC), and sustained decrease in serum CRP levels and lung 
function (FEV 1 ranging from 32% to 80%). It had no significant effects on liver enzymes in 
COPD patients. SB681323, as a specific inhibitor of p38 MAPK, down-regulated the level 
of TNF-α in whole blood from patient with COPD 230.  SB681323 also reduced the number 
of neutrophils in sputum and the concentration of fibrinogen in serum but not the level of 
CRP, IL-8, IL-1β , or IL-6  in serum of COPD patients without receiving inhaled 
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corticosteroid therapy, and this was accompanied by an improvement in FVC but not in FEV 
1231.  Another p38 inhibitor,GW856553( losmapimod), was shown to have no effect on the 
level of CRP, IL-8 and IL-6 in GOLD stage II COPD patients, but it improved hyperinflation 
232. However, there seems some different effect of p38 MAPKs inhibitor on the release of 
IL-8 in vivo and in vitro, as SB203580 (the inhibitor of p38 MAPK) down-regulated the 
release of IL-8 in CSEM-induced primary HBECs and BEAS-2B 207.  
1.1.4.4 NF-κB Pathway 
NF-κB is a protein complex and activated NF-κB that controls the transcription of DNA. 
While in an inactive state, NF-κB is located in the cytosol complexed with the inhibitory 
protein IκBα. Through the intermediacy of integral membrane receptors, a variety of 
extracellular signals can activate the enzyme IκB kinase (IKK). IKK is part of the upstream 
NF-κB signal transduction cascade. The IκBα (inhibitor of kappa B) protein inactivates the 
NF-κB transcription factor by masking the nuclear localization signals (NLS) of NF-κB 
proteins and keeping them sequestered in an inactive state in the cytoplasm. IKK specifically, 
phosphorylates the inhibitory IκBα protein. This phosphorylation results in the dissociation 
of IκBα from NF-κB and thereby activates NF-κB. The activated NF-κB is then translocated 
into the nucleus where it binds to specific sequences of DNA called response elements (RE). 
The DNA/NF-κB complex then recruits other proteins such as coactivators and RNA 
polymerase, which transcribe downstream DNA into mRNA, which, in turn, is translated 
into protein that results in a change of cell function. There are five proteins in the 
mammalian NF-κB family, including NF-κB1(p50), NF-κB2(p52), RelA( p65), RelB and c-
Rel233. Among these proteins, p65 is the specific transcriptional factor for TNF-α234. 
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NF-κB is the key transcriptional factor which controls the transcription of many  proteins 
involved in the inflammation of COPD235. It regulates the release of many inflammatory 
mediators (Table1-2). The expression of activated NF-κB (p65) was up-regulated in the 
bronchial biopsies of COPD patients70. However, there was a down-regulating mechanism in 
COPD patients on the activity of NF-κB pathway, as the release of the inhibitory factor of 
NF-κB, IL-10, was also increased in COPD patients 236. In addition, activated NF-κB is like 
to play an important role in muscle wasting in COPD, as it was required for the transition 
from inflammatory signalling to muscle atrophy signalling237 and in pulmonary emphysema 
animal model with lower body weight the activity of NF-κB was exactly increased238. 
The inhibitors of NF-κB show a significant inhibition on the TNF-α synthesis and release. It 
has been shown that caffeic acid phenethyl ester(CAPE), inhibitor of IKK, could eliminate 
the synthesis of TNF-α which is induced by heat-inactivated S. aureus in primary astrocytes 
derived from C57BL/6 WT239. Similar results were also demonstrated in vitro240.  It was also 
found that BAY 11-7082, another inhibitor of IKK,  inhibited the synthesis of TNF-α 
induced by ET-1241. In addition, CAPE also inhibited the release of IL-8 and IL-
6.mediators242,243.   
1.1.4.5 cAMP Pathway 
Cyclic adenosine monophosphate (cAMP) is the second messenger that is important in many 
biological processes, and has been shown to modulate inflammatory response in vivo and in 
vitro. cAMP can be phosphorated by phosphodiesterases (PDEs), and then loses activity. In 
humans, cyclic AMP works by activating protein kinase A (PKA, cAMP-dependent protein 
kinase). PKA can activate a cAMP response element-binding (CREB). CREB is a cellular 
transcription factor, which can regulate the transcription of gene, causing increased 
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expression of specific genes. Different to other pathways, cAMP pathway is used to down-
regulate the inflammatory response in COPD.  The elevating agents of cAMP (forskolin, 
dibutyryl cAMP and PDE7A inhibitor) abrogated the release of TNF-α induced by 
LPS/PMA244,245. Foskoliin and dibutyryl cAMP also decreased the number of neutrophils 
and increased apoptosis in the pleural cavity in LPS-challenged mice246. 
The cyclic nucleotide PDEs comprise a group of enzymes that degrade the 
phosphodiesterase bond in the second messenger molecules cAMP and cGMP. PDEs are 
important regulators of cell signal transduction mediated by cAMP and cGMP.  PDEs were 
initially isolated from rat brain in the early 1970s using polyacrylamide gel 
electrophoresis247,248. They have been shown widely distributed especially in the lung and 
many cell types249,250. Different PDEs have different substrate requirements. Some are 
cAMP-selective (PDE4, 7 and 8), some cGMP-selective (PDE5, 6, and 9) and others can 
hydrolyse both cAMP and cGMP (PDE1, 2, 3, 10, and 11). PDE4 is the most important drug 
target in COPD. PDE4 is composed by 4 gene families (A, B, C, D). All of CD+4, CD+8, 
Th1, Th2, Th17,eosinophils, neutrophils, monocyte, macrophages, dendritic cell and AECs 
express of PDE4A, 4B and 4D249,251-259. In peripheral blood neutrophils, CD+4 and CD8+T 
cells from patients with mild COPD, the expression of PDE4A, 4B and 4D were unchanged 
compared with the healthy subjects260. However, the expression of PDE4A4 (the subtype of 
PDE4A) was significantly increased in macrophages from BAL fluid of smokers with COPD 
compared with control smokers250. In addition, the distribution of SNP13 allele frequencies 
of the PDE4D gene was significantly different between the COPD and smoker in the 
Japanese population261. 
PDE inhibitors have been used as therapeutic agents for various diseases since 1977262.  In 
2011, the PDE4 inhibitor, roflumilast, was approved by the FDA for treating the 
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exacerbations of patients with severe COPD associated with chronic bronchitis and a history 
of exacerbations. There is a Cochrane Systemic Review that evaluated the efficacy and 
safety of roflumilast and cilomilast(another PDE4 inhibitor) in the management of stable 
COPD patients in 2011. This paper showed that PDE4 inhibitors significantly improved 
FEV1 regardless of COPD severity or concomitant COPD treatment; they also improved the 
quality of life (St George Respiratory Questionnaire [SGRQ]) and COPD-related symptoms, 
but could not improve exercise tolerance263. There was also an improvement in FEV1 in 
Asian COPD patients treated with roflumilast264. No serious adverse events were reported in 
the patients treated with PDE4 inhibitor compared with controls. However, roflumilast was 
associated with weight loss during the trial period263. There is another study on the efficacy 
of roflumilast used concomitantly with long-acting β(2)-agonists (LABAs) to reduce 
exacerbations of COPD patients, which reported that roflumilast reduced the rate of 
moderate or severe exacerbations, with LABA or without LABA 265 . 
PDE4 inhibitors have the potential to target three main mechanisms of COPD: 
bronchoconstriction, mucus hypersecretion and inflammatory response266-268. Rolipram 
blocked secretions of LTC4 caused by eosinophils treated with formyl-met-leu-phe plus 
cytochalasin B (FMLP/B)269. LTC4 can trigger contractions in the smooth muscles lining the 
trachea, which is the main reason for bronchoconstriction270. Roflumilast was shown 
effectively in weakening EGF induced MUC5AC expression in human AECs to decrease the 
mucus hypersecretion271. There is evidence that PDE4 inhibitors regulate inflammatory cell 
chemotaxis to down-regulate the inflammatory response through inhibiting the release of 
chemokines. PDE4 inhibitor( RP73401) inhibited LTB4 production stimulated by LPS/ 
FMLP272. Roflumilast and its active metabolite (roflumilast N-oxide) concentration-
dependently reduced the LPS-stimulated release of CCL2, CCL3, CCL4, CXCL10 from 
human lung macrophages, but without affecting that of CXCL1 or IL-8273. However, the 
 25
release of IL-8 was repressed by rolipram in primary human myometrial smooth muscle 
(HMSM) cells treated with IL-1β274. Rolipram also inhibited GM-CSF production in HMSM 
cells treated with IL-1β273. PDE4 inhibitors (rolipram, RPR-73401, RS-25344-000, 
cilomilast, and roflumilast) suppressed the release of IL-2, IL-4, IL-5, and TNF-α in a 
concentration-dependent manner in peripheral blood mononuclear cells275. 
1.1.4.6 Interactions among Inflammatory Pathways  
NF-κB pathway is a core inflammatory pathway in COPD, which can be regulated by other 
pathways. Activated PI3K phosphorylated Akt, resulting in the activation of NF-κB via 
IKK276. There is also evidence that PI3k may activate NF-κB to express the inflammatory 
gene through regulating the release of ROS. It has been found that LPS-stimulated NCL-
H292 cells secreted MMP-9 via EGFR/PI3K/Rac1/ROS pathway205. ROS directly induced 
the activation of NF-κB277, and NF-κB is the main transcriptional factor of MMP9278.  
On the other hand, cAMP pathway also plays an important role in regulating the activity of 
NF-κB pathway. It has been shown that a down-regulation of NF-κB pathway at the 
transcriptional level is through the activation of CREB, a downstream factor of cAMP-
dependent pathway279,280. CREB has been shown to competitively bind with CREB-binding 
protein (CBP) which is involved in the transcriptional co-activation of NF-κB. CBP can bind 
to both p- NF-κB and p-CREB in nuclear and then form a bridge to the basal transcription 
machinery to activate transcription280. Thus, cAMP pathway can regulate the transcriptional 
activity of NF-κB through competitively bind with CBP. 
In addition, ERK1/2 and p38 MAPK dependent pathways also involve in the regulation of 
NF-κB pathway, however, the regulatory targets of them are different. Activated ERK1/2 
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phosphorylates IKK, but activated p38 pathway directly up-regulate the transcriptional 
activity of NF-κB to activate NF-κB pathway281-283. 
1.1.5  Experimental Models of COPD 
Although patients are the most direct study subjects in disease research, the usage of them 
are widely limited by many factors, such as experimental methods, the research period, and 
medical ethics, etc. So instead researchers select adaptable disease model (animal or cell) to 
replace human as research subjects. Researchers have established wide varieties of disease 
models and even focus on the same disease, there are also many different models to express 
different pathological mechanisms. So the selection and establishment of the adaptable 
disease models are the first and important step in medical studies. 
The existing disease models are divided into two broad categories: animal models and cell 
models of human diseases. These two types of model can satisfy different requirements in 
disease research. They are complementary to each other in their respective fields. 
1.1.5.1 Animal Model of COPD                                                                                                                    
The animal model, using animal as the subject of study, simulates the performance and 
characteristics of human disease. According to the different reflecting degree of human 
disease, animal models are divided into three major types, including homologous, 
Isomorphic and predictive animal models. Homologous animal model is the most similar to 
human who bear the same diseases, have the same causes, symptoms and treatment options. 
However, as the cause of many human diseases is still uncertain, this kind animal model is 
very rare. Isomorphic animal model share the same symptoms and treatments with patients 
with same diseases, which is the most principle model in medical studies and is the most 
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common model. The last type of animal model is predictive animal model. It shares the 
treatment characteristics with patient with a disease. This kind of animal model is always 
used in drug screening.  
The animal model of COPD is mainly divided into two types, according to the application of 
different inductors. Some studies use chemical substances, such as LPS and various enzymes 
to induce the COPD animal model284. All of them can be directly perused in airway to result 
in the local inflammation. These kinds of animal models belong to isomorphic animal model, 
and were used in the earlier studies of COPD. With the improvement of experimental 
technique, more and more researches use CS as inductor to establish the animal model of 
COPD. As this kind of model have the same cause, symptoms and treatment options with 
COPD patients, it belongs to homologous animal model. This is a specific animal model of 
COPD. There is a CS-induced acuate animal model (1~3 days162,285), which specifically 
displayed the abnormal inflammatory response in COPD224. This kind of animal model is 
widely used in the study about inflammation of COPD. The chronic animal model (six 
months or longer), which not only displayed the abnormal inflammation of COPD, but also 
showed the specific pathological manifestations of emphysema286, was more suitable to the 
study about late COPD/emphysema. 
There is a very important factor which can affect the result of the animal model induced by 
CS.  It is the content of effective substances contained in smoke. As we all know, the main 
effective components of cigarette smoke are tar and nicotine and they are also used to 
control the quality of commercial cigarette. Although the contents of these effective 
components are different in the different brands of cigarette, they are fixed in the same brand 
cigarette.  For example, each Marlboro Red contains 12 mg tar and 0.9 mg nicotine. 
Therefore, the selection of cigarette will affect the result of the preparation of CS induced 
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animal model. Besides these commercial cigarettes, there is a standard cigarette which is 
served as an international standard for research purposes and was approved by 
representatives of commercial manufacturers, which is made by the Kentucky Tobacco 
Research & Development Centre. There are more quality control on these reference 
cigarettes than commercial cigarette and provides a basis for comparing data that have been 
collected in different laboratories. The reference cigarette belongs three kinds: 1R3F (The 
reconstituted tobacco sheet portion of this blend was manufactured using the Schweitzer 
Process, 1974), 2R4F (a low nicotine cigarette, 2001) and 1R5F (an ultra low nicotine 
cigarette, 1989). Among these cigarettes, 1R3F is always used in the experimental work. 
1.1.5.2 Cell Models of COPD 
The cell model of human disease is a popular tool in the study about pathological mechanism 
and drug Intervention in vitro.  Different with animal model, the cell model, using cell as the 
subject of study, simulates the performance and characteristics of human disease.  Adaptable 
cell and corresponding inducer are the two major factors which affect the establishment of a 
cell model.   
1.1.5.2.1 Selection of Adaptable Cell for Inflammatory Cell Models of COPD 
As we all know, many kinds of inflammatory mediators are not expressed by cell under 
normal conditions, and even at inflammatory condition cells only express the specific 
inflammatory mediators themselves. Thus, it is very useful to collect the information that the 
expression of inflammatory mediator in the inflammation-related cell from COPD patients, 
which will be used as background information to help us select the adaptable cell for the 
inflammatory cell model of COPD. We collected relevant information from previous studies, 
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summarised the expression of various inflammatory mediators in cells collected from COPD 
patients (Table1-3).  
According to the existing information from these studies, we found these studies used  5 
types of cells as subjects (AM , monocytes ,airway epithelial cells, neutrophils and T cells ) 
and 9 kinds of inflammatory mediators were involved in( IL-8, Gro-α, TNF-α,IL-9, TGF-β, 
MMP-1,MMP-9, ROS and NF-κb). Among these cells, macrophage and AEC showed more 
potent capability on the expression of various inflammatory factors. All of the expressions of 
these mediators were increased comparing with control group.  
Table 1-3 Expression of inflammatory mediators in the cells collected from the patients with 
COPD 





















    
MMP-9 ↑139 
    
NF-κB ↑70 
    
 
The studies about inflammatory pathological mechanism of COPD in vitro mainly focued on 
4 aspects of abnormal inflammation of COPD, including chemotaxis of inflammation related 
cells, release of inflammatory mediators, formation of tissue damage and repair (Fibrosis). 
The studies about the chemotaxis always use AM, AEC and neutrophils as subjects; the 
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studies about the release of inflammatory mediators always use AM, AEC and T cells as 
subjects, and among these cells, AM and AEC are more popular in previous studies; the 
studies about the formation of tissue damage always choose monocytes/AMs as subjects, 
especially using AMs as the representative; the studies about the fibrosis in COPD. We can 
use AEC, macrophage and ASC as subject. If researchers want to detect the regulation of 
NF-κB on the expression of inflammatory mediators, macrophage is a good choice.(Table3) 
1.1.5.2.2 Inducers Involved in Inflammatory Cell Model of COPD 
As we all know, CS and infected pathogens are two main risks in the pathogenesis of COPD. 
However, it is very difficult to simulate the process of CS and infection from human to cells. 
So researchers prepare the substitutes of CS and pathogenic microorganisms, cigarette 
smoke extract medium (CSEM) and LPS. 
Lipopolysaccharide (LPS), a molecule consisting of a lipid and polysaccharide，elicits 
strong inflammatory responses in animals and cells. LPS is found in the outer membrane of 
gram-negative bacteria. Its Acyl chain embeds in the outer membrane of bacteria, and its 
sugar chains expose to the bacterial surface with the antigenic property. LPS is the most 
powerful inductor to prepare the cell model of COPD. It can induce various cells to express 
various inflammatory factors (Table4).  
Although CS is the primary risk of COPD, it is very difficult to use cell as subjects to 
simulate CS process of human.  As this method cannot be performed in cell-culture 
environment, it does not only increase the risk of cells infection, but also result in the 
increasing the ratio of cell death, so cigarette smoke extract (CSE) is applied gradually. The 
preparation of CSE simulates the process of cigarette smoking of human. Machine pump is 
used to simulate human smoking. Airtight pipes are used to connect the cigarette holder, 
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dissolution media and machinery pump. Actually, the dissolution media is cell culture media 
which is used to absorb the substance of smoke. Adjust the pump pressure and smoking 
frequency (typically 7 times per minute), so that the cigarette burn within the prescribed time 
(usually 3 minutes). The difference between commercial and homemade CSE is dissolution 
media. The dissolution media of commercial CSE is a filter, then use solution to dissolve the 
solute on the filter. The dissolution media of homemade CSE is cell culture medium.  The 
medium containing CSE is named CSE medium (CSEM), which can be directly applied in 
the cell culture. However, as CSEM has poor stability, it is usually prepared just before it is 
to be used.  
LPS and CSEM are used as potential inductors of inflammatory cell model of COPD. 
Besides them, there are other two inducers that are also used in the establishment of cell 
model of COPD. TNF-α and IL-β, as pro-inflammatory factors, not only are produced 
through the stimulation of LPS and CSEM, but are also used as inducers to stimulate cells to 
release the inflammatory mediators. Interestingly, TNF-α, as more powerfully pro-
inflammatory factor, can also induce the release of IL-β (table4). 
1.1.5.2.3 Inflammatory Cell Models of COPD 
There are 16 kinds of inflammatory cell models commonly used for the studies of COPD. In 
these models, 5 types of cells are used as subjects (macrophage, airway epithelia, neutrophil, 
monocyte and lung fibroblast), all of them are the structure/functional cells of the lung. ; 4 
kinds of inducers are involved (LPS, CSEM, TNF-α and IL-1β) and 12 kinds of 
inflammatory mediators ((IL-8, Gro-α, MCP-1, MIP-1. TNF-α, IL-1β, IL-6, IL10, GM-CSM, 
INF-γ, TGF-β and MMP-9) are produced by these models. Including IL-10, all of the 
expressions of these inflammatory mediators were increased in ICM of COPD. (Table4) 
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1.1.5.2.4 TNF-α Related Inflammatory Cell Model of COPD  
TNF-α is a monokine which is mainly produced by monocytes, macrophages and AEC.  
LPS, CSEM and IL-1β are the main inductors of these cells to release TNF-α (Table1-4). 
There is a low level of TNF in normal condition. Once cells are stimulated by inducer, the 
release of TNF-α will boost at once. Thus, the establishment of TNF-α related to 
inflammatory cell model is the premise of the study about drug intervention effect on the 
synthesis of TNF-α. There are five inflammatory cell models which can release TNF-α, and 
LPS& CSEM induced macrophages are the main source of the production of TNF-α (Table 
4). 
The human macrophages are derived from differentiated monocytes. The monocyte is a 
mononuclear and a non-granular cell. These cells derive from bone marrow hematopoietic 
stem cells, and developed in the bone marrow, and finally released into the blood. 
Monocytes stay in the blood for 1-3 days, then migrating to different tissues as macrophages. 
Comparing with monocytes in blood, the volume of macrophages becomes greater; the 
number of intracellular lysosomal granules and mitochondria is increased; the phagocytic 
capacity strengthens. Primary macrophages are un-reproductive cells. Under suitable 
conditions, they survive for 2-3 weeks.  Some cancerous mice provide the primary 
reproductive macrophages, such as P338D1 S774A.1, RAW309Cr, but these cells cannot 
develop in the cell lines. Currently reproductive macrophage line, such as RAW264.7, was 
established from a tumor induced by Abelson murine leukemia virus. However, if we want 
to use human macrophages as subjects, we can only obtain them through the differentiation 
of human monocytes. 
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There are two kinds human monocytes commonly used in related studies, THP-1 and U937. 
In 1984, Sundstrom and Nilsson isolated U937 from the histiocytic lymphoma of a 37 years 
old male patient.  Previous studies showed that U937 was induced by human lymphocyte 
culture supernatant, vitamin D3, PMA, to differentiate into human macrophages287-289. 
Before differentiation, U937 is a suspension cell. After differentiation, differentiated mature 
macrophage-like u937 become adherent cell. The volume and intracellular granules are also 
increased. Both LPS and CSEM induced differentiated mature macrophage-like u937 to 
secrete TNF-α (Table1-4). 
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Table 1-4  Summary of the Inflammatory related cell models of COPD 
Inducer Cells IL-8 Gro-α MCP-1 CX3C CXCL10 CCL5 TNF-α IL-1β IL-6 IL-10 IL-12 GM-CSF INFγ TGF-1 MMP-9 
LPS 
Macrophage ↑290   ↑291       ↑291     ↑292     ↑293 
AEC ↑294           ↑295                 
Neutrophils ↑296                             
Monocyte             ↑292   ↑127 ↑292 ↑292       ↑297 
CSEM 
AEC ↑207           ↑298 ↑299             
Fibroblast ↑300                             
Macrophage ↑301                             
Neutrophils ↑302                             
TNF-α AEC   ↑26           ↑303              ↑170 
 
IL-1β 
Fibroblast         ↑304 ↑304           ↑304       
Monocyte                             ↑305 
AEC ↑306                             
H2O2 Neutrophils ↑307                           
IL-17 Macrophage          ↑308                 
IFN-γ AEC       ↑309                       
Cadmium AEC ↑310               ↑310             
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1.2 Panax Ginseng 
Ginseng, Panax ginseng C.A. Meyer, as a precious Chinese traditional medicinal herb, has 
been known for two thousand years. It was first documented in the Shunqiuyundou volum 
of Weishu in 6 B.C. Shunqiuyundou described ginseng as an herb only grow with the 
God’s brilliance. In 200 A.D., another Chinese document, Guangya, defined ginseng as 
essence of earth. 
1.2.1 The King of Herbs-Ginseng 
Ginseng was first documented as herb in Divine Husbandman’s Classic of the Materia 
Medica and its medicinal efficacy was also briefly introduced. Thereafter, ginseng was 
used in clinic. However, as people understood ginseng very little at that time, ginseng was 
just used as common herb. Until 1590, another pharmacy works, Compendium of Materia 
Medica, completely changed the clinical application status of ginseng. Subsequently, 
ginseng was worshiped as god herb and widely used in clinic. Compendium of Materia 
Medica was written by Shizhen Li in the Ming Dynasty. The book organised and 
supplemented the herbs knowledge which was gradually accumulated before the Ming 
Dynasty, and corrected the errors in them. The book was circulated in many countries after 
written and been praised as “Encyclopaedia in 1596” by Darwin. In this book, Ginseng’s 
medicinal efficacy was more comprehensively introduced than before. Ginseng was 
described as a king of herbs which can cure various diseases, and can cure all the 
deficiency syndrome of men and women recorded. This book was also used as later 
clinical application guide of ginseng. 
1.2.1.1 Ginseng and Deficiency Syndrome 
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Deficiency syndrome (DS) is a concept of Traditional Chinese Medicine (TCM). Whatever 
in TCM or modern medical science, DS plays a very crucial role. It promotes the process 
of diseases occurrence, development. Improving the DS can directly reverse the 
occurrence, development and even death of disease.  Ginseng is such an herb which can be 
used in the treatment of all kinds of DS.  
It is well known that there are over thousands of herbs were found, and hundreds of them 
were frequently used. These herbs were classified as different categories based on their 
different therapeutic properties, e.g. medicines that used to relieve superficies syndrome, 
or medicines used to strengthening body resistance. There are dozens of species of Chinese 
Herbs belongs to supplementing and boosting medicines, such as ginseng, astragalus, 
antler, rehmannia, polygonatum, etc. All these medicines have the effective supplementing 
and boosting functions and all can be used in DS. But why only ginseng can be used for 
both men and women to strengthen their deficiencies? Use the modern terminology, the 
DS in TCM concept cover the following two areas, the first is the Sub-health state before 
the onset of disease, and the other is the human body function decline in the process of 
disease development. In TCM theory, whatever which state in above, the key of treatment 
is tostrengthen and consolidate body resistance, and finally to get to the coordination of 
Yin and Yang. This can be analogy to restore the balance of human body ecosystem. 
However, the most important action of ginseng is to strengthen and consolidate body 
resistance. In TCM, this is the theory base that ginseng can be used to treat all kinds of DS.   
There is another meaning that ginseng can treat DS. In all of the herbs, only ginseng was 
used as emergency medicine for saving the life which was threatened by severe deficiency 
syndrome. Ginseng can be used in saving the life of critically ill patients resulted by 
massive blood loss, severe vomit, diarrhea or chronic and serious illness. When only use 
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large numbers of concentrated decoction ginseng, ginseng can result in the strengthening 
of vitality and resurrection. In ancient China, Chinese always treasured ginseng and used it 
when family member near dying. Previous study showed that ginseng inhibited 
cardiomyocyte hypertrophy and heart failure311. The pharmacology studies showed that 
ginseng can be used to strengthen heart, boost blood pressure, regulates glucose 
metabolism and water-electrolyte metabolism312-314。 
1.2.1.2 Ginseng Can Treat Many Kinds of Disease 
As ginseng’s special therapeutical effect on DS, which affects the occurrence and 
development of the disease, Ginseng was appraised as the panacea by later Chinese 
physicians. Ginseng was also used in the treatment of many kinds of modern diseases. The 
studies about modern pharmacology show that ginseng has many pharmacological actions 
such as anti-aging problems, anti-fatigue, antineoplastic, anti-inflammatory etc. 315-318. As 
a result, ginseng has been widely used as a regulator of human multi-system such as 
nervous system, immune system, cardiovascular system, endocrine system, metabolic 
system and the endocrine system319, and also has been used in the treatment of many 
diseases conditions, such as cardiovascular diseases ,certain metabolic conditions, wound-
healing, respiratory diseases , chronic inflammatory diseases and cancers182,311,320-322.  
In summary, ginseng, as the king of herbs, has very prominent position and strong effect 
whatever in ancient China or in modern medical science. It has become the focus and hot 
spots of today pharmacological study. The Pharmacological mechanism of ginseng is very 
complex. Due to ginseng is the compound that composed by different active ingredients, in 
addition, there is a variety of forms on pharmaceutical use of ginseng, the premise on the 
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study of ginseng pharmacological mechanism is to research the main active component in 
ginseng and its application form. 
1.2.2 The Application Forms of Ginseng  
There is a variety of application forms of ginseng, and all of these forms can be divided 
into three categories：the active compounds of ginseng (gisenosides), the standardized 
extracts of ginseng and the orally administered ginseng formulas. 
1.2.2.1 Chemistry of Ginsenosides 
The main bioactive compounds in ginseng are triterpenoid saponins called ginsenosides, 
which can be classified into two groups, namely dammarane and oleanane (Ro) types, 
according to the difference of glycoside-based architecture323. Dammarane type includes 
two sub-types: protopanaxadiols (PDGs) (eg, Rb1, Rb2, Rc, Rd and Rg3) and 
protopanaxatriols (PTGs) (e.g. Rg1, Re and Rf) (Figure1) 324. More than 150 ginsenosides 
have been identified so far323. The content of ginsenodies varies among different ginseng 
species. For example, Panax ginseng C.A. Mey contains Rf which is not present in Panax 
quinquefolium L, although the later contains 24- (R)-pseudoginsenoside F11, which has the 
same molecular weight as Rf325 . Other ginsenosides, Rb1, Rb2, Rc, Rd, Rg3, Re and Rg1 
are present in both species325. The mostly studied ginsenosides include Rb1, Rb2, Rc, Rd, 
Rg3, Re, Rf and Rg1324. It is important to point out that the actions of individual 
ginsenosides in vivo may depend on their bio-transformation or metabolism (e.g. 
hydrolysis) as it has been demonstrated that the bioavailability of ginsenosides is generally 
poor due to a low absorption through the gastrointestinal tract326,327. The major metabolites 
of PDGs are compound K (CK) and Rh2. The major metabolite of PTGs is Rh1327.       
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Dammarane type 













                                            R1                           R2                                                                                                    R1                        R2 
20(S)-Protopanaxadriol   H                   H                       20(S)-Protopanaxatriol    H                 H 
Ginsenoside Rb1         glc(2─1)glc    glc(6─1)glc           Ginsenoside Re        glc(2─1)rha         glc 
Ginsenoside Rb2         glc(2─1)glc    glc(6─1)glc p        Ginsenoside Rf        glc(2─1)glc          H 
Ginsenoside Rc           glc(2─1)glc    glc(6─1)glc f         Ginsenoside Rg1      glc                        glc 
Ginsenoside Rd           glc(2─1)glc    glc 
Ginsenoside Rg3         glc(2─1)glc 
 
Metabolites 
CK                                   H                      H                       Rh1                           glc                        H 
















































Figure 1-1 Structures of ginsenosides 
1.2.2.2 Standardized Extracts of Herbs 
Standardized Extracts of herbs (SEH) are referred to the extraction that satisfied certain 
quality level through standardized production procedures. They are deep processing 
products of herbs. SEH are widely used in China and other countries. In United States, the 
herb extracts are weighted as 95% in herb market, comparing with the raw materials and 
other product market shares that are less than 5%. In Germany, the herb extracts held 10% 
market shares in national medicine market. In China, as the major herb extracts exporter, 
supplies various herb extracts including Ginkgo Biloba, Hypericum Perforatum Linn, 
Acanthopanax, Angelica, Ginseng, etc. All herb extracts must comply with Chinese Herbal 
Medicine Production Quality Management Standards (GAP) and Pharmaceutical 
Production Quality Management Standard (GMP). At the same time, they should satisfy 
advanced technology and quality inspection standards, and use technology and equipment 
such as Macroporous Resin Separation Technology (MRS), High Performance Liquid 
Chromatography (HPLC, HPTLC), Gas Chromatography (GC), Gas Chromatography - 
Mass Spectrometry (GCMS), High Pressure Liquid Chromatography - Mass Spectrometry 
HPLC-MS）. 
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In China, the herb extracts have got some levels of scale of production. The enterprises 
specialized in producing herb extracts are over 200. However, due to the difference of 
purification technology and origin of herb planted, even the same herb extracts but with 
the different brand, the contents of active ingredient still have some difference, which 
results the pharmacology mechanism of these herb extracts has some slightly difference. 
The above reasons determined we need compose prescription from different brands of 
herbs extracts according to different requirement. 
1.2.2.2.1 Standardized Extracts of Ginseng 
Ginseng comprises a variety of active compounds. The pharmacological actions of ginseng 
were also determined by these compounds. Many factors can result in the change of the 
contents of these compounds in ginseng, such as different origin or harvest time of 
ginseng. Accompanied by the inevitably change of the content of these active compounds, 
the pharmacological actions of ginseng will also alter. In order to fix pharmacological 
actions of ginseng, we use ginseng standardized extracts to keep the content ratio of the 
different active compounds at a fixed range. 
As we all know, different active compound of ginseng correspond to the specific 
pharmacological action. For example, polysaccharides of ginseng have the anti-tumour 
property, but ginsenosides have anti-inflammation property328,329. It means that we should 
choose a suitable preparation method to extract ginseng according to medicinal purposes. 
Actually, there are mainly two types of extracts of ginseng in clinical. One is a ginseng 
polysaccharides extracts, using ginseng as representation19 another is ginsenosides extract, 
using G115 as representation329,330. 
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G115 is a commercially available standardized ginseng extracts (Pharmaton SA, 
Switzerland). The total amount of ginsenosides in G115 is adjusted to 4% (w/w). Previous 
studies on G115 using high-performance liquid chromatography (HPLC) demonstrated 
that Rb1, Rb2, Rc, Rd, Re, Rg1 and Rg2 are the main ginsenosides which compose of 
G115324. To compare with other commercial extracts of Ginseng, G115 has higher Rg1 
than others324. In the early application in clinical, G115 was always used for anti-aging 
purpose and previous studies show G115 improved the memory331-333. Later, G115 was 
used in the treatment of Parkinson's disease, and study showed G115 prevented various 
forms of neuronal cell loss including the nigrostriatal degeneration seen in Parkinson's 
disease334. G115 has anti- inflammatory properties335. As we all know, G115 is a 
ginsenosides-extract from Ginseng, so G115 reflect anti-inflammatory characteristic of 
ginsenosides.  
1.2.2.2.2 The Orally Administered Ginseng Formulas 
Orally administered herbal formula is the traditional administration method in Chinese 
medicine. To avoid variability of contents of active compounds of herbs among 
preparations of formulas, many researchers used commercial standardized extracts to 
replace raw herbs to compose the formula.  
1.2.2.3 Ginseng Formula 
From ancient time to current, ginseng is widely used as a main component in the formula 
of TCM. In TCM masterpiece, Treatise on Cold Pathogenic and Miscellaneous Diseases, 
there are 17 prescriptions include ginseng in all 112 prescriptions recorded. Treatise on 
Cold Pathogenic was written by Zhongjing Zhang in the Eastern Han Dynasty of China, 
who was regarded as the saint of Chinese Medicine. The book is a masterpiece that 
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discussed the treatment of various diseases, and was regarded as ancestor of Chinese 
prescriptions. 
Some well known prescriptions using ginseng as main components including (1)Pure 
Ginseng Decoction (Books about Cold Pathogenic) (2) Ginseng, Aconite Decoction 
(Annotation of Women Fang) (3) Ginseng, Aconite, Dragon Bone, and Oyster Shell 
Decoction ( Ye ShiFang) (4) Ginseng-Ant Powder ( Ji Sheng Fang) (5) Ginseng, Poria, 
and White Atractylodes & Powder (Ju Fang) (6) Ginseng Root-Securing Pill (Ye Shi Fang)  
(7) Shengmai Powder (Differentiating Internal and External Source of Sickness). In 
modern time, some physicians composed many prescriptions based on ancient 
prescriptions and experience of themselves, such as Supplemented Ginseng Astragalus 
Decoction that used to treat myasthenia gravis, Ginseng, Curnu Cervi Pantotrichum and 
Qi Grass used to treat cancer, Cinnamon and Ginseng Decoction used to treat chronic 
gastritis. 
1.2.3 Ginseng and COPD 
There is a long history of ginseng to be used in the treatment of COPD in China. Seven 
hundred years before, there is a famous Chinese medicine work in China, named 
JishengFang. In this book, ginseng and ant composed of Shenyi Formula was used to treat 
the chronic cough, shortness of breath, rapid breathing, wheezing after exercise or activity 
and low voice. Although there was no name of emphysema was shown in the work, all of 
these symptoms match the performance of emphysema which is among a group of COPD.  
Recently, ginseng becomes a hot-point herb which is widely used in the treatment of 
various diseases, including COPD. G115 is a commercial standard extract of ginseng. 
Studies showed G115 improved PFTs, MVV, MIP and VO2max in patients with 
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moderately-severe COPD182. Oral administration ginseng formula also improved the FEV1 
and SGRQ in stable COPD patients336.  
Ginseng-Huangqi-Maidong Formula(GHMF) is one of the  effective formula of COPD. It 
is provided by Guangdong Provincial Hospital and is composed by ginseng, Huangqi and 
Maidong. This formula is formed according to the clinical experiences from many famous 
Chinese medicinal doctors and has been used in the treatment of COPD for a long time. In 
order to improve the efficacy and standardize the quality control of GHMF, Guangdong 
Provincial Hospital provided four forms of GHMF for the secondary development. Among 
these forms, there are two forms which are composed by commercial extracts of Ginseng, 
Huangqi and Maidong from Guangdong and Jiangsu. We named them as GHMF-I 
(Guangdong) and GHMF-II (Jiangsu). The other two forms are directly extracted from raw 
herbs using different method. The difference between them is whether or not to contain 
polysaccharide in the final products. So we named them GHMF-III (excluding the 
polysaccharide) and GHMF-IV (including the polysaccharide).  
Although ginseng (G115) and GHMF have a significant efficacy on COPD, the 
pharmacological mechanism of them is still uncertain. We are very interesting in the effect 
of G115, GHMF and ginsenosides on the inflammatory response, especially on the 
production of TNF-α and the activity of NF-κB pathway.   
1.2.4 Effects of Ginseng /Ginsenosides on NF-κB Signalling Pathway 
There is strong evidence that ginseng/ginsenosides can modulate multiple signalling 
components in NF-κB pathway, including NF-κB activation and related DNA binding and 
transcriptional activity, as well as the upstream regulating factors of NF-κB. The summary 
of multiple actions of ginsenosides is illustrated in Fig.1. In general, activation of NF-κB 
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leads to increase in its DNA binding activity and transcriptional activity, while inhibition 
of NF-κB activation leads to decrease in its DNA binding activity and transcriptional 
activity. The actions of ginseng and ginsenosides on NF-κB activation may explain their 
actions subsequent DNA binding and transcriptional activities. Thus detailed analysis is 




































Figure 1-2 Cell signalling targets by ginsenosides on NF-κB signalling and related 
pathways. 
Inactive NF-κB is located in the cytosol in a complex with the inhibitory protein I-κBα. A 
variety of extracellular stress-related signals can initiate phosphorylation of PI3K/Akt, 
IRAK1/TAK1/ERK1/2 to activate I-κB kinase (IKK). Activated IKK phosphorylates IκBα, 
which results in the dissociation of IκBα from NF-κB. Phosphorylated NF-κB is 
translocated into the nucleus and bind with specific sequences of DNA. The DNA/NF-κB 
complex then recruits CBP for co-activation, and then transcribes the mRNA expression of 
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TNF-α. cAMP degraded by phosphodiesterases (PDEs) works by activating protein kinase 
A (PKA). PKA can activate a cAMP response element-binding (CREB). Phosphorylated 
CREB can competitively bind with CBP to inhibit the transcriptional activity of NF-κB. 
Activated IRAK1/TAK1 also phosphorylates p38 MAPK pathway to up-regulate the 
transcriptional activity of NF-κB. 
1.2.4.1 Regulation on NF-κB Activation 
The key signalling components in regulating NF-κB activation include NF-κB, IKK, IκBα 
and phosphorylated products of them337.  In different conditions, ginseng and ginsenosides 
displayed different regulation on the expression of these proteins. Under stressed 
conditions (e.g. treated with inducers such as LPS, H2O2, PMACI, TNBS, TNF-α and 
Streptozotocin), a number of ginseng, ginsenosides and their metabolites have been 
demonstrated to inhibit the expression of NF-κB, p65&p-p65, IKKa&p-IKKa and p-IκBα 
(Table1). In the basic condition (without any inducers), the transgenic ginseng (TG) and 
ginsenoside Rg3 showed the up-regulation on the expression of p-IκBα, and TG also up-
regulated the expression of p-p65 in LLC-1cells338,339(Table1).  We collected the studies 
which involved in the inhibitions of more than one ginsenoside/its metabolite on these 
protein expressions, and tried to compare the distinction between them. We found all the 
papers just qualitatively determined the inhibition of ginsenoside and/or its metabolit on 
these protein expressions, but didn’t do any quantitatively comparison between 
them184,340,341. Thus, the methodological perfection is necessary for the studies about 




Table 1-5 Actions of ginseng and ginsenosides on protein expression related with 
activation of NF-κB  
Protein Test Agent Source Treatment Effects  
NF-κB 
Rb2 N9 microglial cells LPS ↓184  
Rd N9 microglial cells LPS ↓184  
Rg1 
N9 microglial cells LPS ↓184  
pheochromocytoma PC12 cells H2O2 ↓342  
P-65 GSE HMC-1 cell PMACI ↓343  
P-P65 
Rb1 
colon tissue TNBS ↓340  
mouse peritoneal macrophages LPS ↓340  
CK 
colon tissue TNBS ↓340  
mouse peritoneal macrophages LPS ↓340  
Rg1 pheochromocytoma PC12 cells H2O2 ↓342  
GSE LLC-1cells -- ↑338  




human astroglial cells TNF-α ↓341  
u937 LPS ↓341  
Rh2 
 
human astroglial cells TNF-α ↓341  
u937 LPS ↓341  
Re 3T3-L1 cells TNF-α ↓344  
IKBα Rg3 Raw264.7 cells -- ↓339  
p-IKBα 
Rb1 mouse peritoneal macrophages LPS ↓340  
Rb2 N9 microglial cells LPS ↓184  
Rd N9 microglial cells LPS ↓184  
Rg3 Raw264.7 cells -- ↑339  
CK 
mouse peritoneal macrophages LPS ↓340  
human astroglial cells TNF-α ↓341  
u937 LPS ↓341  
Rh2 
human astroglial cells TNF-α ↓341  
u937 LPS ↓341  
Rg1 N9 microglial cells LPS ↓184  
TGS LLC-1cells -- ↑338 
FG Rat pancreas , in vivo Streptozotocin ↓345 
LPS=Lipopolysaccharide; PMA+PMACI=12-myristate 13-acetate plus calcium ionophore; 
GSE= Ginseng extract; TGS=Transgenic ginseng; TNBS=2,4,6-trinitrobenzene sulfuric 
acid; LLC-1= Lewis lung carcinoma cells; FG=Fermented ginseng; STZ= Streptozotocin. 
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1.2.4.2 Regulation on NF-κB DNA Binding Activity 
Many studies showed that ginseng and ginsenosides inhibited the NF-κB DNA binding 
activity in vitro and in vivo. All of the GSE, red ginseng extract (RGE), FG and 
ginsenosides including Rb1, Rc, Re, Rg1, Rg3 and the metabolite of Rg1 (Rh1) inhibited 
the NF-κB DNA binding activity345-349. Ginsenoside Rg3 used as a popular inhibitor of 
DNA binding of NF-κB activity was widely applied in many kinds of inflammatory cell 
models, such as TPA induced human breast epitelial cells (MCF-10A), docetaxel treated 
colon cancer cells and Aβ42 treated BV-2 cells348,350,351. It also inhibited the NF-κB DNA 
binding activity in vivo347. In addition, ginsenoside Rg1 seemed also displayed the more 
powerful inhibition on the DNA binding of NF-κB activity than other ginsenosides (Rb2, 
Rc, Re and Rg1)347. 
1.2.4.3 Regulation on NF-κB Transcriptional Activity  
RGE, GTS and the PTG type ginsenoside Rg1 and its metabolite Rh1 significantly 
inhibited the transcriptional activity of NF-κB347,350,352. Jung et al. showed Rh1 just 
inhibited the transcriptional activity of NF-κB, but not the DNA binding activity of NF-κB 
in LPS induced BV-2 cells352. It meant that Rh1 inhibited the transcriptional activity of 
NF-κB through other way, but not NF-κB pathway.  
Transcriptional activity of NF-κB, as representing terminal-response activity of NF-κB 
pathway, can be regulated by different pathway. It has been known that activation of cyclic 
adenosine monophosphatec (AMP)-dependent pathway can inhibit the activity of NF-κB 
pathway. One of the important cross links of cAMP and NF-κB pathways is 
phorsphorylated cAMP response element-binding (p-CREB), which is an activated 
transcriptional factor of cAMP-dependent pathway and can competitively bind to activated 
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NF-κB, and then inhibit the transcriptional activity of NF-κB279,280. P38 mitogen-activated 
protein kinases(p38 MAPK) pathway also involves in the regulation of transcriptional 
activity of NF-κB. Study showed that blocking p38 activity attenuated the transcriptional 
activity of NF-κB without altering its DNA-binding activity283. Ginseng and ginsenosides 
can also regulate the activity of both two pathways, so maybe they regulate the 
transcriptional activity of NF-κB through many pathways or specific pathway. However, 
to summarize the regulation of ginseng and ginsenosides on these pathways maybe help us 
to find out how to inhibit the transcriptional activity of NF-κB by Rh1.   
1.2.4.4 Interaction with cAMP-dependent Pathway 
Ginseng/ginsenosides can activate cAMP-dependent pathway, and ginsenoside Rg1 and 
Rb1 plays a crucial role in the regulation of ginseng on cAMP depend pathway. Both Rg1 
and Rb1 increased the level of intracellular cAMP, and then increased the activity of 
PKA353. Rg1  increased the level of cAMP in hippocampus of both young and old rats, and 
Rb1 also increased the level of cAMP in rat liver compared with that in controls354. 
However, in the study of Jeong, ginseng total saponin (GTS) inhibited cAMP levels and 
protein expression of PKA in the tissue of locus coeruleus from morphin injected ICR 
mice355. It is possible that the regulation of cAMP by gisenosides depends on the nature of 
individual ginsenosides. As in this study, the content of Rg1 in GTS was very lower, only 
6.42%355. The effect of Rg1 on cAMP maybe was eliminated by other potent ginsenosides.  
It is likely that the effects of ginseng and its related product on cAMP may involve 
phosphodiesterases (PDEs), the key enzyme in cAMP degradation. An early study 
demonstrated that Rg1 inhibited the activity of cAMP-specific PDE in frontal cortex 
striatum, hypothalamus and hippocampus of young and aged rats, and Rg3 concentration-
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dependently inhibited PDE resulting in increase of cAMP, as well as cyclic guanosine 
monophosphate (cGMP) contents in corporal smooth muscles356. 
Summary of existing evidences, we inferred that Rh1 inhibited the transcriptional activity 
of NF-κb through cAMP pathway, as the inhibited transcriptional activity by Rh1 
accompanied with the increased p-CREB expression352. There are some conflicting 
evidences about the regulation of Rh1 on the activity. Jung et al. showed Rh1 just inhibited 
the transcriptional activity of NF-κB, but not the DNA binding activity of NF-κB in LPS 
induced BV-2 cells 352. However, Jung, J. S et al. demonstrated Rh1 significantly inhibited 
the DNA binding activity of NF-κB in IFN-γ-stimulated BV2 microglial cells. Is Rh1 
using p-CREB as a specific signalling component to modulate the transcription activity of 
NF-κB or p-CREB just a cofactor for Rh1 to modulate the transcription activity of NF-κB 
with NF-κB pathway? We need more experiment data to answer this question.  
Many conclusive evidences showed that PTG type gisenoside Rg1 inhibited the 
transcriptional activity of NF-κB not only through down-regulating the up-steam activity 
of NF-κB pathway, but also down-regulating the activity of cAMP pathway347,353. Thus, as 
a more powerful inhibitor of NF- κB pathway, ginsenoside Rg1 can be more widely used 
in the related study. 
1.2.4.5 Interaction with p38 MAPK Pathway 
PDG type ginsenosides seems to play a key role in the inhibition of ginseng on the activity 
of p38 MAPK pathway. Studies demonstrated that PDG type ginsenoside Rb1, Rb2, Rg3 
and CK, but not Rc or Rd, significantly inhibited the expression of p-p38340,357,358. 
Although many studies proved that ginsenoside Rb1, Rb2, Rg3 and CK down-regulated 
the activity of up-stream phosphorylation response and/or DNA binding activity of NF-
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κB340,184, 339, 341,347 , there are still lack of the direct evidence that ginsenoside Rb1, Rb2, 
Rg3 and CK inhibited the transcriptional activity of NF-κB through down-regulating the 
up-stream activity of NF-κB and the activity of p38 MAPK pathway. In addition, 
ginsenoside Rb1 displayed the inhibition on the up-stream activity of NF-κB and activity 
of p38 MAPK pathway and the up-regulation on the cAMP pathway340, 44. It may be the 
more powerful inhibitor on the activity of NF-κB pathway than Rg1, however, this 
hypothesis need more experimental results to verify. 
1.2.4.6 Regulation on Upstream Pathway  
It is possible that ginseng and ginsenosides may act on the upstream regulating factors of 
NF-κB pathway to modulate its activity, in particular TAK1/ extracellular signal-regulated 
kinase1/2( ERK1/2) and phosphoinositide 3-kinase( PI3K)/Akt pathways (Figure 2). As 
we all know, TAK1 can activate ERK1/2 pathway, and ERK1was used to activate IKK in 
NF-κB pathway281,282. Ginsenoside Rg1 and its metabolit (CK) have been shown to inhibit 
the p-IκB through inhibiting phorsphorylation of IRAK-1(p-IRAK1) which is known to 
activate TAK1, and this decreased expression of p-IRAK1 by Rb1 and CK accompanied 
with the down-regulation on the expression of phorsphorylated ERK1/2 (p-ERK1/2)340. 
There is a bidirectional regulation of ginseng and ginsenosides on the activity of ERK1/2 
pathway. Under stress conditions, FG, GSE, TGS, Rb1, CK and Rg1significantly inhibited 
the expression of p-ERK1/2340,343,345,359-361, except one study showing no effect of Re on 
ERK1/2 expression in TNF-α induced 3T3-L1 adipocytes344 (Table3). On the other hand, 
under basal conditions, RG, Rg1 and CK were shown to enhance the expression of p-
ERK1/2 under362-364. Choi compared the effects of the traditional GSE and novel TGS on 
the expression of P-ERK1/2 in human mast cell line cells, and found that EGS had more 
significant inhibition than GSE343.  
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Table 1-6 Actions of Ginseng/Ginsenosides on the Expression of p-ERK1/2 
Test agent Source Treatment Effect 





human astroglioma cells PMA ↓360  
mouse peritoneal macrophages LPS ↓340  
mouse skin, in vivo PMA ↓361  
MDA-MB-231 cells -- ↑362  
Re 3T3-L1 adipocytes TNF-α --344  
Rg1 
 
human breast cancer cells -- ↑363  
rat basophilic leukemia-2H3 cells SP+DNP-BSA ↓365  
FG 
pancreas tissue of Sprague Dawley rat STZ ↓345  
RINm5F cells STZ ↓359  
RG HUVECs -- ↑364  
GSE human mast cell line  PMA+PMACI ↓343  
TGS human mast cell line  PMA+PMACI ↓343  
SP+DNP-BSA=Substance P+dinitrophenyl-bovine serum albumin; HUVECs= human 
umbilical vein endothelial cells. 
Many studies have demonstrated that ginseng/ginsenosides may act on PI3K/Akt pathway. 
Zhou et al.  found GSE significantly reduced infarct size in a dose-dependent manner, and 
this effect of GSE on infract was abolished by LY294002 (an inhibitor of PI3K) and Akt 
inhibitor IV (an inhibitor of Akt protein kinase)366. The difference in actions of 
ginsenosides on PI3K/Akt pathway has been reported. In mouse model of ischemia-
reperfusion (I-R) injury, GSE, TGS, Rb1 and CK protected the myocardiumin in I-R injury 
through increasing the expression of phorsphorylated-PI3K (p-PI3K)367-370. Ginsenoside 
Rd, also increased the expressions of p-PI3K in the study of anti-apoptotic371. In addition, 
ginsenoside Rb1 rapidly increased the expression of p-Akt in human aortic endothelial 
cells372, and ginsengoside Rg3 elevated the enzyme activities of PI3-kinase in ECV 304 
human endothelial cells373. However, similar with the regulation on NF-κB activation, in 
the inflammatory condition, ginsenoside Rb1 significantly inhibited the phosphorylation of 
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AKT induced by high glucose357; CK, the metabolite of Rb1, also prevented the 
phosphorylation of Akt in basic fibroblast growth factor (bFGF) treated human umbilical 
vein endothelial cells (HUVECs)358. 
1.2.4.7 Actions of Ginseng/Ginsenosides on TNF-α Production  
Most of the studies showed the down-regulation of ginseng and ginsenosides on the 
expression and /or lease of TNF-α (Table5).  Only one paper reported that ginseng 
extracted by saline increase the protein level of TNF-α in anti-CD3 and the outer 
membrane protein of P. aeruginosa (OMP)/ Concanavalin A (ConA) treated the primary 
lung cells from CBA/J mice374. In this paper, Song et al. established a T helper type 2 
(Th2)-like response cell model through being treated by monoclonal hamster anti-mouse 
CD3 without sodium azide (anti-CD3), and then stimulated by OMP/ConA to release 
TNF-α. The extract of ginseng collaborating with OMP and ConA promoted a Th1-like 
response to up-regulate the release of TNF-α and IFN-γ. However, in Th1-like response to 
cell model, ginseng demonstrated the significant down-regulation on the release of TNF-α. 
As we all know, that activated macrophages induced a strong polarized Th1-like T cell 
response375. The extract of red RG significantly reduced the expression of TNF-α in LPS 
induced monocyte-derived macrophage THP-1 cells376. Thus, there should be a 
bidirectional regulation of ginseng on the release of TNF-α in different type of cell model. 
In addition, different extraction methods may be another possible factor which influences 
the effect of ginseng extracts on the release of TNF-α.  
Ginseng extracted by saline up-regulated the production of TNF-α, but RG extracted by 
water down-regulated it. Previous study provided a similar result that the aqueous and 
alcoholic extracts of ginseng have opposite regulation on the release of TNF-α. In this 
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paper, aqueous extract of ginseng , but not alcoholic extract of ginseng up-regulated the 
release of TNF-α377.  We couldn’t confirm whether different extract methods were the 
reason leading to opposite regulation of the ginseng extracts on TNF-α, as there are no -
results of HPLC in these studies. It is just an assumption and need more experimental data 
to prove it. 
All of the studies involved in ginsenosides showed the significant inhibition on the 
production of TNF-α (Table5). There seemed to be no difference of the regulation on the 
production of TNF-α between PDGs and PTGs184. Wu showed both PDGs (Rb2& Rd) and 
PTGs (Rg1& Re) inhibited the protein level of TNF-α in LPS induced N9 microglial 
cells184. Although Rg1 showed stronger inhibition compared with other ginsenosides, 
another PTG (Re) showed the similar inhibition with PDGs.  
There are two aspects affect the widespread use of ginseng, low absorption rate and 
complex actions (sometime opposing or contradictory). Many studies focused on finding 
novel ginseng extracts to increase absorption rate and/or be beneficial to biological 
activity. Different ginseng extracts, such as fermented ginseng (FG)359and transgenic 
ginseng(TG)378 have been used in the studies, and they showed significant inhibition on 
TNF-α 
.  
Table 1-7 Actions of ginseng and ginsenosides on the TNF-α expression 
Products cell/tissue Treatment Effects 
FG RINm5F insulinoma cells streptozotocin ↓*359 
RG 
pancrease tissue, in vivo diethyldithiocarbamate ↓Δ379 
THP-1 cells LPS ↓*376 
TG HMC-1 cells PMA&PMACI* ↓#378 
Ginseng lung cells of CBA/J mice anti-CD3,OPM&ConA ↑#374 
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Rb1 
PBMC&FLS cells IFN-γ, LPS or IL-1 ↓#380 
Raw264.7& U937 cells LPS ↓#381 
HaCaT cells Capsaicin ↓#382 
Rb2 
N9 microglial cells LPS ↓#184 
Raw264.7& U937 cells LPS ↓#381 
Rc Raw264.7& U937 cells LPS ↓#381 
Rd N9 microglial cells LPS ↓#184 
Rg1 N9 microglial cells LPS ↓#184 
Rg3 
murine BV2 microglial cells β-amyloid ↓ Δ351 
ears tissue, in vivo Oxazolone ↓*383 
Re N9 microglial cells LPS ↓#184 
Rf ears tissue, in vivo Oxazolone ↓*383 
Rh2 ears tissue, in vivo Oxazolone ↓*383 
 murine BV2 microglial cells LPS/IFN-γ ↓Δ384 
*: gene expression 
Δ: protein expression 
#: protein level 
1.2.5 Yin and Yang Actions of Ginseng and Ginsenosides  
“Yin” and “Yang” are two important ancient philosophical concepts in China. “Yin” covers 
a variety of inhibition and down-regulating response, and “Yang” covers a variety of 
promotion and up-regulating response. It has been reported previously that ginseng has a 
complex action on modulation of cell functions with both “Yin” and “Yang” aspects. For 
example, it has been shown that Rg1 stimulates angiogenesis, whereas Rb1 exerts an 
opposing effect, and mechanistic studies revealed that such responses were mediated 
through the PI3K/Akt pathway385 . In this review, ginseng and ginsenosides also displayed 
the “Yin” and “Yang” actions on the activity of NF-κb pathway and the production of 
TNF-α. We found different conditions may be the main reason resulting in these opposite 
actions. In non-inflammatory condition, such as cancer cell models, immune cell models 
and normal cells, ginseng and ginsenosides display up-regulation (Yang action) on the 
activity of NF-κB pathway and the production of TNF-α, but in inflammatory model 
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ginseng and ginsenosides demonstrate significant down-regulation(Yin action). In 
addition, opposite regulation of individual ginsenosides maybe also play a role in it, as 
different extract method also result in the opposite action of ginseng in the same 
inflammatory cell model377.    
In conclusion, ginseng and ginsenosides have multiple actions on NF-κB signalling 
pathway and TNF-α production, including modulation of NF-κB activation and related 
DNA binding and transcriptional activities, upstream regulating pathways such as 
TAK1/ERK1/2 and PI3K/ Akt, as well as other potential mechanisms through P38 MARK 
and cAMP pathways. The difference in actions of individual ginsenosides may be involved 
in diverse pharmacological activities of ginseng. Given TNF-α and certain NF-κB 
signalling components are defined or potential drug targets, further studies on the actions 
of ginsenosides on TNF-α and NF-κB pathways may facilitate the development of novel 
agents to target the relevant mechanisms for potential therapeutic application for treating 
chronic inflammatory diseases. 
1.3 Objectives of my Ph.D Thesis 
In this project, we hypothesized that ginsenosides, G115 and GHMFs may target TNF-α 
and NF-κB signalling pathway. To test our hypothesis, we have: 
a) Finished the review: Regulations of cellular NF-κB pathway by ginseng and 
ginsenosides 
b) Finished the review: Inflammatory cells, mediators and singling pathways in COPD 
c) Set up inflammatory models in vitro. 
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d) Investigated the effect of ginseng and ginsenosides on cytokines production induced by 
LPS. 
e) Investigate the effect of ginseng and ginsenosides on NF-κB pathway induced by LPS 
f) Investigate the effect of ginseng and ginsenosides on cAMP pathway induced by LPS  
In addition, we also put forward hypothesis that TNF-α inhibitors used in the 
conjunction in the MTX provide a better efficacy against the progression of JD in 
patients with active RA comparing with MTX used alone; the degree of the disease 
activity of RA is important factor for the efficacy of TNF-α inhibitors on the 
progression of DJ in active RA patients. To test our hypothesis, we have used Meta 
analysis to -  
g) Compare the effect of TNF-α inhibitors used alone and combined with MTX on the RP 
of active RA patient.  
h) Investigate the correlation between the degree of activity of RA and the efficacy of 
TNF-α inhibitors on RP in active RA patients 




Chapter 2. Establishment of Inflammatory Cell Models Related to COPD 
2.1 Introduction 
The main pathology of COPD is persistent inflammation in the airway and lungs (see 
Section1.1.1). In order to understand the actions of ginseng and its cellular mechanisms on 
COPD, it is important to study the effects of ginseng on inflammatory mechanisms using 
an appropriate cell model. 
LPS and CSE are commonly used in studies on inflammatory mechanism of COPD and 
macrophages are the common cell type to study various inflammatory mediators386,387. As 
there are no commercially available human macrophage cell lines, researchers use PMA 
induced U937 cells differentiation to macrophage-like U937 cells in related studies (see 
Section1.1.5.2.4). Previous studies have shown that LPS and CSE can stimulate 
macrophages to release TNF-α, IL-1β, IL-6 and other cytokines through the activation of 
the NF-κB pathway241,388,5,6. LPS can also elevate the production of cAMP to activate the 
cAMP pathway389. Thus, aim of this part of my project was to establish the inflammatory 
cell models using LPS and CSE induced macrophage-like U937 cells. The focus was on 
the cytokine, in particular TNF-α production and the changes of NF-κB and cAMP 
pathways. 
2.2  Materials and Method 
2.2.1 Materials 
Phorbol 12-myristate 13-acetate (PMA), Lipopolysaccharide (LPS), Bay11-7082, 
Forskolin, H89, Cilostamide (PDE3 inhibitor), Rolipram (PDE4 inhibitor), Sildenafil 
 59
citrate salt (PDE5 inhibitor) and Penicillin-Streptomycin were purchased from Sigma 
(Aldrich PTY LTD, Australia). 
RPMI1640, heat-inactivated fatal bovine serum, Opti-MEM® Reduced Serum Medium 
and MEM Non-Essential Amino Acids Solution were purchased from Gibco (Invitrogen 
Australia Pty Limited, Australia). The ELISA Kits of TNF-α, IL-1β and IL-6 were from 
GE (GE Healthcare Australia Pty. Ltd, Australia). Cyclic AMP EIA Kit was purchased 
from Cayman (Sapphire Bioscience Pty. Ltd, Australia). Phospho-IKKα/β (Ser176/180) 
antibody, IKKβ antibody, Phospho-NF-κBp65 (Ser536) antibody, NF-κB p65 antibody, 
Phospho-CREB (Ser133) antibody, CREB (48M2) antibody, Phospho-IκBα antibody and 
IκBα antibody were purchased from Cell Signalling (Genesearch PTY. Ltd.). NE-PER 
nuclear & cytoplasmic extraction kit was obtained from Thermo Fisher (Thermo Fisher 
Scientific Australia Pty Ltd). Dual-Glo® Luciferase Assay System and with reporter lysis 
buffer was purchased from Promega (Promega Australia). Attractene Transfection Reagent 
and Signal NF-κB Reporter (luc) Kit was purchased from QIAGEN (QIAGEN Pty. Ltd.). 
2.2.2 Method 
2.2.2.1 Cell Culture 
U937 cells were obtained from the lab of Bernard O’Brien (Bernard O’Brien Institute of 
Microsurgery, The University of Melbourne, Victoria, Australia) and cultured in 
RPMI1640 medium supplemented with 100 units/ml penicillin, 100 μg/ml streptomycin 
and 10% heat-inactivated fetal bovine serum at 37°C and 5% CO2 in humidified air and 
harvested at the log phase of growth. 
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To differentiate suspension U937 cells into adherent macrophages, cells (106cells/ml) were 
incubated in petri dish (24x106cells/dish) for 24 hours in the presence of 10 ng/ml PMA. 
The differentiated cells were made quiescent in fresh completed RPMI without PMA for 
48 hours and during which the culture medium was replaced daily. U937 macrophages 
were obtained as slightly modified method described previously390-392. 
2.2.2.2 Preparation of Cigarette Smoke-treated Cell Culture Medium 
CSE was obtained from four cigarettes (Marlboro Red, 12 mg tar, 0.9 mg nicotine each). 
Briefly, smoke from combustion cigarettes was bubbled through 50 ml of culture medium 
and the burning time of each whole cigarette is 3 minutes. In order to avoid the difference 
among different cigarettes, the absorbance of this CSE was adjusted to 1.0 (optical density, 
OD) at 320 nm, which was used  as the stock CSE (defined as 100 %)393. For cell 
experiments, the stock CSE was diluted with the cell culture medium at 5-fold dilution 
(20%). 
2.2.2.3 Cytokines Assay 
Macrophage-like U937 cells were detached with trypsin, washed, resuspended in medium 
at 106cells/ml and incubated in 96-well plates (105cells/well). After 24 hours, treated with 
LPS (1μg/ml) for 6 hour or added 5–fold dilution of raw CSEM for 18 hours; or treated 
with LPS (1μg/ml) in absence or presence of Bay11-7082, Forskolin, H89, Cilostamide, 
Rolipram or Silderafil for 6 hours. The supernatant of the test samples was collected and 
stored at -80°C to determine TNF-a, IL-1β and IL-6.The concentrations of TNF-a, IL-1β 
and IL-6 in the culture supernatants were determined by human enzyme-linked 
immunosorbent assay (ELISA) kit, according to the manufacturer’s protocol.  
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2.2.2.4 cAMP Assay 
Macrophage-like U937 cells were cultured in 24-well cell culture plates at a concentration 
of 1x106 cells/well. After 24 hours, cells were treated with 1μg/ml LPS in the absence or 
presence. After 6 hours, the cell culture medium was aspirated. The cells were placed on 
the ice and washed by cold PBS for three times. Adding 0.25ml lysis buffer (0.1 M HCl) in 
each well. After 10 minutes, the total cell lysates were centrifuged at 6000g for 10 minutes. 
The supernatants were assayed directly using the cAMP EIA kit from Cayman Chemical 
according to the manufacturer’s instruction (Sapphire Bioscience Pty. Ltd, Australia). 
2.2.2.5 Western Blot 
Macrophage-like U937 cells were detached with trypsin, washed, resuspended in the 
medium at 106cells/ml and incubated in 6-well plates (2.5x106 cells/ well) for 24 hours. 
Cells were treated with LPS (1μg/ml) for 5, 15, 30 or 60 minutes. Samples were washed by 
cold PBS and put on ice for protein collection. The cells were lysed using RIPA buffer and 
plus protease and phosphatase inhibitors on the day of use to obtain total protein 
(Appendix1). The lysate was immediately scraped, collected into microcentrifuge tubes 
and vortexed for 15 seconds. The samples were extracted by high-speed centrifugation at 
14000Xg for 15 minutes to precipitate the insoluble materials. The nuclear and 
cytoplasmic protein were lysed and separated by NE-PER nuclear & cytoplasmic 
extraction kit (Thermo Fisher Scientific Asutralia Pty Ltd) according to manufacturer’s 
instructions. Protein was quantified using Bradford Protein concentration assay (Appendix 
2). The total protein was adjusted at 1.5μg/μl. The nuclear and cytoplasmic protein was 
adjusted at 1μg/μl. 
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Protein levels were measured by Western blot analysis. Protein samples were loaded in 
wells of SDS-polyacrylamide gel (10%acrylamide, Appendix 3) for electrophoresis at 90V 
for 30 minutes and then increased the voltage to 150v for another 60 minutes in running 
buffer (Appendix 4). The separated gel was transferred to PVDF by electrophoresis at 100 
V for 120 minutes in transferring buffer (Appendix 4). The membranes were washed once 
by TBS-T (Appendix 4) and then blocked for 1 hour in TBS-T containing 1% (wt/vol) 
bovine serum albumin (BSA). After washing the membranes with TBS-T 6 times, the 
membranes were incubated with primary antibody of target protein overnight at 4°C. 
Polyclonal antibodies were diluted in different concentrations in TBS-T containing 3% 
(wt/vol) BSA before incubation. The concentrations of these antibodies were 1:2000 
(Phospho-IKKα/β), 1:600 (Phospho-Iκα, NF-κB and Phospho-NF-κB) and 1:1000 (CREB 
and Phospho-CREB). After incubation with primary antibody in TBS-T containing 5% 
(wt/vol) skim milk or 3% BSA, membranes were washed with TBS-T for  6 times again 
and treated with anti-rabbit antibody (1:3000) for 2 hours in room temperature. After six 
washes with TBS-T, the blots were incubated with chemiluminescence reagent and 
exposed to X-ray film. After exposure, membranes were stripped by stripping buffer 
(Appendix 4) at 50°C for 15 minutes, washed for 3 times, incubated with blocking buffer 
for 1 hour and washed for another6 times. The stripped membranes were prepared for the 
second- time incubation of primary antibodies, including IKKβ (1:2000), IκBα(1:600) and 
β-Tublin used as internal control(1:3000). These membranes were also incubated with the 
second antibody, including anti-rabbit antibody (1:2000) or anti-mouse antibody (1:3000) 
for 2 hours. 
2.2.2.6 NF-κB Reporter Assay 
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Macrophage-like U937 cells were seeded in 24-well plate (2.5x 105/well). After 24h, 
refresh medium with 500μl Opti-MEM® containing 1.5μl attractene transfection reagent 
(QIAGEN Pty. Ltd.) and 0.6μg NF-κB promoter-firefly/Renilla luciferase (40/1)/negative 
control/positive control (QIAGEN Pty. Ltd.) each well. After 18 hours incubation, 
refreshed the cell with normal culture medium for another 6 hours, and then refreshed the 
medium with 1μg/ml LPS. After 6 hours, the cells were rinsed with cold PBS and lysed 
with 100μl reporter lysis buffer (Promega) in each well. The lysate was centrifuged at 
15,000 × g for 5 minutes at 4°C, and the supernatant was harvested.  Both firefly and 
Renilla luciferase levels were measured by a luminometer using the Dual-Glo® Luciferase 
Reporter Assay System (Promega Australia). 
2.2.2.7 PDE Assay 
Macrophage-like U937 cells were seeded in 6-well plates (2x 106/well). After 24h, cells 
were treated with or without 10μM Rolipram394, following incubation with 1μg/ml LPS for 
4 hours. The medium were aspirated and the cells washed with ice-cold PBS, which was 
then aspirated before lysis buffer was added. The lysis buffer used to extract PDE for PDE 
assay was made from 50 mM Tris (pH 7.5), 1.5 mM EDTA, 1 mM benzamidine, 0.1 mM 
sodium orthovanadate, 1 mM DTT and supplemented with a protease inhibitor cocktail for 
use with mammalian cells. Lysis was allowed to progress on ice for 1 hour before gentle 
agitation. The homogenate was subjected to centrifugation 10 minutes at 12,000xg (4°C) 
and the supernatant was stored at –80°C for further analysis. 
PDE activity was determined using the method described by Thompson and Appleman 
two-step procedures with modification394-396. Briefly, cells were incubated with the 
incubation mixture and treated with various test agents (0.1 ml/sample) at 30°C for 10 
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minutes. The incubation mixture (0.4 ml) contained 1 μM cAMP, [3H]cAMP in 40 mM 
Tris-Cl buffer (pH 8.0) containing 3.75 mM β-mercaptoethanol and 15 mM MgCl2. The 
reaction was terminated by incubation for 1 minute in a boiling water bath, and the 
crotalus atrox snake venom was added for 5-min incubation at 30°C. The hydrolyzed 
nucleotide was separated using an A-25 anion exchange resin column. The reaction 
combined with scintillation cocktail, which was quantified by scintillation counting. 
Protein concentration was determined using the Bradford method. 
2.3 Statistical Analysis 
All values presented are mean ± SEM of the given number (n) of experiments. The two-
group comparison was conducted by Student’s t-test. The multi-group comparisons were 
conducted by one-way analysis of variance (one-way ANOVA) followed by Bonferroni’s 
test. P values of 0.05 or less were considered to be statistically significant and tests were 
performed using GraphPad Prism version 5.0 Software (GraphPad Software, Inc La Jolla, 
CA). 
2.4 Results 
2.4.1 Release of Cytokines in LPS and CSEM Induced Cell Models 
In unstimulated macrophage-like U937 cells, the basal level of TNF-α was barely 
detectable. Cells treated with LPS (1μg/ml) or CSE (20%) significantly increased the 
release of TNF-α. There is a significant increase in TNF-α release (600 and 500-fold) in 
cells after the treatment with LPS(6 hours) or CSE(18 hours) respectively, compared  with 
the blank control (p<0.001; Fig.2-1-A). There was no statistically difference between LPS 
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and CSEM on TNF-α release (p>0.05; Fig.2-1-A). In addition, LPS also significantly 
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Figure 2-1 Release of TNF-α induced by LPS&CSE and the release of IL-1β & IL-6 
induced by LPS in macrophage-like U937 cells. 
Macrophage-like U937 cells were treated with or without 1ug/ml LPS for 6 hours; or 
treated with or without CSE (20%) for 18 hours. The concentration of TNF-α (A), IL-1β 
and IL-6(B) were tested by ELISA. Data represent the mean ±SEM (n=3) performed in 
duplicate. *p < 0.001 Vs blank vehicle by Student’s t-test. Student’s t-test also was used to 
compare the difference between LPS and CSE group. 
2.4.2 Production of cAMP in LPS Induced Macrophage-Like U937 Cells 
Macrophage-like U937 cells treated with LPS (1μg/ml) for 6 hours had a significant higher 


















Macrophage‐like U937  cells were  treated with or without 1μg/ml  LPS  for 6 hours. The 
level  of  cAMP  was  tested  by  EIA  method.  Data  represents  the  mean±SEM  (n=3) 
performed in duplicate. *p < 0.05 Vs blank vehicle by Student’s t‐test. 
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2.4.3 Expression of Phosphorylated Proteins in NF-κB and cAMP Pathways in LPS 
Induced Macrophage-Like U937 Cells 
To confirm the involvement of the activation of IKK, IκBα, p65 and CREB in LPS 
induced macrophage-like U937 cells, the time course of expressions of p-IKK, p-IκBα, p-
p65 and p-CREB were analysed by Western blot. Stimulation with LPS (1μg/ml) induced 
a rapid phosphorylation of IKK as early as 5 minutes, with the maximal activity was 
observed at 15 minutes. Similarly, the activated IκBα was appeared at 5 minutes, and the 
maximal activity of at 30 minutes. LPS increased the expression of p-p65 in a time-
dependent manner; with the maximal effect at 30 minutes and then declined after 30 
minutes. The expression of p-CREB was not significantly changed at 5 and 15 minutes, 
but it was increased at 30 minutes, and this increase was sustained at 60 minutes. (Fig.2-3) 
 
Figure 2‐3   Expression of Phosphorylated Proteins  in NF‐κB and cAMP Pathways  in LPS 
Induced Macrophage‐Like U937 Cells.  
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Macrophage-like U937 cells were treated with or without LPS (1μg/ml) at 5, 15, 30, 60 
minutes. The expression of p-IKK, p-IκBα, p-p65 and p-CREB were analysed by western 
blot using p-IKK, p-IκBα, p-p65 and p-CREB antibodies as described in the methods. Β-
Tublin was used as a loading control. 
2.4.4 Effects of Bay11-7028 and Foskolin on the Expression of Proteins in NF-κB and 
cAMP Pathways in LPS Induced Macrophage-Like U937 Cells 
Bay11-7082, but not Foskolin, significantly inhibited the expression of p-IKK, p-IκBα, p-
p65 and IKK, IκBα, p65 induced by LPS (p<0.001, p>0.05; Fig. 2-4-A&B). Foskolin 
statistically increased the expression of p-CREB (p<0.001), but not CREB (p>0.05) 
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Figure 2-4 Effects of Bay11-7028 and Foskolin on the Expression of Proteins in NF-κB 
and cAMP Pathways in LPS Induced Macrophage-Like U937 Cells. 




corresponding antibodies as described  in  the methods.  Β‐Tublin was used as a  loading 
control.  Data  represents  the  mean  ±  SEM  (n=3).  *p<0.001,  Vs  control  vehicle  using 
Student’s t‐test. 
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2.4.5 Effect of NF-κB and cAMP Pathways on the Release of TNF-α by LPS Treated 
Macrophage-Like U937 Cells 
The activated NF-κB and cAMP pathways were associated with increased TNF-α 
production by LPS, the effects of Bay11-7082, the inhibitor of NF-κB pathway (1, 10 and 
100μM) and Foskolin, the elevator of cAMP pathway (0.1, 1 and 10μM) on  the release of 
TNF-α were tested with or without LPS (1μg/ml) treatment. BAY11-7082 significantly 
inhibited the release of TNF-α at 10μM and 100μM (p<0.001; Fig.2-5-A). Foskolin also 
statistically inhibited TNF-α release at 1μM (p<0.01) and 10μM (p<0.001; Fig.2-5-A). At 
100μM, BAY11-7082 almost completely inhibited the LPS-induced release of TNF-α (Fig. 
2-5-A). At 10 μM, both Bay11-7082 and Foskolin reduced 70% the release of TNF-α 
induced by LPS (Fig. 2-5-A). The presence of Bay11-708(10μM) and Foskolin (10μM) 
caused a further inhibition of TNF-α release (p<0.001), and the inhibition of Foskolin 
(10μM) was significantly reduced by H89 (2μM; Fig. 2-5-B), an antagonist of cAMP 
pathway. In addition, in order to investigate the role of PDEs on LPS-induced TNF-α 
release, the effects of specific PDE inhibitors (PDE3 inhibitor, Cilostamid; PDE4 inhibitor, 
Rolipram and PDE5 inhibitor, Sildenafil) on the release of TNF-α were studied. 
Macrophage-like U937 cells were treated with LPS (1μg/ml) in the absence or presence of 
Cilostamid, Rolipram and Sildenafil (0.1μM, 1μM and 10μM) for 6 hours. Rolipram, a 
cAMP-specific PDE inhibitor, significantly inhibited the release of TNF-α at all 
concentrations tested (p<0.001). Cilostamid, an inhibitor of cAMP & cGMP PDE, only 
reduced the release of TNF-α at 0.1μM (p<0.001). In contrast, Sildenafil, a cGMP PDE 
inhibitor, had no significant effect at 0.1 and 1 μM, but increased the release of TNF-α 
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Figure 2-5  Effect of NF-κB and cAMP pathways on the release of TNF-α by LPS treated 
macrophage-like U937 cells. 
 Macrophage-like U937 cells were treated with or without LPS(1μg/ml) in absence or 
presence of Bay11-7082(1μM, 10μM, 100μM), Foskolin (0.1μM, 1μM, 10μM)(A), Bay11-
7082(10μM)&Foskolin (10μM), Foskolin (10μM) &H89(2μM)(B), Cilostamide (0.1μM, 
1μM, 10μM), Rolipram (0.1μM, 1μM, 10μM) or Sildenafil (0.1μM, 1μM, 10μM) (C) for 6 
hours. The concentration of TNF-α was tested by ELISA. Data represents the mean±SEM 
(n=3) in duplicate.  *p < 0.05; **p < 0.01; ***p < 0.001, Vs control vehicle, by one-way 
ANOVA followed by Bonferroni’s test. # p<0.001, Vs Bay11-7081&Foskolin treatment 
vehicle by one-way ANOVA followed by Bonferroni’s test. Δ p<0.001, Vs Foskolin&H89 
treatment vehicle by ne-way ANOVA followed by Bonferroni’s test. 
2.4.6 Effect of NF-κB and cAMP Pathways on the Transcriptional Activity of NF-κB in 
LPS Induced Macrophage-Like U937 Cells 
In order to investigate the involvement of NF-κB and cAMP pathways in the 
transcriptional activity of NF-κB induced by LPS, the effects of Bay11-7028, Foskolin and 
H89 on the transcriptional activity of NF-κB induced by LPS were determined.  
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Macrophage-likeU937 cells were pre-treated with or without LPS (1μg/ml) in absence or 
presence with Bay11-7082(10μM), Foskolin (10μM), H89(2μM), Bay11-
7082(10μM)&Foskolin (10μM) or Foskolin (10μM)&H89(2μM) for 6 hours. LPS 
increased 90% transcriptional activity of NF-κB, and this was significantly inhibited by 
Bay11-7082(p<0.001) and Foskolin (p<0.001) respectively.  There was no significant 
difference of the effect between Bay11-7082 and Foskolin (p>0.05). Bay11-7082 plus 
Foskolin further inhibited the transcriptional activity of NF-κB induced by LPS 
(p<0.05,p<0.001). H89, an inhibitor of cAMP pathway, didn’t affect the transcriptional 
activity of NF-κB induced by LPS (p>0.05). However, it significantly weakened the effect 
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Figure 2-6  Effect of NF-κB and cAMP Pathways on the Transcriptional Activity of NF-
κB in LPS Induced Macrophage-Like U937 Cells. 
Macrophage-like U937 cells were treated with or without LPS(1ug/ml) in absence and 
presence with Bay11-7082(10μM),  Foskolin (10μM),  H89(2μM),  Bay11-
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7082(10μM)+Foskolin(10μM) or Foskolin(10μM)+ H89(2μM) for 6  hours. The 
transcriptional activity of NF-κB was measured by the Dual-Glo® Luciferase Reporter 
Assay System. Data represent the mean ± SEM (n=3) in duplicate. *<0.001, Vs blank 
vehicle Student t-test. #<0.001, Vs control vehicle by one-way ANOVA followed by 
Bonferroni’s test. Δ<0.05; ΔΔp< 0.001, Vs Bay11-7082+Foskolin vehicle by one-way 
ANOVA followed by Bonferroni’s test. δ< 0.001, Vs Foskolin vehicle by one-way 
ANOVA followed by Bonferroni’s test. 
2.4.7 PDE4 Activity in LPS Induced Macrophage-Like U937 Cells 
PDE4 activity in LPS-induced U937 cells were studied using a specific PDE4 inhibitor 
Rolipram. Cells pre-treated with Rolipram (30μM) for 2 hours, then treated with 





























Figure 2-7  PDE4 Activity in LPS Induced Macrophage-Like U937 Cells.  
Cells were pre-treated with or without Rolipram(30μM) for 2 hours, and then treated with 
or without LPS(1μg/ml) for 4 hours.  PDE4 activity was quantified by scintillation 
counting. Data represents the mean ± SEM (n=3) performed in duplicate. *p<0.001, Vs 
blank vehicle by Student t-test. 
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2.5 Discussion  
LPS and CSE induced macrophage-like U937 cells have been frequently used as the 
inflammatory cell model to study the pathogenesis of COPD46,300. Findings from our study 
showed that both LPS and CSE caused a massive release of TNF-α in macrophage-like 
U937 cells (600-fold and 500-fold increase), which is consistent with previous 
studies46,393,397. In addition, LPS also significantly increased the release of IL-1β and IL-6. 
The findings on the activation of IKK, IκBα, p65, and the increased transcriptional activity 
of NF-κB by LPS indicate that NF-κB pathway is significantly activated in LPS induced 
macrophage-like U937 cells. Overall, these results suggest that LPS and CSE inducing 
macrophage-like U937 cell models are suitable for studying the inflammatory mechanisms 
related to TNF-α and NF-κB pathways. In addition, the present study also observed that 
LPS elevated cAMP levels and increased the expression of activated p-CREB and PDE4 
activity, indicating that cAMP pathway is also activated by LPS, which is also consistent 
with previous studies394,398,399. 
The effects of activated NF-κB and cAMP pathways on the release of TNF-α induced by 
LPS  is further supported by the findings of using NF-κB pathway inhibitor (Bay11-7082), 
cAMP pathway elevator (Foskolin) and cAMP pathway inhibitor(H89). The activated 
cAMP pathway seems to involve in the regulation of TNF-α release induced by LPS, as 
Foskolin reduced the release of TNF-α and this effect was blocked by H89. There seems to 
be a synergy effect between the inhibited NF-κB pathway and the activated the cAMP 
pathway on the release of TNF-α induced by LPS, as Foskolin further enhanced the action 
of Bay11-7082 on TNF-α release  and both of them almost abolished the release of TNF-α 
induced by LPS .   
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The effect of activated cAMP pathway on the transcriptional activity of NF-κB induced by 
LPS was also demonstrated in this part of my project. Foskolin showed no effect on the 
expression of IKK, IκBα and p65, but it significantly inhibited the transcriptional activity 
of NF-κB induced by LPS, and this inhibition of activity was almost completely eliminated 
by H89. It indicated that the activated cAMP pathway inhibited the transcriptional activity 
of NF-κB induced by LPS, but not through down-regulating the expression of the key 
proteins in NF-κB pathway, which was consistent with previous studies279,280. In addition, 
there seems to be a synergy effect between the inhibited up-stream activity of NF-κB 
pathway and the activated the cAMP pathway on the transcriptional activity of NF-κB 
induced by LPS, as Foskolin further elevated the inhibition of Bay11-7082 on the 
transcriptional activity of NF-κB and both of them almost completely inhibited the 
transcriptional activity of NF-κB.   
In addition, we also showed that Bay11-7082 not only inhibited the expression of total 
IKK, but also non-specifically inhibited the expression of p-IκBα, p-IKK, p-p65 IκBα and 
p65. Interestingly, IκBα as a stable factor binding with NF-κB to inhibit the activation of 
NF-κB (see Section1.1.4.4), was also inhibited by Bay11-7082. Previous study proved that 
down-regulating expression of IκBα can elevate the activity of NF-κB pathway. Our 
results indicate that there is a bidirectional regulation of Bay11-7082 on the activity of NF-
κB pathway. 
There is evidence that PDE4 plays an important role in the production of TNF-α in 
macrophages induced by LPS. It has been reported that there was a 90% decrease in TNF-
α mRNA accumulation in the LPS inducing macrophages from PDE4B-deficient mice394. 
Rolipram (PDE4 inhibitor) also significantly inhibited the release of TNF-α in 
macrophages induced by LPS and in vivo400,401. The effect of Cliostamide (PDE3 inhibitor) 
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on LPS-inducing release of TNF-α in macrophages has not been reported, although some 
studies showed that Cliostamide significantly inhibited the production of TNF-α in 
HUVECs induced by LPS, this result also was proved in vivo 402. On the other hand, 
sildenafil was shown to have no effect on the release of TNF-α in ovalbumin (OVA) 
challenged mice403. In the present study, it was found that LPS significantly increased the 
PDE4 activity in macrophage-like U937 cells, Rolipram and Cliostamide but not Sildenafil 
significantly inhibited the release of TNF-α induced by LPS. These findings are consistent 
with previous observations, confirming the involvement of mainly PDE4, also PDE3 but 
not PDE5 in LPS-induced cytokine release in macrophage-like U937 cells. The reason for 
a slight increase of TNF-α production by high concentration of sildenafil is not clear. One 
possibility is that the down-steam product of PDE5, cGMP, may have an opposite effect of 
cAMP to regulate TNF-α release404. Further study is necessary to elucidate the exact 
mechanism involved.  
In summary, LPS inducing macrophage-like U937 cells exhibited an elevated cytokine 
levels and activated NF-κB pathway which is the main source of TNF-α production. LPS 
also activates cAMP and PDE4 pathways to regulate cytokine release to avoid the excess 
production of inflammatory mediators. These findings indicate that this cell model is ideal 
for studying the mechanism involved in the regulation of cytokines and related NF-κB and 
cAMP pathways, as well as the effects of ginseng and ginsenosides on inflammatory 
mediators relevant to COPD. 
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Chapter 3. Regulation of Ginseng and Ginseng-Related Products on 
Cytokines  
3.1 Introduction 
Ginseng is a well-known medicinal herb which has been widely used in the treatment of 
COPD and other conditions (see Section1.2.3). Ginseng and ginseng related products, such 
as G115 and some ginseng formulas have been shown in clinical trials with significant 
improvement on lung function and quality of life of COPD patients182,336. However, the 
pharmacological mechanism of G115 and ginseng formula in COPD is still not clear. 
Given the importance of inflammation in the pathogenesis mechanisms of COPD, it is 
possible that the anti-inflammatory effect of ginseng may play an important role in its 
therapeutic efficacy on COPD. The support evidence is that ginsenosides, the major active 
components of ginseng and G115, have been demonstrated with anti-inflammatory actions 
(see Section1.2.4.7). 
One of the key inflammatory mediators involved in COPD is cytokine, such as TNF-α, IL-
1β and IL-6, which plays an important role in  inducing, maintaining and amplifying the 
inflammatory response in COPD13. Previous studies have demonstrated that inhibiting the 
release and activity of cytokines improved the symptom of COPD patients (see 
Section1.1.3). However, there is certain deficiency in the study on the effects of ginseng 
and ginseng related products on the release of cytokine. Firstly, most previous studies used 
individual ginsenosides, often ignored their metabolites. It has been known that the 
absorption of some ginsenosides through the gastrointestinal tract is very low in vivo326,405. 
For some ginsenosides, such as Rb1, the metabolites are more important in mediating the 
biological effects of ginseng in vivo405. Secondly, there is deficiency in the study on the 
correlation between the regulation of the ginseng and ginseng formula on the release of 
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cytokines. Therefore, we are difficult to determine that the regulation of ginseng formula 
on cytokines is related to that of ginseng. 
Thus, the objective of the study described in this chapter was to investigate the effects of 
ginseng, ginseng formulas and ginsenosides on the release of cytokines in the established 
inflammatory cell model as described in Chapter2. The specific research aims were to 
investigate the effect of different kinds of GHMFs, G115 and ginsenosides on the release 
of TNF-α and other cytokines (IL-1β and IL-6) in LPS-induced macrophage-like U937 
cells, and the study possible correlations of their actions.  
3.2 Materials and Method 
3.2.1 Materials 
All herbal compounds tested were the highest grade (purity > 99%) available from Chinese 
National Institute for the Control of Pharmaceutical and Biological Products (Beijing, 
China). GHMFI & II were obtained from Guangdong Provincial Hospital and GHMFIII 
&IV were prepared by Mr Xifeng Zhai from the Chinese medicine research laboratory at 
RMIT University. G115 was supplied by Pharmaton SA (Switzerland). The details of other 
materials are described in section 2.2.1 
3.2.2 Method 
3.2.2.1 Cell culture 
See Section 2.2.2.1 
3.2.2.2 Preparation of Cigarette Smoke-Treated Medium 
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See Section 2.2.2.2 
3.2.2.3 Cytokines Assay 
PMA induced Macrophage-like U937 cells were treated with Rb1, Rg1, Rg3, Rh1, Rh2, 
CK (1, 10 and 100μM), GHMF-I, GHMF-II(0.1, 1 and 10mg/ml), GHMF-III and GHMF-
IV, G115(0.01, 0.1 and 1mg/ml) or vehicles for 2 hours, and with LPS (1μg/ml) for 6 
hours. The supernatant of the test samples was collected to determine the concentrations of 
TNF-α, IL-1β and IL-6 using ELISA kits, according to the manufacturer’s protocol. Other 
details see section 2.2.2.3. 
3.3 Statistical Analysis 
All values are presented as mean ± SEM of the given number (n) of experiments. The two-
group comparison was conducted by Student’s t-test. The multi-group comparisons were 
conducted by one-way ANOVA followed by Bonferroni’s test or by Tukey’s post hoc 
according different aims. Correlation analysis was performed to determine the relationship 
between G115 and GHMF-III on the release of TNF-α in different cell models. P values of 
0.05 or less were considered to be statistically significant and tests were performed using 
GraphPad Prism version 5.0 software (GraphPad Software, Inc La Jolla, CA). 
3.4 Result 
3.4.1 Effects of GHMFs on the Release of TNF-α in LPS induced macrophage-like U937 
cells 
The release of TNF-α from macrophage-like U937 cells was significantly inhibited by all 
GHMFs tested (0.1, 1 and 10mg/ml for GHMF-I and GHMF-II, and 0.01, 0.1 and 1mg/ml 
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for GHMF-III and GHMF-IV) (p<0.001; Fig 3-1). The most effective concentration of 
GHMF-I and GHMF-II was at 1mg/ml. GHMF-I demonstrated more potent  inhibition on 
TNF-α release than GHMF-II at 10mg/ml, but not at 1mg/ml (p<0.001; Fig.3-1-A). The 
most effective concentration of GHMF-III and GHMF-IV was at 1mg/ml, and GHMF-III 
showed more potent inhibition on TNF-α release than GHMF-IV at any concentration 
(P<0.01), especially at 0.1mg/ml and 1mg/ml (p<0.001, Fig.3-1-B). At 1mg/ml, GHMF-III 


















































































Figure 3-1 Effects of GHMFs on the Release of TNF-α in LPS induced macrophage-like 
U937 cells.  
Macrophage-like U937 cells were treated with different concentrations (0.01-10 mg/ml) of 
GHMFs or vehicles. GHMF were composed by the commercial herbal extracts (A), or 
raw-herbs (B). Cells were treated with test agents for 2 hours, and then induced by 
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LPS(1μg/ml)  for 6 hours. The effect of GHMF-I and GHMF-III on the release of TNF-α 
was also compared at 1mg/ml (C). The concentration of TNF-α was tested by ELISA. Data 
represent the mean±SEM (n=3) in duplicate.  *p < 0.001, Vs control vehicle by one-way 
ANOVA followed by Bonferroni’s test. #<0.01; ##p < 0.001, Vs GHMF-I and Δ<0.01; 
ΔΔ<0.001,Vs GHMF-III at the same concentration by one-way ANOVA followed by 
Tukey’s post hoc test.  
3.4.2 Effects of GHMF-III and G115 on the Release of TNF-α in macrophage-like U937 
cells Induced by LPS or CSE 
After the pre-treatment of cells with G115 (0.01, 0.1 and 1mg/ml) for 2 hours and then 
stimulation with LPS for another 6 hours, the release of TNF-α was significantly inhibited 
by G115 at 0.01mg/ml (p<0.05,p<0.01), 0.1mg/ml (p<0.001) and 1mg/ml(p<0.001). The 
most effective concentration of G115 is at 1mg/ml, which was more potent than that at 
0.01mg/ml (p<0.001). No significant differences between the inhibitions of G115 and 
GHMFIII on the LPS-induced TNF-α release at the same concentration were observed 
(p>0.05; Figure3-2-A). In CSE induced cell model, G115 and GHMF-III significantly 
decreased the level of TNF-α at 0.1mg/ml and 1mg/ml (p<0.001). At 0.01mg/ml, GHMF-
III but not G115 statistically inhibited the release of TNF-α (P<0.001). GHMF-III 
demonstrated more powerful inhibition than G115 at 0.01mg/ml (p<0.001) and at 
0.1mg/ml (p<0.01; Fig.3-2-B). The correlation between the effects of GHMF-III and G115 
on the release of TNF-α in LPS or CSE inducing cell models was conducted. There was a 
significant correlation between the effects of GHMF-III and G115 on the release of TNF-α 
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Figure 3-2 Effects of GHMF-III and G115 on the Release of TNF-α in macrophage-like 
U937 cells Induced by LPS or CSE.  
After treatment with or without G115 or GHMF-III (0.01, 0.1 and 1mg/ml) for 2 hour, 
macrophage-like U937 cells were induced by LPS(1μg/ml)(A) or CSE (20%)(B) in 
absence or presence for 6 or 18 hours respectively, The concentration of TNF-α was tested 
by ELISA. Data represent the mean ± SEM (n=3) in duplicate.  *p < 0.05; **p < 0.01; 
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***p < 0.001, Vs control (LPS or CSE) vehicle by one-way ANOVA followed by 
Bonferroni’s test. # p<0.001, Vs G115 or GHMF-III at 1mg/ml by one-way ANOVA 
followed by Bonferroni’s test. Δ p < 0.001; ΔΔp< 0.001, Vs G115 at the same 
concentration by one-way ANOVA followed by Tukey’s post hoc test.  Correlation 
analysis was performed to determine the relationship between G115 and GHMF-III on the 
release of TNF-α in different cell models. 
3.4.3 Effects of Ginsenosides and Their Metabolites on the Release of TNF-α in 
Macrophage-Like U937cells Induced by LPS. 
In order to investigate the effects of main active components of G115 on the release of 
TNF-α, cells were treated with ginsenoside Rb1, Rg1, Rg3 and their metabolites( CK, Rh1 
and Rh2) at 0.1, 1 and 1μM for 2 hours and then stimulated with LPS for another 6 hours. 
Ginsenoside Rb1 significantly inhibited the release of TNF-α at 1μM (p<0.05) and 10μM 
(p<0.01), but not at 100μM (p>0.05). Its metabolites, CK, also significantly inhibited the 
TNF-α release at 10μM (p<0.05) and 100μM (p<0.01), but not at 1μM (p>0.05) (Fig.3-3-
A). Both Rg1 and its metabolite (Rh1) significantly inhibited the release of TNF-α at 
10μM (p<0.01; p<0.05) and at 100 μM (P<0.001), but not at 0.1μM (p>0.05, Fig.3-3-B). 
There was no significant difference in the effects of Rb1/Rg1 and its metabolite(CK/Rh1) 
at any concentrations (p>0.05, Fig.3-3-A&B). Similarly, Rg3 significantly inhibited TNF-
α release at 1μM (p<0.01) and 10μM (p<0.001), but not at 100μM (p>0.05).  The 
metabolite (Rh2) had no effect on the release of TNF-α at 1μM and 10μM (p>0.05). At 
100μM, Rh2 enhanced the release of TNF-α (p<0.01, Fig.3-3-C). Ginsenoside Rb1 and 
Rg3 display more powerful inhibitions on the release of TNF-α at 10μM than at 100μM, 
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Figure 3-3 Effects of Ginsenosides and their metabolites on the release of TNF-α in LPS 
induced macrophage-like U937 cells. 
Macrophage-like U937 cells were treated with different concentrations (1μM, 10μM, 
100μM) Rb1 / CK(A), Rg3 / Rh2(B) or  Rg1 / Rh1(C) or vehicle for 2 hours, and then 
induced by LPS (1ug/ml)for 6 hours. The concentration of TNF-α was tested by ELISA. 
Data represent the mean±SEM (n=3) in duplicate.  *p < 0.05; **p < 0.01; ***p < 0.001, 
Vs control vehicle by one-way ANOVA followed by Bonferroni’s test. One-way ANOVA 
followed by Tukey’s post hoc test was used to test the difference between the effects of 
ginsenosides and its metabliltesat any concentrations. 
3.4.4 Effects of GMHM-III, G115, Rb1 and Rg1 on the Release of IL-1β and IL-6 in 
Macrophage-Like U937 Cells Induced by LPS. 
In order to investigate the effects of G115, GHMF-III, Rb1 and Rg1 on the release of other 
cytokines, cells were treated with GHMF-III(1mg/ml), G115(1mg/ml), Rb1(10μM) or 
Rg1(10μM) for 2 hours, and then stimulated with LPS(1μg/ml) for another 6 hours. The 
secretion of IL-1β was significantly inhibited by GHMF-III (p<0.001), G115 (p<0.001), 
Rb1 (p<0.05) and Rg1 (P<0.01) compared with the control group. There was no significant 
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difference in the effects of these agents (p>0.05; Fig. 3-4-A). The secretion of IL-6 
induced by LPS was also significantly inhibited by GHMF-III (p<0.001), G115 (p<0.01), 
Rb1 (p<0.001) and Rg1 (P<0.001). GHMF-III and Rg1 displayed the more powerful 
inhibition on the release of IL-6 than G115 (p<0.05; Fig. 3-4-B). 
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Figure 3-4  Effects of GHMF-III, G115, Rb1 and Rg1 on the release of IL-1β and IL-6 in 
LPS induced macrophage-like U937 cells. 
The concentrations of IL-1β(A) and IL-6(B) were determined by ELISA. Data represent 
the mean ± SEM (n=3) in duplicated.  *<0.05; **p < 0.01;  ***p < 0.001, Vs control 
vehicle by Bonferroni’s test. One-way ANOVA followed by Tukey’s post hoc test was 
used to test the different regulation among GHMF-III, G115,Rb1 and Rg1 on the release of 
TNF-α, # p<0.05. 
3.5 Discussion 
As mentioned in Chapter 1, the key pathological mechanism of COPD is consistent 
inflammation of the lung and airway, and cytokines play an important role in this process 
(see Section 1.1.3). It has been shown that TNF-α leads to the amplification of 
inflammation, emphysema and the weight loss of COPD50,171,172. TNF-α inhibitors, as 
powerful drugs against inflammatory response, have been used in the treatment of 
COPD176. However, the side effect, medical cost and uncertain efficacy have affected their 
clinical application in COPD180,181. Therefore, identifying other agents with actions of 
TNF-α inhibition may help to improve the current therapies for COPD. In this regard, the 
present study has found for the first time that ginseng and several ginseng formulas 
inhibited TNF-α release from macrophage-like U937 cells induced by LPS. The inhibition 
of LPS induced cytokine release by ginseng and ginseng formula is further supported by 
the finding that ginseng and ginseng formula as well as ginsneosides also inhibited IL-1β 
and IL-6 release induced by LPS, indicating they may act through inhibition of NF-κB 
pathway (Further evidence on that will be discussed in Chapter 4).These findings provide 
supporting evidence at cell level for the use of ginseng and ginseng related products for 
treating COPD.  
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Among several ginseng formulas tested, GHMF-III showed more effective inhibitory 
effect on the release of TNF-α than other formulas (p<0.01). GHMF-III is a GHMF 
excluding polysaccharide. It is possible that polysaccharide in the ginseng extracts may be 
responsible for such difference. Previous studies have demonstrated that polysaccharides 
can up-regulated the product of many inflammatory factors such as TNF-α, IL-1β, IL-6, 
IL-12, GM-CSF and IFN-γ to aggravate the inflammatory response406-408, so the 
polysaccharides in GHMF-I, II and IV may actually weaken the anti-inflammatory action 
of these formulas. In addition, GHMF-I demonstrated more significant inhibition on the 
release of TNF-α than GHMF-II. The difference between GHMF-I and GHMF-II may be 
caused by the different content of active components in each GHMF. Further study is 
necessary to determine the contents of active components in these formulas.  
G115, a standardized extract of ginseng, and GHMF-III showed a significant inhibition on 
the release of TNF-α in LPS and CSE induced macrophage-like U937 cells. Previous study 
demonstrated that G115 significantly increased the release of TNF-α in LPS induced 
animal model329. There may be an opposite regulation of G115 on the release of TNF-α in 
vivo and in vitro. The present study also found a correlation between the effect of GHMF-
III on the release of TNF-α and that of G115 in both LPS and CSE cell models, indicating 
the main active component of GHMF-III is likely to be similar to that of G115.  In addition, 
GHMF-III showed a more powerful inhibition on the secretion of TNF-α than G115 in 
CSE but not LPS- cell model, indicating it may more suitable for the treatment of cigarette 
smoking induced inflammation.  
Given the ginsenosides are the main active compounds for ginseng (G115) and GHMF-III, 
the present study also investigated the effects of different ginsenosides on LPS-induced 
cytokine release. Ginsenosides Rb1 and Rg3 significantly inhibited the release of TNF-α at 
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a non-concentration-dependent manner. Ginsenosides Rg1 significantly inhibited the 
release of TNF-α at a concentration-dependent manner. These results were similar to 
previous studies184,351,380,382,383. The difference of inhibition among Rb1, Rg3 and Rg1 may 
be caused by the difference of absorption rate of them, as previous study showed that the 
gastrointestinal-tract absorption rate of Rg1 was higher than that of Rb1 and Rg3405. As a 
proof of this guess, the metabolite of Rb1, CK displayed the similar concentration-
dependent inhibition on the release of TNF-α with Rg1. The metabolite of Rg1 (Rh1) also 
inhibited the release of TNF-α induced by LPS at a concentration-dependent manner. In 
contrast, the metabolite of Rg3 (Rh2) didn’t affect TNF-α release at low concentrations, 
but enhanced the release of TNF-α at high concentration. However, this result is not 
consistent with previous studies, as Rh2 was found to inhibit the release of TNF-α in LPS/ 
INF-γ inducing murine BV2 microglial cells, and in the ears tissue from the rat induced by 
oxazolone383,384,409. It is not clear whether such difference is due to different cell type 
involved. Comparing the inhibition of ginsenosides and their metabolits, we found there 
was a similar inhibition on TNF-α between Rg1 and Rh1; the difference of inhibition 
between Rb1 and CK seemed to be related with the low absorption rate of Rb1. However, 
it is still uncertain that the up-regulating mechanism of Rh2 on TNF-α induced by LPS. 
In summary, the present study demonstrated that ginseng and several ginseng formulas 
significantly inhibited LPS and CSE induced the release of TNF-α and/or other cytokines 
from macrophage-like U937 cells. Among these, GHMF-III and G115 are the most 
effective. The actions of ginseng and ginseng formula are likely to be mediated by the 
active compounds ginsenosides. Among the ginsenosides studied, Rb1, Rg3 and Rg1 may 
be the main contributors to the actions of ginseng. Further study is warranted to investigate 
if the effects of GHMF-III, G115, Rb1 and Rg1 on cytokine release are through inhibition 
of NF-κB pathway. 
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Chapter 4. Regulation of G115, GHMF-III and Ginsenosides on NF-κB 
Pathway 
4.1 Introduction 
NF-κB is the key transcriptional factor which regulates the transcription of many 
inflammatory factors/proteins involved in COPD235, such as TNF-α, IL-IL-1β and IL-
6410,411.  Findings as described in the Chapter 3 have demonstrated that G115, GHMF-III, 
Rg1, Rb1, Rg3, CK, Rh1 significantly inhibited the production of TNF-α induced by LPS. 
Moreover, the inhibition of G115, GHMF-III, Rb1 and Rg1 on TNF-α release was 
accompanied by a significant inhibition of IL-1β and IL-6 release induced by LPS.  These 
findings indicate that ginseng and ginsenosides may inhibit the TNF-α release through 
down-regulating the activation of NF-κB. Thus, we hypothesise that ginseng and 
ginsenosides inhibit the release of TNF-α through decreasing the activity of NF-κB 
pathway in LPS induced macrophage-like U937 cells.  
LPS activates NF-κB through a series of phosphorylation reactions (PRs), including the 
phosphorylation of IKK, IκBα and NF-κB412. Phosphorylated IKK can activate IκBα, and 
then activate NF-κB. In the study described in the last Chapter3, the inhibitor of IKK 
(Bay11-7082) almost completely inhibited the release of TNF-α induced by LPS, 
indicating that PRs are likely to be involved in the cellular generation of TNF-α. Evidence 
from previous studies suggests that ginseng/ginsenosides may regulate NF-κB pathway. 
For example fermented ginseng significantly inhibited the expression of p-IκBα345; 
ginsenosidesRb1, Rb2, Rd, Rg1 and the metabolits of ginsenosides(CK and Rh2)also 
significantly inhibited the expression p-IκBα340,184,341; in addition, the expression of p-IKK 
was also down-regulated by CK and Rh2341. However, the regulating mechanism of G115, 
GHMF-III, Rg1, Rb1, Rg3, CK, Rh1 and Rh2 on PRs in NF-κB pathway was still 
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uncertain. As in these PRs, the activation of any upstream protein (IKK, IκBα), finally 
resulting in the activation of NF-κB, if we want to confirm initiator-protein which is 
triggered by the ginseng and ginseng-related products, we should screen the effect of them 
on the expression of all total proteins and their corresponding phosphorylated products in 
these PRs. However, there is no one paper that comprehensively analysed the regulation of 
G115, GHMF-III, Rg1, Rb1, Rg3, CK, Rh1 or Rh2 on the protein expression in these PRs.   
In the NF-κBpathway, activated NF-κB needs to be transmitted into the nucleus to achieve 
its transcriptional activity. Transcriptional activity of NF-κB is another important 
regulating target in NF-κB pathway. It displays the terminal action of NF-κB pathway, and 
can be regulated by various factors including cAMP dependent pathway279,280.  Previous 
studies showed that activated CREB, the downstream factor of cAMP-dependent pathway, 
competitively inhibited transcriptional activity of NF-κB9,10. Similarly, as described in 
Chapter 3, Foskolin(the elevator of cAMP) reduced the LPS-induced TNF-α production 
which was eliminated by the PKA inhibitor H89, indicating an interaction between cAMP 
and NF-κB pathway. Although there is no previous studies on the involvement of such 
mechanism in the anti-inflammatory actions of ginseng, there is evidence that ginsenoside 
Rb1 and Rg1 increased intracellular cAMP and the activity of PKA353.  Interestingly, the 
metabolite of Rg1(Rh1) significantly inhibited the transcriptional activity of NF-κB , but 
not the DNA binding activity of  NF-κB in LPS induced BV-2 cells, and this inhibited 
transcriptional activity of NF-κB by Rh1 accompanying with the up-regulating expression 
of p-CREB in nucleus352.  Therefore, G115, GHMF-III, Rg1, Rb1, Rg3, CK, Rh1 or Rh2 
may up-regulated the activity of cAMP pathway to decrease the transcriptional activity of 
NF-κB. 
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The level of cellular cAMP is regulated by PDE (see Section 1.1.4). Since cAMP-specific 
PDE inhibitors, especially PDE4 inhibitor (Rolipram) significantly inhibited the LPS-
induced TNF-αproduction in U937 cells (See Chapter 3), it is possible that ginseng and 
certain ginsenosides may act as PDE inhibitors to regulate cellular cAMP . Previous 
studies showed that ginsenoside Rg1 and Rg3 were used as cAMP-specific PDE inhibitors 
for decreasing the activity of cAMP-specific PDE to up-regulate the level of cAMP356.  We 
inferred that G115, GHMF-III, Rg1, Rb1, Rg3, CK, Rh1 or Rh2 could regulate the activity 
of cAMP pathway induced by LPS, and they perhaps played these actions through 
regulating the activity of PDE4. Thus the aim of studies described in this chapter is to 
investigate the effects of GHMF-III, G115 and ginsenosides on regulation of activity of 
NF-κB and cellular cAMP pathways and their relationships to inhibition of the 
transcriptional activity of NF-κB.  Specifically,  to investigate ⑴the regulations of GHMF-
III, G115, ginsenoside Rb1, Rg1, Rg3 and their metabolites on expression of total & p-
IKK, IκBα and p65; ⑵the regulations of GHMF-III, G115, ginsenoside Rb1, Rg1, Rg3 
and their metabolites on the level of cAMP and the expression of CREB & p-CREB; (3) 
the effects of G115, GHMF-III and ginsenoside Rg1 on the transcriptional activity of NF-
κB ; (4) the effects of G115, GHMF-III and ginsenoside Rg1 on the activity of PDE4, 
using LPS induced macrophage-like U937 cells. 
4.2 Materials and Method 
4.2.1 Materials 
See Section 2.2.1&3.2.1 
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4.2.2 Method 
4.2.2.1 Cell Culture 
See Section 2.2.2.1 
4.2.2.2 cAMP Assay 
Cells were incubated with G115 (1mg/ml), GHMF-III (1mg/ml) or Rb1, Rg1, Rg3, CK, 
Rh1, Rh2 (10μM) for 2 hour, and then treated with 1μg/ml LPS in the absence or presence 
for 6 hours. The supernatants of cell lysates were assayed directly using EIA method 
according to the manufacturer’s instruction (Sapphire Bioscience Pty. Ltd, Australia). The 
details see Section 2.2.2.4 
4.2.2.3 Western Blot 
Cells were incubated with or without G115 (1mg/ml), GHMF-III (1mg/ml) or Rb1, Rg1, 
Rg3, CK, Rh1, Rh2 (10μM) for 2 hour, and then treated with 1μg/ml LPS in the absence or 
presence for 15, 30 or 60 mins respectively. The protein from the lysed cells was measured 
by Western blot analysis. The details see Section 2.2.2.5 
4.2.2.4 NF-κB Reporter Assay 
The transfected macrophage-like U937 cells were pre-incubation with or without G115 
(1mg/ml), GHMF-III (1mg/ml) or Rb1, Rg1, Rg3, CK, Rh1, Rh2(10μM) for 2 hour, and 
then treated with 1μg/ml LPS in the absence or presence for 6 hours. The lysate of cells 
were measured by Dual-Glo® Luciferase Reporter Assay System (Promega Australia). 
The details see Section 2.2.2.6 
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4.2.2.5 PDE Assay 
Macrophage-like U937 cells were treated with or without 10μM Rolipram394, 1mg/ml 
G115, 1mg/ml GHMF-III or 10μM Rg1 for 2 hour, following incubation with or without 
1μg/ml LPS for 4 hour.  The lysate were assayed for PDE activity using the method of 
Thompson and Appleman two-step procedures  with modification394-396. The details see 
Section 2.2.2.7. 
4.3 Statistical Analysis 
See Section 3.3 
4.4 Result 
4.4.1 Effects of G115, GHMF-III, Ginsenosides and their Metabolites on the Expression 
of IKK, IκBα, P65 and their phosphorylated products in NF-κB Pathway in Macrophage-
like U937 Cells Induced by LPS.  
In order to observe the effect of G115(1mg/ml), GHMF-III(1mg/ml), Rb1(10μM), 
CK(10μM), Rh2(10μM), Rg1(10μM) and Rh1(10μM) on the expression of p-IKK, p-IκBα, 
p-p65 and total IKK, IκBα, p65, the macrophage-like U937 cells were pre-treated with the 
test agents for 2 hours, and then induced by LPS for 15 minutes (for p-IKK and IKK 
expressions) or 30 minutes (forp- IκBα&IκBαand p-p65&p65 expressions). Bay11-7082, 
the inhibitor of IKK, was used as a positive control. Bay11-7082(10μM) displayed a 
significant inhibition on the expression of p-& total IKK, p-& total IκBα and p-& total 
p65(p<0.001) (Table-4-1-A,B&C).  Foskolin, an elevator of cAMP pathway, had no 
significant effect on the expression of these proteins (p>0.05; Table4-1-A, B&C). Rh2, the 
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metabolite of Rg3, also couldn’t inhibit the expression of these proteins (p>0.05; Table4-1-
A, B&C). 
As the start point in PRs of NF-κB pathway, the expression of p-IKK induced by LPS was 
significantly inhibited by G115 (p<0.001), GHMF-III(p<0.001), Rb1(p<0.001), 
CK(p<0.05), Rg3(p<0.05), Rg1(p<0.001) and Rh1(p<0.05; Fig.4-1-A). Only 
G115(p<0.01), GHMF-III(p<0.001), Rb1(p<0.001) and Rg3(p<0.05)inhibited the 
expression of IKK induced by LPS at the same time(Fig.4-1-B).   
The expression of p-IκBα was significantly inhibited by G115 (P<0.01), GHMF-
III(P<0.01), Rb1(P<0.001), CK(P<0.01), Rg3(P<0.05), Rg1(p<0.001)and Rh1(p<0.05) 
(Fig.4-2-A). Although Rg1 and Rb1 tended to have more powerful inhibition on the 
expression of p- IκBα, no statistically significant difference  with other test 
agents(p>0.05)was observed. G115 and GHMF-III significantly up-regulated the 
expression of IκBα (p<0.05, p<0.01). Gisenoside Rb1 also increased the expression of 
IκBα induced by LPS (p<0.05; Figure4-2-B). 
The expression of p-p65 was significantly inhibited by G115 (p<0.001), GHMF-
III(p<0.01),Rb1(p<0.001), CK(p<0.01), Rg3(p<0.001), Rg1(p<0.01) and 
Rh1(p<0.05;Fig.4-3-A). There was no significant difference among the test agents on p-
p65 expressions (p>0.05). Only ginsenoside Rg3 displayed the down-regulation on the 




Rg3(10μM) + + + + + + + + + + +
Bay11‐7082(10 μM) ‐ + ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐
Rh1(10μM) ‐ ‐ + ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐
Rh2(10μM) ‐ ‐ ‐ + ‐ ‐ ‐ ‐ ‐ ‐ ‐
LPS(1μg/ml) ‐ ‐ ‐ ‐ + ‐ ‐ ‐ ‐ ‐ ‐
Rolipram(1μM) ‐ ‐ ‐ ‐ ‐ + ‐ ‐ ‐ ‐ ‐
CK(10μM) ‐ ‐ ‐ ‐ ‐ ‐ + ‐ ‐ ‐ ‐
Rg1(10μM) ‐ ‐ ‐ ‐ ‐ ‐ ‐ + ‐ ‐ ‐
G115(1mg/ml) ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ + ‐ ‐
GHMF‐III(1mg/ml) ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ + ‐















































Macrphage-like U937 cells were treated with or without Bay11-7082(10μM), 
Foskolin(10μM), G115(1mg/ml), GHMF-III(1mg/ml) and Rb1, Rg1, Rg3, CK, Rh1, 
Rh2(10μM) for 2 hour, and then stimulated with or without LPS(1μg/ml) for 15 minutes. 
The expression of p-IKK and IKK was measured by western blot using p-IKK antibody 
and IKK antibody as described in the methods (A&B). Β-Tublin was used as a loading 
control. Data represent the mean ± SEM (n=3). *<0.05; **p < 0.01; ***p < 0.001, Vs 
control vehicle by one-way ANOVA followed by Bonferroni’s test. 
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LPS(1μg/ml) + + + + + + + + + + +
Bay11‐7082(10μM) ‐ + ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐
Rolipram(1μM) ‐ ‐ + ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐
Rb1(10μM) ‐ ‐ ‐ + ‐ ‐ ‐ ‐ ‐ ‐ ‐
Rh2(10μM) ‐ ‐ ‐ ‐ + ‐ ‐ ‐ ‐ ‐ ‐
Rh1(10μM) ‐ ‐ ‐ ‐ ‐ + ‐ ‐ ‐ ‐ ‐
Rg1(10μM) ‐ ‐ ‐ ‐ ‐ ‐ + ‐ ‐ ‐ ‐
Rg3(10μM) ‐ ‐ ‐ ‐ ‐ ‐ ‐ + ‐ ‐ ‐
CK(10μM) ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ + ‐ ‐
G115(1mg/ml) ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ + ‐











































Figure 4-2  Effects of ginseng and ginseng related products on the expression of p-IκBα 
and IκBα in macrophage-like U937 cells induced by LPS.  
Macrphage-like U937 cells were treated with or without Bay11-7082(10μM), Foskolin 
(10μM), G115 (1mg/ml), GHMF-III(1mg/ml) and Rb1, Rg1, Rg3, CK, Rh1, Rh2(10μM) 
for 2 hour, and then stimulated with or without LPS(1μg/ml) for 30 minutes. The 
expression of p-IκBα (A) and IκBα(B) was measured by western blot using p- IκBα 
antibody and IκBα antibody as described in the methods. Β-Tublin was used as a loading 
control. Data represent the mean ± SEM (n=3)*<0.05; **p < 0.01; ***p < 0.001, Vs 
control vehicle by one-way ANOVA followed by Bonferroni’s test. 
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LPS(1μg/ml) + + + + + + + + + + +
Bay11‐7082(10μM) ‐ + ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐
Foskolin(10μM) ‐ ‐ + ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐
Rh1(10μM) ‐ ‐ ‐ + ‐ ‐ ‐ ‐ ‐ ‐ ‐
Rg1(10μM) ‐ ‐ ‐ ‐ + ‐ ‐ ‐ ‐ ‐ ‐
Rh2(10μM) ‐ ‐ ‐ ‐ ‐ + ‐ ‐ ‐ ‐ ‐
Rg3(10μM) ‐ ‐ ‐ ‐ ‐ ‐ + ‐ ‐ ‐ ‐
CK(10μM) ‐ ‐ ‐ ‐ ‐ ‐ ‐ + ‐ ‐ ‐
Rb(10μM) ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ + ‐ ‐
G115(1mg/ml) ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ + ‐









































Figure 4-3  Effects of ginseng and ginseng related products on the expression of p-p65 and 
p65 in macrophage-like U937 cells induced by LPS. 
Macrphage-like U937 cells were treated with or without Bay11-7082(10μM), Foskolin 
(10μM), G115(1mg/ml), GHMF-III(1mg/ml) and Rb1, Rg1, Rg3, CK, Rh1, Rh2(10μM) 
for 2 hour, and then stimulated with or without LPS(1μg/ml) for 30 minutes. The 
expression of p-p65 (A) and p65(B) was measured by western blot using p- p65 antibody 
and p65 antibody as described in the methods. Β-Tublin was used as a loading control. 
Data represent the mean ± SEM (n=3). *<0.05; **p < 0.01; ***p < 0.001, Vs control 
vehicle by one-way ANOVA followed by Bonferroni’s test. 
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4.4.2 Effects of G115, GHMF-III, Ginsenosides and their Metabolites on the 
Transcriptional Activity of NF-κB Induced by LPS. 
To investigate the effects of G115, GHMF-III, Rb1, Rg1, Rg3, CK, Rh1 and Rh2 on the 
transcriptional activity of NF-κB induced by LPS, U937 cells were pre-treated with or 
without G115(1mg/ml), GHMF-III(1mg/ml) and  Rb1, Rg1, Rg3, CK, Rh1, Rh2(10μM) 
for 2 hours, and then were induced by LPS(1μg/ml) for 6 hours. The transcriptional 
activity of NF-κB induced by LPS was significantly inhibited by  G115(p<0.001), GHMF-
III(p<0.001), Rb1(p<0.001),Rg1(p<0.01), Rg3(p<0.001), CK(p<0.001) and Rh1(p<0.01),  







LPS (1μg/ml) ‐ + + + + + + + + +
GHMF‐III(1mg/ml) ‐ ‐ + ‐ ‐ ‐ ‐ ‐ ‐ ‐
G115(1mg/ml) ‐ ‐ ‐ + ‐ ‐ ‐ ‐ ‐ ‐
Rb1(10μM) ‐ ‐ ‐ ‐ + ‐ ‐ ‐ ‐ ‐
CK(10μM) ‐ ‐ ‐ ‐ ‐ + ‐ ‐ ‐ ‐
Rg3(10μM) ‐ ‐ ‐ ‐ ‐ ‐ + ‐ ‐ ‐
Rh2(10μM) ‐ ‐ ‐ ‐ ‐ ‐ ‐ + ‐ ‐
Rg1(10μM) ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ + ‐
























Figure 4-4 Effects of GHMF-III, G115, Ginsenosides and their Metabolites on the 
transcriptional activity of NF-κB in macrophage-like U937 cells induced by LPS.  
Macrphage-like U937 cells were treated with or without GHMF-III (1mg/ml), G115 
(1mg/ml) and Rb1, CK, Rg3, Rh2, Rg1, Rh1 (10μM) for 2 hours, and then stimulated with 
or without LPS(1μg/ml) for 6hours. The transcriptional activity of NF-κB was measured 
by the Dual-Glo® Luciferase Reporter Assay System. Data represent the mean ± SEM 
(n=3) in duplicate. *p<0.05;**p<0.01; ***p<0.001 Vs LPS vehicle by one-way ANOVA 
followed by Bonferroni’s test.  
4.4.3 Effects of G115, GHMF-III, Ginsenosides and their Metabolites on the Level of 
cAMP in LPS Induced macrophage-like U937 cells 
In order to test  the effects of G115,GHMF-III,Rb1, Rg1, Rg3, CK, Rh1 and Rh2 on 
cAMP pathway, U937 cells were treated with or without Rolipram (1μM), G115 (1mg/ml), 
GHMF-III(1mg/ml), Rb1(10 μM), CK(10 μM), Rg3(10 μM), Rh2 (10 μM), Rg1(10 μM) 
and Rh1(10 μM) for 2 hours, and then stimulated by LPS (1μg/ml) for 6 hours. LPS 
slightly increased the level of cAMP, however, there was no statistically difference on the 
level of cAMP between LPS and blank group (p>0.05). As positive control, Rolipram 
almost increased 40% of production of cAMP induced by LPS. The level of cAMP 
induced by LPS was also significantly up-regulated by G115 (p<0.05), GHMF-III (p<0.0g) 
and ginsenoside Rg1 (p<0.01),  but not Rb1, Rg3, CK, Rh1 or Rh2 (p>0.05).  Rolipram 
displayed a significant increase in cAMP level than G115 (p<0.001), GHMF-III (p<0.001) 






LPS(1mg/ml) ‐ + + + + + + + + + +
Rolipram(1μM) ‐ ‐ + ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐
GHMF‐III(10mg/ml) ‐ ‐ ‐ + ‐ ‐ ‐ ‐ ‐ ‐ ‐
Rg1(10μM) ‐ ‐ ‐ ‐ + ‐ ‐ ‐ ‐ ‐ ‐
Rb1(10μM) ‐ ‐ ‐ ‐ ‐ + ‐ ‐ ‐ ‐ ‐
G115(10mg/ml) ‐ ‐ ‐ ‐ ‐ ‐ + ‐ ‐ ‐ ‐
CK(10μM) ‐ ‐ ‐ ‐ ‐ ‐ ‐ + ‐ ‐ ‐
Rh1(10μM) ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ + ‐ ‐
Rh2(10μM) ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ + ‐
















Macrophage‐like  U937  cells  were  treated  with  or  without  Bay11‐7082(10μM), 
Rolipram(1μM),  G115(1mg/ml),  GHMF‐III(1mg/ml)  and  Rb1,  Rg1,  Rg3,  CK,  Rh1, 
Rh2(10μM) for 2 hour, and then stimulated with or without LPS(1μg/ml) for 6 hours. The 
level  of  cAMP  was  measured  by  EIA.  Data  represent  the  mean  ±  SEM  (n=3)  in 
duplicate.*p<0.05; **p < 0.01,***p<0.001 Vs control vehicle by one‐way ANOVA followed 
by  Bonferroni’s  test.#p<0.01;  ##p<0.001,  Vs  Rolipram  vehicle  by  one‐way  ANOVA 
followed by Bonferroni’s test. 
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4.4.4 Effects of G115, GHMF-III and Ginsenosides Rg1 on the Expression of CREB and 
p-CREB in LPS Induced Macrophage-like U937 Cells. 
LPS(1μg/ml) + + + + +
Foskolin(10μM) ‐ + ‐ ‐ ‐
GHMF‐III(10μM) ‐ ‐ + ‐ ‐
Rg1(10μM) ‐ ‐ ‐ + ‐

















































As the positive control, Rolipram significantly increased the expression of c-CREB 
induced by LPS, compared with LPS group (p<0.001; Fig.4-6-A). However, it had no 
significant effect on the expression of total CREB (p>0.05; Fig.4-6-B). The expression of 
p-CREB induced by LPS was also significantly increased by ginsenoside Rg1 (p<0.001), 
GHMF-III (p<0.001) and G115 (p<0.01). Ginsenoside Rg1 displayed the more significant 
up-regulation on the expression of c-CREB than G115 (P<0.05; Fig.4-6-A). Among Rg1, 
GHMF-III and G115, only Rg1 up-regulated the expression of total CREB compared with 
LPS group (p<0,05;Fig.4-6-B) 
4.4.5 Effects of G115, GHMF-III and Ginsenoside Rg1 on the Activity of PDE4 in LPS 
Induced Macrophage-like U937 Cells 
U937 cells with 1μg/ml LPS elicited a significant increase in PDE4 activity. The LPS 
increased PDE4 activity was significantly inhibited by 10μM Rg1 (p<0.001), 1mg/ml 
GHMF-III (P<0.001) and 1mg/ml G115 (P<0.05). No significant difference was observed 
among the effects of Rg1, GHMF-III and G115on Rolipram-sensitive PDE activity 











LPS(1μg/ml) ‐ + ‐ ‐ ‐
Rg1(10μM) ‐ ‐ + ‐ ‐
GHMF‐III(1mg/ml) ‐ ‐ ‐ + ‐






















Figure 4-7 Effects of G115, GHMF-III and Ginsenoside Rg1 on the Activity of PDE4 in 
LPS Induced Macrophage-like U937 Cells. 
Macrophage-like U937 cells were pre-treated with or without Rolipram (30μM), 
Rg1(1mg/ml), GHMF-III(1mg/ml) and G115(1mg/ml) for 2 hour, and then induced by 
LPS(1μg/ml) for 4 hours. PDE4 activity was quantified by scintillation counting. Data 
represent the mean ± SEM (n=3) performed in duplicate. *<0.001, Vs blank vehicle by 
T’student test.#<0.05; ##<0.001, Vs control vehicle by one-way ANOVA followed by 
Bonferroni’s test. 
4.5 Discussion 
NF-κB pathway is the important inflammation-related pathway, which involves the 
pathogenesis of abnormal inflammation of COPD (see Section 1.1.4.4).  In this part of my 
project, ginseng and its related products displayed the different regulation on the activity 
of NF-κB pathway induced by LPS. 
GHMF-III, as a ginseng formula, displayed a similar and more potent regulation on the 
activation of PRs in NF-κB pathway induced by LPS with G115 (the standardised extract 
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of ginseng), as both of them not only inhibited the expression of activated products of PRs 
in NF-κB induced by LPS, including p-IKK, p-IκBα and p-p65, but also inhibited the 
expression of total IKK and IκBα induced by LPS. Only PDG type ginsenoside Rb1 
displayed the similar regulation on the activation of PRs induced by LPS in NF-κB 
pathway with G115 and GHMF-III, so it seemed that G115 and GHF-III displayed the 
pharmacological actions of Rb1 on the activation of PRs induced by LPS in NF-κB 
pathway. Another PDG ginsenoside Rg3 displayed the analogous regulation with Rb1 on 
the activation of PRs induced by LPS in NF-κB pathway, but couldn’t increase the 
expression of IκBα. Previous study showed that Rg3 inhibited the expression of IκBα in 
RAW264.7 cells without any stimulation339. We inferred that Rg3 perhaps displayed the 
dissimilar regulation on the expression of IκBα at different condition. The PTG type 
ginsenoside Rg1 also inhibited the expression of p-IKK, p-IκBα and p-p65, but couldn’t 
inhibit the expression of total protein.  
There were some differences of the regulation on the activity of RPs between the 
metabolite and the PDG type ginsenoside. CK, the metabolite of Rb1 showed the similar 
effect as Rg1 and Rh1. It inhibited the expression of phosphorylated proteins, but not the 
expression of total protein of PRs. Rh2, the metabolite of Rg3 had no obvious effect  on  
the activation of PRs in NF-κB, which however, was different with a previous study 
showing that Rh2 inhibited the expression of p-IκBα in TNF-α induced human astroglial 
cells341. The reason for these discrepancies is not clear, but it may be related to different 
cell lines used. Further study is necessary to elucidate the exact mechanisms involved.  
Previous studies only involved in the regulation of Rb1, Rg1 and Rh1 on the 
transcriptional activity of NF-κB, and all of them display significant inhibition on it (see 
Section 1.2.4.3). In this part of our project, we also investigated the regulation of other 
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ginseng and its related products on the transcriptional activity of NF-κB induced by LPS as 
supplementary. We found that G115, GHMF-III, Rg3 and CK also inhibited the 
transcriptional activity of NF-κB induced by LPS and the inhibition of Rb1, Rg1 and Rh1 
on it also was proved.  
Interestingly, both GHMF-III and G115 up-regulated the activity cAMP pathway, the 
effect may link directly to their inhibitory actions on the transcriptional activity of NF-κB. 
GHMF-III and G115 mainly displayed the pharmacological action of PTG type 
ginsenoside Rg1 on the regulation of cAMP pathway, as only GHMF-III, G115 and 
ginsenoside Rg1, but not Rb1, Rg3, CK, Rh1 or Rh2, up-regulated the level of cAMP 
induced by LPS, which was accompanied with the increase of the expression of p-CREB. 
Thus, it is possible that the cAMP-component actions of G115 and GHMF-III are 
mediated by Rg1 in these ginseng extracts.  Given these agents also inhibited the 
transcriptional activity of NF-κB, it is likely that a synergistic action may be involved in 
the regulatory actions of ginseng on NF-κB pathway. .In addition, the up-regulation of 
cAMP by GHMF-III, G115 and Rg1 is associated with the decreased in activity of PDE4, 
which indicates that GHMF-III, G115 and Rg1 may act as PDE4 inhibitor to reduce the 
PDE4 activity, resulting in the increase of cellular cAMP levels. Liang reported earlier that 
Rb1 also increased the level of intracellular cAMP in rat liver compared with that in 
controls353 , but this was not confirmed in our study.   
G115 is a ginsenoside-extract from ginseng and PDGs (Rb1, Rb2, Rc and Rd) and 
PTGs(Re, Rg1 and Rg2) are the main active components of it324. Thus, G115 maybe 
display both pharmacological actions of PDGs and PTGs. This hypothesis has been proved 
in my project that G115 exhibited more potent inhibition on the activity of NF-κB pathway 
and up-regulation on the activity of cAMP pathway than Rb1(PDGs) and Rg1(PTGs) used 
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alone. It indicates that crude extracts of ginseng may target more broadly than purified 
individual ginsenosides. GHMF-III showed the similar regulation on the activity of NF-κB 
and cAMP pathways, however as the chemical information for GHMF-III is not fully 
characterized, further study about the chemical construction of GHMF-III is necessary. 
In conclusion, the study has clearly demonstrated that ginseng and ginsenosides can 
regulate NF-κB pathway in LPS induced macrophage-like U937 cells. They act via at least 
two separate mechanisms: inhibition of the activity of PRs in NF-κB to decrease the 
activity of NF-κB, and  activation of cAMP pathway, via inhibition of PDE, which in turn 
to inhibit the transcriptional activity of NF-κB. The study also discovered a non-specific 
inhibition of Bay11-7082 on the expression of p-IKK, p-IκBα, p-p65, IκBα and p65. In 
addition, there are differences among ginseng and ginseng related products on the 
regulations of cAMP pathway, as only G115, GHMF-III and ginsenoside Rg1 share 
similar actions on activation of cAMP pathway. Some of the findings in the study have not 
been reported previously. These new findings may help to understand the mechanism of 
anti-inflammatorty actions of ginseng and ginseng related products.  
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Chapter 5.  Efficacy of TNF-α Inhibitors on Radiological Progression in 
Active Rheumatoid Arthritis- A systematic review 
5.1 Introduction 
Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disorder characterized by 
inflammation of the articular synovium, resulting in bony erosions, deformity and 
ultimately, joint destruction (JD). RA is one of the most common and costly diseases, 
affecting about 0.3-1.2% of the population and 20%-35% of the patients stop work during 
first 2-3 years in disease3,413-416. The prevalence of work disability can be decreased 
through slowing and arresting the progression of JD.  Therefore preventing the progression 
of JD is the key treatment objective of RA417.  
5.2 JD and Active RA 
5.2.1 JD of RA Patients 
JD is an important part of illness development in RA418 and occur throughout the whole 
course of disease, the functional loss and irreversible disability caused by JD are the most 
important manifestations leading to the medical cost of RA419-421. Preventing the 
progression of JD not only can improve life quality of patients, but also can lead to 
substantial savings in medical costs422-424. Hence, the control of the progression of JD is 
delineated  as the key treatment goal outlined in the Guidelines of American College of 
Rheumatology (ACR)417. 
JD in RA is the result of a series of inflammatory responses. First, a large number of 
inflammation-related cells is attracted to the joint cavity to cause  secretion of various 
inflammatory mediators which results in the occurrence of synovitis secondary to swelling 
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of synovial cells, excess synovial fluid, and the development of fibrous tissue (pannus) in 
the synovium425. These inflammatory response lead to the destruction of articular cartilage 
and the fusion of bone under cartilage. JD is the most important pathological 
manifestations of RA and the progression of JD can be evaluated by x-ray426. 
5.2.1.1 Scoring of the Radiological Progression of JD in RA 
It has been known that joint external manifestations do not correspond to the inner JD in 
patients with RA. Therefore, radiographic outcome, the gold standard for JD progression 
assessment, is widely used in the clinical setting426. There are many kinds of scoring 
systems for calculating the radiographic outcome, including Steinbrocke, Kellgren, Sharp 
and Lanser scoring systems420,421,427,428. Among these, Sharp system is commonly used to 
monitor the progression of JD through continuous improvement 429-431.  
The improved Sharp method defines erosions as: 0 = Normal, 1 = Discrete erosions, 2 to 3 
= Larger erosions according to surface area involved, 4 = Erosions extending over middle 
of the bone, and 5 = Complete collapse. Generally, 15 areas from the hands to wrists and 
six areas from the feet are used to calculate the joint space narrowing score. The maximum 
joint space narrowing score is 120; the maximum erosion score is 160 for hands and wrists, 
and 120 for feet. Thus, the maximum Sharp radiographic score is 448.17431. The 
progression of JD in RA patients and the efficacy of therapeutic drugs can be evaluated 
using the Sharp scoring system.   
5.2.2 Active RA 
American Rheumatism Association (ARA) first proposed that RA should be divided into 
active RA and inactive RA according to the classification criteria for RA 432. Later the 
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Rome criteria was introduced since some histological features as proposed in ARA criteria 
could not be used in the population setting433. 
5.2.2.1 Criteria of Active RA 
Currently, there is still no real “gold standard” to judge RA disease activity. Nevertheless, 
many clinical trials have used the Disease Activity Score (DAS) as an assessment method 
to value RA activity. DAS is a combined index to assess important impact factors affecting 
RA activity, such as the number of swollen and tender joints and measures the Erythrocyte 
sedimentation rate (ESR)/C-reactive protein (CRP). DAS is  usually scored between 0 and 
10 to indicate RA activity434. The DAS28 is analogous to the DAS but includes simplified 
28-joint counts435.  
5.2.3 JD  in Patients with Active RA 
Many rheumatologists believe that patients with active RA have most JD. Kirwan et al 
collected related clinical data and illustrated that continued disease activity is obvious  in 
the whole course of RA, accompanied with temporal fluctuations reflected in a gradual 
increase in JD436. Further studies support that active RA is the main developing period of 
JD437,438. Interestingly, although the patients in early stage of RA displayed  slow and 
slight disease progression and  only some of these patients will develop into RA439, the 
patients in early stage of active RA also showed the significant JD438,440,441.   
In addition, one study showed that the fluctuation in RA disease activity is directly related 
to changes in radiologic progression in patients with active RA442. This indicates that the 
change of RA disease activity may affect the progression of JD, and also the efficacy of 
therapeutically drugs of RA for treating JD. 
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5.3 Treatment of JD in patients with active RA 
5.3.1 Treatment of RA 
In 1970s, some rheumatologists proposed a "pyramid" treatment protocol for RA treatment 
based on  past  experience443. They believe that the treatment of RA should follow a step-
by-step three line administration protocol. RA treatment drugs can be divided into Non-
steroidal anti-inflammatory drugs (NSAIDS) as the first-line drugs, disease modifying 
anti-rheumatic drugs(DMARDs), such as Methotrexate (MTX), as the second-line drugs, 
and the glucocorticoid  as the third-line drug. Patients from early, middle and late stages of 
RA are corresponded to the use of the first-line, the second-line and the third-line drugs 
respectively. However, subsequent accumulating clinical evidence  indicates that the use of 
a single drug was not enough to control the RA progression, and then many 
rheumatologists proposed an "inverted pyramid"(step down)  treatment protocol in 1989444. 
This protocol suggests to treat RA patients using all three line drugs in conjunction, and 
gradually reduces the types and doses of drugs, and finally using one or two kinds of drugs 
with small doses for long-term maintenance of steady state of RA. Although the "inverted 
pyramid" protocol caused some controversy, it has been used as the reasonable and 
preferred treatment protocol for RA treatment by global rheumatologists. However, the 
therapeutic treatment of RA has not been significantly improved until the clinical 
application of TNF-α inhibitors. TNF-α inhibitors significantly improved the American 
College of Rheumatology core criteria 20 (ACR20), DAS score and  Health Assessment 
Questionnaire(HAQ) scores,  as well as swollen joint count, tender joint count, and CRP 
level445-447. Most importantly, TNF-α inhibitors significantly inhibited the progression of 
JD in active RA 437,438,446,448-452.  
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MTX and TNF-α inhibitors are the most important and popular anti-JD progression drugs 
in patients with RA. However, according to the efficacy, side effect and medical costs, 
these drugs are often used in different conditions. For example, low-dose MTX was used 
for treating the patients with early RA443,453,454, but for the patients with active RA TNF-α 
inhibitors displayed showed more efficacy on the progression of JD than MTX437,438,446,448-
452. 
5.3.2 Efficacy of MTX on the Progression of JD in Patients with Early RA 
MTX, formerly known as amethopterin, is an anti-metabolite and anti-folate drug. It has 
been widely used in the treatment of autoimmune diseases, including RA, psoriatic 
arthritis and Crohn's disease455-457. MTX in low doses is generally safe and well tolerated 
as the preferred therapy for the treatment of RA458. Previous studies demonstrated that 
low-dose MTX used for up to one year significantly slowed the radiographic progression 
of JD in patients with early RA, though not anyone was responsive to the treatment with 
MTX453,454.  As patients with early RA always displayed slight JD, MTX is suitable for 
retarding mild JD, but not moderate or severe JD. Many studies showed that MTX used in 
conjunction with other DMARD type drugs, such as Sulfasalazine, Ciclosporin and 
Azathioprine, to increase the efficacy of these drugs459-461. Thus, there is a synergy effect 
between MTX and other drugs to inhibit the progression of JD.  
5.3.3 Efficacy of TNF-α Inhibitors on the JD Progression in Active RA Patients 
TNF-α is an important inflammatory mediator and play an important role in initiating and 
perpetuating inflammatory and tissue damage in the rheumatic joint462,463. Thus, down-
regulating the activity of inflammatory mediators to inhibit the progression of JD in 
patients with active RA became the core therapeutic objective in RA treatment. 
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TNF-α inhibitors have been used in the treatment of RA since 2000. Three TNF-α 
inhibitors are  currently approved by the FDA and the European commission(EC) for the 
treatment of RA, which are infliximab (Remicade), etanercept (Enbrel) and adalimumab 
(Humira). These drugs are also listed in the Pharmaceutical Benefits Scheme (PBS) in 
Australia. ACR recommended using TNF-α inhibitors as biological DMARD to treat RA, 
especial to treat active RA464. There are  strong evidence that TNF-α inhibitors displayed 
more powerful inhibition on the progression of JD in active RA comparing with MTX 
used alone437,438,446,448-452.  
TNF-α inhibitors for the treatment of active RA can be used alone and in combination with 
MTX. Many studies have shown that TNF-α inhibitors, Infliximab (INF), Adalimumab 
(ADA), and Etanercept (ETA), can retard the progression of JD when used alone or in 
combination with MTX in active RA patients437,446,448-452,422. In the guideline of biological 
drug in RA, ACR believed there was no distinction between these two different 
administration of TNF-α inhibitor on the efficacy of active RA417. However, many 
rheumatologists were more inclined to use TNF-α inhibitors in conjunction with MTX to 
inhibit the progression of JD in active RA patients437,446,448-452. The rational for this is not 
well defined as all drugs for RA have obvious side effects465,466.  It is important for the 
patients and rheumatologists to select drugs based on evidence of efficacy and safety. In 
addition, there are still certain unanswered questions about the treatment of TNF-α 
inhibitors in the JD of active RA patients, including factors affecting the efficacy of TNF-α 
inhibitors, and which type of TNF-α inhibitor provide a better efficacy. The aim of this 
systemic review is to quantitatively assess all the randomised controlled trials that assessed 
the effect of TNF-α inhibitors on radiological progression (RP) of JD in active RA to 
answer these questions. 
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Based on the available evidence, we hypothesized that TNF-α inhibitors used in 
conjunction with MTX provide a better efficacy against the progression of JD in patients 
with active RA comparing with TNF-α used alone, as well as MTX used alone. In addition, 
the degree of the disease activity of RA is an important factor for the efficacy of TNF-α 
inhibitors on the progression of JD in active RA patients. To test our hypothesis, we have 
used meta-analysis to -  
 Compare the effect of TNF-α inhibitors used alone and in combination with MTX 
on the RP of active RA patient.  
 Investigate the correlation between the degree of activity of RA and the efficacy of 
TNF-α inhibitors on RP in active RA patients 
 Compare the effect of different types of TNF-α inhibitors on RP in active RA 
patients 
5.4 Methods 
5.4.1 Search Strategy 
A search was conducted which was not restricted by language for all publications on TNF-
α inhibitors and RA between January 1966 and July 2012. The electronic database 
included PubMed, Embase, Cumulative Index to Nursing and Allied Health Literature 
(CINAHL), Database of Abstracts of Reviews of Effects (DARE), Cochrane Central 
Register of Controlled Trials (CENTRAL), and the Cochrane Database of Systematic 
Reviews. We also searched for the articles published in the conference, unpublished trials 
and those trials in progress.  We supplemented search by checking references cited in 
published systematic reviews and by references to the bibliographies of the articles 
extracted from the literature reviews.  
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The search used the following medical subject headings (MeSH) and relevant keywords: 
(1) “Arthritis, Rheumatoid, or “Rheumatoid Arthritis”; (2) “TNFR-fc”, “Infliximab”, 
“Adalimumab”, or “Etanercept”; (3) “methotrexate” or “MTX” ; (4) “joint destruction” or 
“joint damage”. (5) “Radiological progression”. 
5.4.2 Inclusion Criteria 
All randomised trials that used TNF-α inhibitors alone, or in combination with MTX, 
reported the radiological progression of arthritis as an outcome, and patients with active 
RA, were included. 
Articles were excluded based on abstracts if they did not pertain to RA and TNF-α 
inhibitors. Selected abstracts were excluded if they did not report radiological progression 
of arthritis as an outcome, and they were reviews or animal studies. Full texts of selected 
articles were reviewed and excluded if they were duplicated studies, were not randomized 
trials, and subjects were not at active stage (Fig.5-1). 



















5.4.3 Outcome Measurement 
Radiological outcome is deemed as the gold standard for assessing the progression of JD 
in RA426. Sharp and Lanser scoring systems were recommended as the main method to 
assess the progression of JD in all radiological assessment method429. According to these 
methods, researcher can calculate the mean change (MC) of radiological scores between 
the baseline and after treatment of patients with RA and the percentage progression of JD 
above a certain cut-off level, which is equivalent to the risk ratio (RR) of every study. 
Recommended cut-off levels for progression were 0 or 0.5, as well as the smallest 
detectable difference (SDD) in order to account for measurement errors. In this project, all 
papers used the Sharp scoring system as the measure method at the end point. Using this 
method, MC and RR, as two outcomes of the end point, can be calculated in patients with 
active RA. 
5.4.4 Data Extraction 
Data were extracted from the papers which were collected according to the inclusion 
criteria by two independent reviewers. Disagreements were resolved by consensus 
involving in a third investigator. If the results which we needed were not expressed in the 
article, we approached the investigators by letter for more information. Four investigators 
were approached; two of them responded. 
Descriptive information was also collected, including the name of the study, year of 
publication, total number of participants, intervention, the list of study providing available 
data about RR & MC and trial quality. 
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5.4.5  Assessment of Study Quality  
Two independent reviewers blindly evaluated methodological quality of each study using 
Jadad scale, and disagreements were resolved by a third assessor. It contains three 
questions: the type of the study (randomized and double-blinded), the description of the 
withdrawals and dropouts; one point is awarded for each affirmative answer. One 
additional point is given or deducted if the study satisfy or dissatisfy the demand of the 
quality of the randomization and blindness. The Jadad scale goes from 0 to 5, and scores of 
3 or higher indicate a good methodological quality467. 
5.5  Statistical Analysis 
In all selected study, the RR was calculated as the primary outcome. MC in radiological 
scores between baseline and after therapy, along with the 95 % confidence intervals (95% 
CL) was calculated as the secondary outcome.  Data were dealt with Comprehensive meta-
analysis to pool results of comparable studies (RevMan5.1).  
As data exclusion was finished by two reviewers independently, to quantify the level of 
agreement between reviewers, Cohen's kappa coefficient was calculated.  The κ statistic is 
a statistical measure of inter-rater agreement, and values were ranged from +1 (perfect 
agreement) to -1(complete disagreement).  
Heterogeneity was evaluated with Cochran’s Q test statistic for collection of studies with 
large sample sizes, and quantified using the I2 statistic. Values of I2 equal to 25%, 50%, 
and 75% representing low, moderate, and high heterogeneity respectively. When there was 
a significant heterogeneity (I2>50%) among the independent studies, we used random-
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effects meta-analysis; when the heterogeneity was insignificant (I2<50%) among the 
related studies, the fix-effects meta-analysis was done.   
To assess whether the efficacy of TNF-α inhibitors on the progression of JD in active RA 
patients was modified by clinical and demographic variables, we pre-specified a list of 13 
variables for subgroup analysis. Variables were chosen on the basis of either biological 
plausibility (e.g., age, the percent of baseline administration medicine, or different kinds of 
TNF-α inhibitors) or known risk factors of JD in RA (e.g. DAS28, ESR and CRP). Each 
variable was used as the standard to divide available studies into different subgroup, and 
the subgroup analysis was done for them to confirm whether there was a significant 
distinction between subgroups. 
To analyse the heterogeneity, studies were divided into different subgroups according to 
the results of subgroup analysis. “Complemented with MTX” and “different type of TNF-α 
inhibitors” were confirmed as two major factors to modify the efficacy of TNF-α inhibitors 
on RR of the progression of JD in patients with active RA, so we divided our studies into 5 
subgroups (INF combination with MTX, ETA combination with MTX, ADA combination 
with MTX, ETA alone and ADA alone) according to these two factors. Meta-analysis was 
done for pooling results of independent studies in each subgroup. 
To assess the correlation between the treatment efficacy and the duration of RA, age, 
DAS28, or CRP, meta-regression was used. Duration of RA, age, DAS28, CRP and ESR 
were used as independent variables, and log risk ratio was used as dependent variable. 
There are statistically significant correlation between two variables, if p<0.05. 
We assessed publication bias using the Egger’s regression. Publication bias was assessed 
via a funnel plot—in which the log RR was plotted against the standard error for all studies 
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included. There is not publication bias if p>0.05. If publication bias was detected, the 
effect of such bias was assessed with the fail-safe number method. The fail-safe number 
was the number of unpublished studies that would be needed to nullify the observed result 
to statistical non-significance at α=0.05 level.  
5.6 Results 
Of the 8291 references screened, 7 clinical trials were included in the final analysis (Fig.5-
1). There were three types of TNF-α inhibitors involved in these 7 trials, including INF, 
ADA, and ETA. All of these TNF-α inhibitors were recommended by ACR417. 7 trials 
included 11 types of treatment groups (different drug administration methods), such as  
MTX+INF 3mg/kg every 8wk, MTX+INF 3mg/kg every 4wk, MTX+INF 10mg/kg every 
8wk, MTX+INF 10mg/kg every 4wk, MTX+INF 6mg/kg every 8wk, MTX+ETA 50mg 
weekly, MTX+ ETA 25mg twice week, MTX+ADA 40mg every other week,  ETA 25mg 
twice week,  ADA 40mg every other week and ADA 20mg every week treatment groups 
(Tab.5-1). As all treatment groups in these trails were analysed separately, we regarded 
these treatment groups as the independent studies for further meta-analysis. As a result, the 
placebo group was counted repeatedly. Every independent study which provided available 
data about RR and MC was marked in the “table 5-1”. In total 14 independent studies, 
there were 12 independent studies providing available results of RR of the progression of 
JD in active RA patients, and 11 independent studies providing available results of MC of 
the progression of JD in active RA patients (Tab.5-1). In all of 7 clinical trials, there were 
2 types of comparisons involving in the effect of TNF-α and MTX inhibitors on RR of the 
progression of JD in active RA patients, including TNF-α inhibitors used alone comparing 
with MTX and TNF-α inhibitors in combination with MTX comparing with MTX. In the 
first comparison, there were 9 independent studies providing available results of RR of the 
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progression of JD in active RA patients. In the second comparison, there were 3 
independent studies providing available results of RR of the progression of JD in active 
RA patients.  
In total, 5704 individuals were analysed, whose mean age were between 49.99 and 56.62 
years old. The mean span of the disease duration was very large. It was between 8.73 and 
131.58 months.  All the studies performed measure of radiographic progression after one 
year（48, 52 or 54 weeks）, and so one year was chosen as observation time of end point 
(Tab.5-1).  
The quality of all trials was good.  The Jadad scales of all trials were 3 or higher, which 
meant a good methodological quality (Tab.5-1). Only two studies didn’t use double-blind 
method446,451. Only one study didn’t record the result of withdrawal and dropout451. 
Cohen’s kappa coefficient was calculated, and result was 0.79. It meant that data exclusion 





Table 5-1 Characteristics of Studies 
Study No. of duration of  
  Intervention 
  Trial  
(year) patients radiographs  RR＊
MC
Quality 
     (weeks)       
UK group   Base-line  MTX+INF(3mg/kg every 8wk) Vs MTX √ √   
(1999)446 428 /54wks MTX+INF(3mg/kg every 4wk) Vs MTX √ √ 5 
    /102wks MTX+INF(10mg/kg every 8wk) Vs MTX √ √   
      MTX+INF(10mg/kg every 4wk) Vs MTX √ √   
ASPIRE group 
1490 
Base-line MTX+INF(3mg/kg every 8wk) Vs MTX + placebo                √ √ 
5 












Base-line          
5 (2005)
450
  /48wks ETA(25mg twice weekly)+placebo Vs MTX+placebo √  - 
  /96wks MTX+ETA(25mg twice weekly) Vs MTX + placebo   √  - 
  /144wks                                     
PREMIER 
study 
  Base-line ADA(40mg every other week)+placebo Vs MTX+placebo √  -   
(2006)437 799 /48wks MTX+ ADA(40mg every other week) Vs MTX + placebo   √  - 4 
    /96wks         
BBOTT study 619 Base-line ADA(40mg every other week)+ placebo Vs MTX+ placebo   - √   
(2004)468  /52wks ADA(20mg every week)+ placebo vs MTX+ placebo       - √ 5 
RR= the risk ratio; MC= Mean change in radiographic scores between baseline and after treatment.  
* Number of RR and MC may not add up to 100% of total because data provided by some studies were empty or not available.
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Figure 5-2 Comparison between the Effect Size of TNF-α Inhibitors and MTX on RR of 
JD in Patients with Active RA 
In 12 independent studies which compared the effect of MTX and TNF-α 
inhibitor(including TNF-α inhibitor used alone and in combination with MTX) on RR of 
joint damage in active RA patients, we used random effects model for heterogeneity 
(P=0.00001, I2=81%). The effect size of TNF-α inhibitors group was significantly better 
than MTX group (Z=6.27, P<0.00001). The use of TNF-α inhibitors was associated with a 
57% reduction in progression of JD comparing with MTX used alone (RR 0·43, 95% CI 
0.33–0.56; Fig.5-2). All the studies displayed the consistent beneficial efficacy of TNF-α 
inhibitors comparing with the efficacy of MTX on RR of  the progression of JD in active 
RA patients (Fig. 5-2). Of 11 independent studies which compared the effect of MTX and 
TNF-α inhibitors(including TNF-α inhibitor used alone and in combination with MTX) on 
MC in active RA patients, we used random effect model for heterogeneity (P=0, I2=84%). 
The effect size of TNF-α inhibitors groups was also significantly better than MTX groups 
(Z=-6.921, P=0). The use of TNF-α inhibitors was associated with a JD scores improvement 
of -2.313(-2.663 - -1.963; Table:5-2). 
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Table 5-2 Comparison between the effect size of TNF-α inhibitors and MTX on MC of the 

















every 8wk -5.7 1.55 2.401 -8.737 -2.663 -3.678 0 
UK 
MTX+INF3mg/kg 
every 4wk -5.4 1.776 3.155 -8.881 -1.191 -3.04 0.002 
UK 
MTX+INF10mg/kg 
every 8wk -6.8 1.273 1.621 -9.295 -4.305 -5.341 0 
UK 
MTX+INF10mg/kg 
every 4wk -7.7 1.364 1.861 
-
10.374 -5.026 -5.645 0 
ASPIRE 
MTX+INF3mg/kg 
every 8wk -3.3 0.65 0.423 -4.574 -2.026 -5.077 0 
ASPIRE 
MTX+INF6mg/kg 
every 8wk -3.2 0.641 0.411 -4.457 -1.943 -4.989 0 
BeSt MTX+INF3-
10mg/kg every 
8wk -5.8 1.449 2.1 -8.64 -2.960 -4.003 0 
TEMPO ETA25mg 
twice weekly -1.17 0.288 0.083 -1.734 -0.606 -4.067 0 
TEMPO 
MTX+ETA25mg 
twice weekly -2.3 0.363 0.132 -3.012 -1.588 -6.336 0 
BBOTT 40mg 
every other week -2.6 0.675 0.455 -3.923 -1.277 -3.853 0 
BBOTT 
MTX+20mg every 
other week -1.9 0.667 0.455 -3.207 -0.593 -2.848 0.004 
 
Effect size -2.313 0.179 0.032 -2.663 -1.963 -12.935 0 
 
We also compared the effect between TNF-α inhibitor combined with MTX/TNF-α 
inhibitor used alone and MTX on RR of the progression of JD in active RA patients. In 10 
independent studies which compared the effect of MTX and TNF-α inhibitor in 
combination with MTX on RR of the progression of JD in active RA patients, we used 
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random effects model for heterogeneity (P=0.001, I2=67%). We found the effect size of 
TNF-α inhibitor in combination with MTX on RR of the progression of JD was 
significantly inhibited than that of MTX (Z=6.98; P=0.00001). In 2 independent studies 
which compared the effect of MTX and TNF-α inhibitor used alone on RR of the 
progression of JD in active RA, we used fixed effects model for heterogeneity (P=0.79, 
I2=0). We found TNF-α used alone also displayed a more distinctive advantage than MTX 
on RR of the progression of JD in active RA patients (Z=3.83, P=0.0001; Fig.5-3). 
Comparing the effect of these two subgroups, we found there was a significant difference 
between TNF-α inhibitors used alone and combined with MTX on RR of the progression 
of JD in active RA patients(P=0.0001;Table5-3). In addition, TNF-α inhibitors combined 
with MTX was associated with a 31% reduction on RR of the progression of JD 
comparing with TNF-α inhibitors used alone (Fig.5-3).  
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Figure 5-3 Comparison between the size effects of TNF-α inhibitors/combined with MTX 
and MTX on RR of the progression of JD in patients with active RA 
 
 
There was a significant heterogeneity among the data from studies selected in our project, 
when we tried to put the related data together to do meta-analysis (I2>50%). In order to 
find which reason caused these heterogeneities, the subgroup analysis was done. We found 
that there was a significant distinction among the effect size of subgroups on RR of the 
progression of JD in activated RA patients, when we divided the group according to 
whether using MTX as a complementary or different type of TNF-α inhibitors(p<0.0001, 
p=0.00007). In addition, dividing the group according to the degree of HAQ also resulted 
in the significant distinction between the effect size of subgroups on RR of the progression 
Study or Subgroup
1.1.1 Combination vs MTX
ASPIRE 3mg/kg every 8wk
ASPIRE 6mg/kg every 8wk
BeSt 3mg/kg every 8wk
COMET 50mg weekly
PREMIER 40mg every other
TEMPO 25mg twice weekly
UK 10mg/kg every 4wk
UK 10mg/kg every 8wk
UK 3mg/kg every 4wk
UK 3mg/kg every 8wk
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 0.11; Chi² = 27.06, df = 9 (P = 0.001); I² = 67%
Test for overall effect: Z = 6.98 (P < 0.00001)
1.1.2 TNF vs MTX
PREMIER 40mg every other
TEMPO 25mg twice weekly
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 0.00; Chi² = 0.07, df = 1 (P = 0.79); I² = 0%
Test for overall effect: Z = 3.83 (P = 0.0001)
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.14; Chi² = 57.32, df = 11 (P < 0.00001); I² = 81%
Test for overall effect: Z = 6.27 (P < 0.00001)
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 128
of JD in activated RA patients (p=0.02). However, there was no statistic difference 
between the effect sizes of subgroups on RR of the progression of JD in activated RA 
patients, when we divided the group according to whether took DMARDs before, whether 
took Corticosteroids/ Glucocorticoid before, whether took NSAIDs before, whether RF 
appeared a  positive response, the level of CRP(mg/L), the level of ESR(mm/h), the degree 
of DAS28, the number of swelling joints, the number of tender joints, the compliance of 
RA patients, the age of patients or the duration of RA(months)(p>0.05;Table5-3) 
Table 5-3 Subgroup analysis for confirming the influencing factors of heterogeneities. 
 
Subtotal(n)  RR(95%CL) P value 
Complementarity 
TNF-α inhibitors 860 0.77(0.67,0.88) 0.0001 
Combinated with 
MTX 3957 0.43(0.33,0.56) 
Different type of TNF-α inhibitor 
Inflixmab 1744 0.23(0.17,0.32) 0.00007 
Etanercept 767 0.56(0.47,0.66) 
Adalimab 1056 0.67(0.6,0.76) 
Previous took DMARDs,No.%  
20-40 2596 0.48(0.34,0.68) 0.84 
0-19 916 0.45(0.25,0.81) 
Previous took Corticosteroids or Glucocorticoid ,No.%  
40-65 1602 0.45(0.32,0.62) 0.8 
15-39 2120 0.47(0.31,0.72) 
Previous took NSAID,No.%  
≥80 1745 0.41(0.24,0.70) 0.62 
60-79 921 0.34(0.21,0.56) 
RF positive,No.% 
≥75 445 0.28(0.15,0.56) 0.56 
55-74 1980 0.36(0.21,0.61) 
CRP(mg/L) 
250-350 681 0.60(0.38,0.93) 0.2 
20-50 3041 0.41(0.29,0.56) 
ESR(mm/h) 
46-55 921 0.34(0.21,0.56) 0.48 
35-55 1064 0.25(0.13,0.49) 
DAS28 
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6.0-8 532 0.61(0.47,0.80) 0.14 
4-5.9 916 0.41(0.26,0.65) 
HAQ 
≥1.6 1532 0.48(0.35,0.66) 0.02 
＜1.6 235 0.20(0.10,0.41) 
Number of swelling joints(0-68 possible joints) 
20-29 3246 0.45(0.33,0.60) 0.62 
10.0-19 476 0.49(0.37,0.66) 
Number of tender joints(0-71 possible joints) 
27-36 3246 0.45(0.33,0.60) 0.62 
17-26 476 0.49(0.37,0.66) 
Compliance 
>95 235 0.20(0.10,0.41) 0.11 
60-80 2908 0.38(0.27,0.54) 
Age(years) 
≤52 1736 0.40(0.26,0.60) 0.5 
>52 681 0.33(0.31,0.64) 
Duration of RA(months)  
125-132 1501 0.47(0.32,0.69) 0.83 
60-80 2221 0.44(0.31,0.64) 
NSAID =non-steroidal anti-inflammatory drugs; RF= Rheumatoid factor; CRP=C-reactive 
protein; ESR= erythrocyte sedimentation rate; DAS28=28-joint Disease Activity Score; 
HAQ=Health Assessment Questionnaire. 
* Number may not add up to 100% of total because of missing data in some variables.  
Through subgroup analysis, we found “whether using MTX as a complementary” and 
“different types of TNF-α inhibitors” were two major factors which strongly modify the 
efficacy of TNF-α inhibitors on RR of the progression of JD in activated RA patients. 
Thus, we divided 12 independent studies into 5 subgroups (including INF combination 
with MTX, ETA combination with MTX, ADA combination with MTX, treated with ETA 
and treated with ADA groups) according these two major factors. In five subgroups, only 
first two subgroups (INF combination with MTX and ETA combination with MTX) were 
composed by multi-studies, and other subgroups just comprised one trial. There was low 
heterogeneity in first two subgroups (p=0.38 I2=6%; p=0.86 I2=0). Both effect sizes of INF 
combination with MTX and  ETA combination with MTX on RR of the progression of JD 
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in activated RA were better than that of MTX used alone 
(Z=9.35,p<0.00001;Z=6.49,p<0.00001). INF used with MTX displayed a 77% (RR 0·23, 
95% CI 0.17–0.32) and ETA displayed a 52% (RR 0·48, 95% CI 0.39–0.60) reduction RR 
of the progression of JD in patients with activated RA comparing with MTX used alone. 




Figure 5-4 Comparing between the effect size of TNF-α inhibitors combined with MTX 
and MTX on RR of the progression of JD in active RA patients after grouping according 




5.1.1 Infliximab combination with MTX
ASPIRE 3mg/kg every 8wk
ASPIRE 6mg/kg every 8wk
BeSt 3mg/kg every 8wk
UK 10mg/kg every 4wk
UK 10mg/kg every 8wk
UK 3mg/kg every 4wk
UK 3mg/kg every 8wk
Subtotal (95% CI)
Total events
Heterogeneity: Chi² = 6.36, df = 6 (P = 0.38); I² = 6%
Test for overall effect: Z = 9.35 (P < 0.00001)
5.1.2 Etanercept combination with MTX
COMET 50mg weekly
TEMPO 25mg twice weekly
Subtotal (95% CI)
Total events
Heterogeneity: Chi² = 0.03, df = 1 (P = 0.86); I² = 0%
Test for overall effect: Z = 6.49 (P < 0.00001)
5.1.3 Adalimab combination with MTX




Test for overall effect: Z = 5.97 (P < 0.00001)
5.1.5 Treat with Etanercept




Test for overall effect: Z = 2.05 (P = 0.04)
5.1.6 Treat with Adalimab




Test for overall effect: Z = 3.25 (P = 0.001)
Total (95% CI)
Total events
Heterogeneity: Chi² = 57.32, df = 11 (P < 0.00001); I² = 81%
Test for overall effect: Z = 13.04 (P < 0.00001)
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We used meta-regression analysis to examine the correlation between the common risk 
leading to the progression of JD and the effect size of TNF-α inhibitors on the RR of the 
progression of JD in active RA patients. These risk factors included the duration of RA, 
age, DAS28, CRP and ESR. We selected the available independent studies for these risk 
factors, 10 studies for the duration of RA, 11 studies for the age, 6 studies for DAS28, 9 
studies for CRP and 7 studies for ESR (Table5-4).We noted there was no correlation 
between log RR and the increased disease duration/age (p=0.23, p=0.25; Table5-4). There 
was a significant negative correlation between log RR and the increased the degree of 
DAS28, CRP and ESR (p=0.026, p=0.0073, p=0.014; Table5-4) 
Table 5-4 Summary of meta-regression analysis 
 
 Slope (CL95%) P value Available studies 
Duration of RA 0.00189(0.00026, 0.00352) 0.23 10 
Age 0.075 (0.036, 0.114) 0.25 11 
DAS28 0.23(-0.009,0.47) 0.026 6 
CRP 0.00017 (-0.0008,0.0012) 0.0073 9 
ESR 0.085 (-0.028, 0.198) 0.014 7 
 
Egger’s regression analysis showed that publication bias was present (p=0·0002; Figure5-
5). We therefore used the fail-safe methods to estimate the number of potential missing 
studies needed to significantly change the conclusion of our findings. This analysis showed 
that, to nullify our estimated effect size, 484 studies with non-significant findings would be 
needed. In view of the fact that there have been no more than 10 studies published over the 
last 8 years, it is highly improbable that such a large number of similar studies would have 
gone unpublished or have been missed out by our extensive search strategy. Furthermore, 
the missing studies were likely to be small, the effect of which is probably very negligible. 
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Figure 5-5 Funnel plot to assess publication bias 
 
5.7 Discussion 
The main finding of this systemic review is that TNF-α inhibitors (used alone and in 
combination with MTX) significantly improved the progression of JD compared with 
MTX alone in active RA patients. Through further analysis, we found that both two 
administrations of TNF-α inhibitors significantly retarded the progression of JD compared 
with MTX in active RA patients respectively, and TNF-α inhibitors in combination with 
MTX displayed the more powerful inhibition on the progression of JD than TNF-α 
inhibitors used alone in active RA patients. These findings indicate a better efficacy can be 
achieved when using TNF-α in conjunction with MTX to prevent the progression of JD in 
active RA patients.  
It should be pointed out that heterogeneity was observed in the present study with the 
pooled data from the selected studies, but not with dividing these studies into different 
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subgroups, according to identified impact factor for meta-analysis. Many factors may 
affect the heterogeneity in meta-analysis. We have summarized 13 common factors 
specific to RA, including complementary with MTX, different types of TNF-α inhibitors, 
HAQ, took DMARDs before, took / Glucocorticoid before, took NSAIDs before, RF 
appeared a  positive response, CRP, ESR, the number of swelling joints, the number of 
tender joints, the compliance of RA patients, the age of patients and the duration of 
RA(months)437,450,469-473. Among these factors, complementary with MTX and different 
types of TNF-α inhibitors seems the main reason for the heterogeneity. After we divided 
the all involved studies into subgroups according these two main factors, the 
heterogeneities in subgroups disappeared. TNF-α inhibitors in combination with MTX 
displayed the most powerful inhibition on the progression of JD in active RA patients 
comparing with TNF-α inhibitors/ MTX used alone.  
Among the three types of TNF-α inhibitors approved by the FDA, ADA is constructed 
from a fully human monoclonal antibody, while INF is a mouse-human chimeric antibody 
and ETA is a TNF receptor-IgG fusion protein. Comparing the effect of different types of 
TNF-α inhibitors on the progression of JD in active RA patients, we found that INF in 
combination with MTX displayed more powerful inhibition on the progression of JD than 
EDA or ADA in combination with MTX. This result indicates that to control the 
progression of JD of active RA patients, INF in combination with MTX seems a good 
choice. There is no one paper about INF used alone to improve the progression of JD in 
active RA. However, comparing the effect of EDA and ADA used alone on the 
progression of JD in active RA patients, we found that there is no distinction between the 
inhibitions of them on the progression of JD. 
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The degree of activity of RA was directly related to changes in radiologic progression in 
patients with active RA442. In this study, we have also found that the degree of activity of 
RA affected the efficacy of TNF-α inhibitors on the progression of JD in active RA.  Three 
important markers of RA activity are CRP, ESR and DAS28. We found there was a 
negative correlation between the therapeutic effect by TNF-α inhibitors and the increased 
level of CRP, ESR or DAS28.  This suggests that a better outcome for the patients with 
higher level CRP, ESR or DAS28 than those patients with lower level CRP, ESR or 
DAS28.   
In summary, the present study has demonstrated that TNF-α inhibitors in combination with 
MTX has a better efficacy on the progression of JD in active RA than TNF-α 
inhibitors/MTX used alone, and INF in combination with MTX exhibits more powerful 
effect than other types of TNF-α inhibitors. In addition, CRP, ESR and DAS28 are factors 
affecting the efficacy of TNF-α inhibitors on progression of JD in active RA patients. The 
evidence obtained may provide a guide /support for rheumatologists and patients to select 
and best use of anti-RA drugs.    
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Chapter 6. General Discussion 
6.1 Major Findings of this Project 
As mentioned in Chapter 1, COPD is characterised by a persistent inflammation in the 
airway and lungs which results in airway obstruction. Current treatments for COPD are 
still not satisfactory and there is a need to develop new therapies targeting inflammatory 
mechanisms. Ginseng is a well-known medicinal herb and has been used in the treatment 
of COPD. Understanding the mechanism of anti-inflammatory actions of ginseng and 
ginseng based formulas will facilitate the development of novel agents for treating COPD 
and other inflammatory diseases. The main objective of this project is to study the action 
and mechanism of ginseng and ginsenosides on cytokine mediators in inflammatory cells 
models.The key hypothesis is that ginseng and ginsenosides may target TNF-α, cAMP and 
NF-κB signalling pathway to exert their anti-inflammatory actions. In order to test this 
hypothesis, a cell inflammatory model was firstly set up using macrophage-like U937 cells 
induced by LPS or CSE, which then be used to evaluate the effects of ginseng and 
ginsenosides on cellular release of cytokines and activation of NF-κB and cAMP 
pathways.  
Firstly, a cell inflammatory model was successfully set up using macrophage-like U937 
cells induced by LPS and CSE. The model exhibited significant activation NF-κB 
pathway, supported by the findings of increased release of cytokine (NF-α, IL-1β and IL-
6) and up-regulated expression of key NF-κB proteins (IKK, p-IKK, IκBα, p-IκBα, p65 
and p-p65), as well as the transcriptional activity of NF-κB by LPS and/or CSE. In 
addition, a possible interaction between NF-κB and CAMP pathways was also 
demonstrated with findings of effects of NF-κB pathway inhibitor (BAY11-7082), cAMP 
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pathway activator and inhibitor (Foskolin and H89) on TNF-α release, and on the 
transcriptional activity of NF-κB by LPS (Fig. 6-1).  


























Figure 6-1: Establishment of LPS induced macrophage-like U937 cell models and the 
interaction between NF-κB and cAMP pathways in this model. 
“↑” is used to display the up-regulating effect of LPS on the expression of p-IKK, p-IκBα, 
p-p65 and p-CREB, the level of cAMP, the activity of PDE4, the transcriptional activity of 
NF-κB and the release of IL-1β, IL-6 and TNF-α in macrophage-like U937 cells. “↓” is 
used to display the inhibitory effect of Bay11-7082 on the expression of p-IKK, p-IκBα, p-
p65, IKK, IκBα and p65, the transcriptional activity of NF-κB and the release of TNF-α 
induced by LPS. “↑” is used to display the up-regulation of Foskolin on the level of cAMP 
and the expression of p-CREB induced by LPS; “↓” is used to display the down-regulation 
of Foskolin on the transcriptional activity of NF-κB and the release of TNF-α induced by 
LPS. “X” is used to display H89 abolished the inhibition of Foskolin on the transcriptional 
activity of NF-κB and the release of TNF-α induced by LPS. 
 Secondly, the effects of ginseng (G115) and several ginseng formulas (GHMFs) as well as 
ginsenosides on the release of cytokines were investigated. GHMF I&II, composed by 
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commercial herbal extracts from China, displayed the similar inhibition on the release of 
TNF-α, GHMF-III, composed by raw-herbal extracts without polysaccharide components, 
displayed more potent inhibition on the release of TNF-α than that of GHMF-IV which 
was prepared in the same way as GHMF-III except including polysaccharide components, 
indicating that the polysaccharide components in ginseng may weak the anti-inflammatory 
actions of ginseng.It was found that the release of TNF-α was significantly inhibited by 
GHMF-III, Rb1, Rg1, Rg3, CK and Rh1 in LPS induced cell model and G115and GHMF-
III in CSE induced cell model. GHMF-III, G115, Rb1 and Rg1 also inhibited the release of 
IL-1β and IL-6 induced by LPS. Among the GHMFs tested, GHMF-III seemed to be most 
potent.  
Thirdly, the effects of ginseng and ginsenosides on the activation of NF-κB signalling 
proteins were investigated. G115, GHMF-III, Rb1, Rg1, Rh1 and CK, but not Rh2 
significantly inhibited the expression of IKK, p-IKK, IκBα, p-IκBα, p65 and p-p65 
(Table6-1) and decreased the transcriptional activity of NF-κB induced by LPS. G115, 
GHMF-III and Rg1, but not Rb1, Rh1, CK and Rh2 also significantly increased the 
cellular level of cAMP and the expression of p-CREB, but inhibited the activity of PDE4 
induced by LPS. These findings indicate that ginseng has a significant inhibition of 
cytokine release and activation of NF-κB pathway in LPS-induced macrophage-like U937 
cells. In addition, ginseng and ginseng related products may also act as PDE4 inhibitor to 




Table 6-1 Regulation of Ginseng and Ginseng related products on the expression of 
proteins in RPs of NF-κB pathway 
p-IKK IKK p-IκBα IκBα p-p65 p65 
G115 ↓*** ↓** ↓** ↑** ↓*** no 
GHMF-III ↓*** ↓*** ↓** ↑* ↓** no 
Rb1 ↓*** ↓*** ↓** ↑* ↓*** no 
CK ↓* no ↓*** no ↓** no 
Rg3 ↓* ↓* ↓* no ↓*** ↓* 
Rh2 No no no no no no 
Rg1 ↓*** no ↓*** no ↓** no 




Finally, as a separate research objective in the present project, a systemic review was 
conducted to evaluate the clinical efficacy of TNF-α inhibitors in the treatment of 
progression of JD in active RA. Data from randomised controlled trials were collected and 
a meta-analysis was conducted to compare the effects of TNF-α inhibitors on the 
radiological progression of active RA patients when used alone or combined with MTX, 
and to study the correlation between the degree of activity of RA and the efficacy of 
different types of TNF-α inhibitors. It was found that TNF-α inhibitors showed a better 
efficacy on the progression of JD in active RA than that of MTX, and TNF-α inhibitors in 
combination with MTX produced a better efficacy than TNF-α inhibitors used alone. 
Among different types of TNF-α inhibitors, infliximab in combination with MTX 
exhibited a better efficacy than other types of TNF-α inhibitors on the progression of JD in 
active RA patients. The markers of RA activity, including CRP, ESR and DAS28, were 
shown to be associated with the efficacy of TNF-α inhibitors on progression of JD in 
active RA. These findings may help to guide clinical use of TNF-α inhibitors to treat JD in 
active RA patients.  
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6.2 Inflammatory Cell Model 
LPS and CSE induced macrophage-like U937 cells have been used as inflammatory cell 
models for studying the pathogenesis of human-COPD394,396,474. It has been demonstrated 
that inflammatory mediators generated by macrophage-like U937 cells in response to LPS 
and CSE, initiate and/or amplify abnormal inflammations in COPD279,394,475. Previous 
studies showed that LPS induced macrophages to secrete a broad-spectrum inflammatory 
mediators, including TNF-α, IL-1β, IL-6, IL-8, IL-10, IL-12, TGF-β and MMP-1474,475.  
CSE, as a specific pathogen of COPD, also stimulated macrophage to release the IL-8, 
TNF-α, IL-1β, IL-6 and IL-17279,280,476-478.The present study has focused on the regulation 
of ginseng and its related products on the release of TNF-α. TNF-α is powerful 
inflammatory mediator released by LPS and CSE induced cell models279,394,396. The 
demonstration of TNF-α release and activation of related NF-κB pathway are a clear 
indication of success of the cell model. In this regard, the present results are consistent 
with previous findings279,394,394., 
6.3 Actions of G115 and Ginseng Formulas 
G115 is a standardized extract of ginseng with ginsenosides as its main active components 
and a clinical trial has demonstrated its efficacy in moderately-severe COPD condition 220. 
However, the pharmacological mechanism involved is not clear. The finding that G115 
inhibited the release of TNF-α in LPS and CSE induced macrophage-like U937 cells 
indicate it may act through inhibition of inflammatory mediators. Thus the study provides 
experimental evidence to support the use of G115 for COPD. We also proved G115 and 
GHMF-III inhibited the release of TNF-α through down-regulating the activity of NF-κB 
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and up-regulating the activity of cAMP pathways to inhibit the transcriptional activity of 
NF-κB induced by LPS.  
The present study has tested several ginseng formulas. All these formulas are developed 
based on clinical experience Guangdong Provincial Hospital in China. These formulas are 
three herb formulations with ginseng as main ingredient. The first type of GHMF is 
composed by commercial extracts of individual herbs. This type of GHMF is convenient 
for standardization of application of GHMF in clinic. This kind of preparation is more 
easily administrated than traditional oral decoction. In this project, we compared the effect 
of GHMFs from different pharmaceutical companies. GHMF-I is composed by extracts 
from Guangdong, and GHMF-II composed by extracts from Jiangsu. Although GHMF-I 
demonstrated more significant inhibition on the release of TNF-α than GHMF-II at low 
and high concentration, at middle concentration (the most effective concentration) of 
GHMF-I&II, there was no distinction between the release of TNF-α of them. The second 
type of GHMF is extracted from traditional mixture of raw herbs with different extracting 
techniques. The most significant difference between GHMF-III and GHMF-IV is 
polysaccharide components. The findings that GHMF-III exhibits a more powerful 
inhibition on TNF-α release than GHMF-IV indicates that polysaccharide component of 
ginseng may affect the anti-inflammatory actions of ginsenosides. Studies have shown that 
ginsenosides displayed inhibitions on inflammatory response, such as decreasing the 
release of cytokines, down-regulating the activity of inflammation-related pathway, 
etc479,480. On the other hand, the polysaccharides of many herbs have been used in the 
treatment of cancers, such as Ginsan which is the polysaccharide extract from ginseng. 
Previous studies demonstrated that Ginsan showed an anti-tumor effect through increasing 
the production of inflammatory factors, such as TNF-α, IL-1β, IL-6, IL-12, GM-CSF and 
IFN-γ to aggravate the inflammatory response481-483. Thus, the polysaccharide in GHMF-
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IV may weaken the anti-inflammatory effect of GHMF-IV comparing with GHMF-III. 
This is consistent with the finding that GHMF-III, as only GHMF excluding 
polysaccharide, displayed the most potent inhibition on TNF-α release among all GHMFs 
tested. Thus, GHMF-III may have a potential for further development as ginseng-based 
formula for the treatment of COPD. 
In the classical theory of Chinese medicine, there is usually the main herb in a formula 
which displays the pharmacological characteristics in the course of treatment of diseases, 
and other herbs in the formula usually play a supporting role. However, this theory 
although seems to have been verified in clinic, is difficult to be proved in the experimental 
setting. In this project, we chose TNF-α as a target, and tried to find the correlation 
between the ginseng and GHMF-III on the inhibition of the release of TNF-α induced by 
LPS. We found that there is a significant correlation between the GHMF-III and G115 on 
the inhibition on the release of TNF-α induced by LPS/CSEM, indicating the action of 
GHMF-III may mainly related to ginseng. However, further study is necessary to exclude 
the contributions of other herbs on this effect.  
6.4 Actions of Ginsneosides 
6.4.1 PDGs & PTGs 
The main bioactive compounds in ginseng are ginsenosides, which can be classified into 
two types, dammarane and oleanane (Ro). The dammarane type ginsneosides includes two 
sub-types: protopanaxadiols(PDGs) and protopanaxatriols (PTGs)(see Section 1.2.2.1). 
PDGs and PTGs include the most commonly used ginsenosides, such as Rb1, Rb2, Rc, Rd 
and Rg3(PDGs) Rg1, Re and Rf (PTGs)324. Some studies have shown that PDGs and PTGs 
displayed different effects on the specific biological mechanisms. For example, Liu found 
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that PDGs inhibited the pancreatic lipase activity in a dose-dependent manner, but PTGs 
showed no such effect.  In the present study, Rb1 and Rg3 were selected as the 
representative of PDGs and Rg1 as the representative of PTGs to test their effects on the 
release of TNF-α and NF-κB pathway in macrophage-like U937 cells induced by LPS. 
Both ginsenoside Rb1 and Rg3 significantly inhibited the release of TNF-α induced by 
LPS, accompanied with down-regulations of the expression of IKK, p-IKK, p-IκBα and p-
p65, as well as the decreased the transcriptional activity of NF-κB. Rb1 also increased the 
expression of IκBα and Rg3 also decreased the expression of p65. These results indicate 
that PDGs type ginsenoside Rb1, Rg3 inhibited the release of TNF-α through down-
regulating the NF-κB pathway. Similarly, Ginsenoside Rg1 significantly inhibited the 
release of TNF-α induced by LPS, accompanied with inhibition of the expression of p-
IKK, p-IκBα and p-p65and decrease in the transcriptional activity of NF-κB. In addition, 
Rg1 increased the level of cAMP, the up-regulated expression of p-CREB and CREB. The 
results indicate that Rg1 not only inhibited the activity of NF-κB pathway, but also up-
regulated the activity of cAMP pathway to inhibited the release of TNF-α induced by LPS. 
Most likely Rg1 achieved the up-regulation of cAMP pathway through inhibition of the 
activity of PDE4. Since Rb1 had no effect on cAMP level, the results suggest that PDGs 
may act on mainly on NF-κB pathway, while PTGs may regulate both NF-κB and cAMP 
pathways to inhibit the release of TNF-α, which is partly through inhibiting the activity of 
PDE4. Such different actions of ginsenosides may help to understand the complex actions 
of ginseng. 
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6.4.2 Metabolites of Ginsenosides 
The study on the effect of metabolites of ginsenosides is very important, as the absorption 
of some ginsenosides through the gastrointestinal tract is very low in vivo326,327.  Most of 
metabolites displayed the analogous pharmacological actions to corresponding 
ginsenosides. Previous studies showed that both ginsenoside Rb1 and its metabolite, CK, 
significantly inhibited the expression of p-p65 and p-IκBα in LPS induced mouse 
peritoneal macrophages340. In addition, both ginsenoside Rg1 and its metabolit, Rh1, 
activated cAMP pathway and decreased the transcriptional activity of NF-κB. In the 
present study, rRg1 and Rh1 also showed the analogous regulation on the expression of 
proteins in NF-κB pathway, the transcriptional activity of NF-κB and the release of TNF-α 
induced by LPS. However, Rh2, the metabolite of ginsenoside Rg3 couldn’t inhibit the 
expression of proteins in NF-κB pathway, the transcriptional activity of NF-κB and the 
release of TNF-α induced by LPS as Rg3, and increased the release of TNF-α induced by 
LPS at high concentration. The regulatory mechanism of Rh2 on TNF-α is still uncertain. 
It maybe involve in some specific mechanism. 
6.5 Interaction between NF-κB and cAMP Pathways 
It is known that NF-κB can be activated by a series of the PRs in NF-κB pathway, and then 
enter into nucleus to transform into promoter to classically transcribe the mRNA 
expression of TNF-α484. This is supported from findings of the present study ,as well as the 
effect of Bay11-7082, an inhibitor of NF-κB pathway (see Chapter 4). . 
One of interesting finding is the interaction between NF-κB and cAMP pathways. It has 
been demonstrated that the transcriptional activity of NF-κB can be inhibited by activated 
cAMP pathway through its down-stream factor (p-CREB) competitively binding with 
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CBP279,280. The elevated the level of cAMP also decreased the release of TNF-α, which 
was accompanied with the activation of cAMP pathway485. However, there was no 
evidence on inhibition of release of TNF-α by activated cAMP pathway through down-
regulating the transcriptional activity of NF-κB. In the present study, Foskolin, a cAMP 
pathway stimulator, had no effect on the activity of PRs in NF-κB pathway, but 
significantly inhibited the release of TNF-α induced by LPS486, the effect accompanied 
with the increased levels of cellular cAMP and expression of p-CREB, and the decreased 
transcriptional activity of NF-κB. The effects of Foskolin were blocked by the cAMP 
pathway inhibitor H89. Thus, it is most likely that activated cAMP pathway cause down-
regulate the release of TNF-α through inhibiting the transcriptional activity of NF-κB. 
6.6 Inhibition by Ginseng and Ginseng Related Products on the Release of IL-1β and IL-6 
IL-1β and IL-6 are the important inflammatory factors in COPD. A previous study in IL-
1β type 1 receptor knockout mice showed that IL-1β was involved in the formation of 
emphysema487. IL-1β was also involved in the regulation on the production of MMPs488. 
The role of IL-6 in the phathogensis of COPD is still uncertain, however, it has been 
shown that IL-6 was increased in sputum, bronchoalveolar lavage, and exhaled breath 
condensate of COPD patients, especially during exacerbations124,489. The concentration IL-
6 was also increased in the plasma of COPD patients125,126,227, particularly during 
exacerbations228. In the present study, G115, GHMF-III, Rb1 and Rg1 significantly 
decreased the secretion of IL-1β and IL-6 induced by LPS, the effect was very similar with 
the inhibitions by these agents on the release of TNF-α. These results further support the 
anti-inflammatory effect of ginseng and ginseng products, and their actions on NF-κB 
pathway. 27,28. 
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6.7 Use of TNF-α Inhibitors for Treating JD in Patients with Active RA. 
Controlling the progression of JD is the most important treatment consideration for 
managing RA. However, there was no effective drug available to control or slow the 
progression of JD in active RA until the recent application of TNF-α inhibitors419. Now 
there  clear evidence showing that both TNF-α inhibitors used alone and combined with 
MTX significantly improved the progression of JD in active RA patients through valuing 
the radiological scores of these patients437,446,448-452. However, there is still no evidence to 
verify which kind of administration of TNF-α inhibitors in combination with MTX or 
using alone is better and which particular TNF-α inhibitors are more beneficial for the 
improvement of JD in active RA patients. In addition, we are also unclear that the affecting 
factor of efficacy of TNF-α inhibitors on the progression of JD in active RA patients. The 
present meta-analysis reveal that TNF-α inhibitors (used alone and combined with MTX) 
significantly improved the progression of DJ, comparing with MTX used alone, in active 
RA patients. Thus, the synergic action of TNF-α inhibitors and MTX should be considered 
as a preferred treatment option for managing progression of DJ in active RA patients. 
Among the TNF-α inhibitors, INF in combination with MTX seems to be more potent than 
others. In addition, the finding of a negative correlation between the inhibition of 
progression of DJ by TNF-α inhibitors and the increased level of CRP, ESR or DAS28 
indicates that a better clinical outcome may be achieved for RA patients with higher level 
CRP, ESR or DAS28 than those patients with lower level CRP, ESR or DAS28. Thus, it is 
recommended that TNF-α inhibitors in conjunction with MTX should be used to treat the 
progression of DJ for active RA patients, especially for those with the high active risk. 
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6.8 Limitations of the Study 
The present study has achieved the main research objective to identify the mechanism of 
anti-inflammatory actions of ginseng and ginseng related products. However, the study 
also has some limitations.  
First, the nature of study is in vitro and limited to LPS and CSE related mechanisms. It is 
not clear if the observed actions of ginseng also occur in other inflammatory conditions 
and more importantly in vivo. Previous studies showed that RG, PDGs, Rg3, Rf and Rh2 
significantly inhibited the release of TNF-α in diethyldithiocarbamate and LPS induced 
animal model379,383;  Rg1  increased  the level of cAMP in hippocampus of both young and 
old rats, and Rb1 also increased the level of cAMP in rat liver compared with that in 
controls354. These results indicate that TNF-α as well as NF-κB and cAMP pathways may 
also be the target of ginseng and ginsenosides in vivo. 
Second, the present study has used a commercial cell line U937. It is important to extend 
the study to primary cells. Previous study demonstrated that ginseng significantly inhibited 
the release of TNF-α in OMP, ConA or  anti-CD3 induced lung cells from CBA/J mice  
374; Rb1 and CK down-regulated the expression of p-IκBα and p-p65 in mouse peritoneal 
macrophages induced by LPS340. These results show that ginseng and ginsenosides may 
also involve in the regulation on the release of TNF-α and the activation of the key 
proteins in NF-κB pathway in primary cells. 
Thirdly, the present study only studied key proteins in NF-κB and cAMP pathways, It is 
not clear if other mechanisms, including PI3K/Akt and ERK1/2 and P38, are also 
involved, as all of them contribute the activation of NF-κB pathway (see chapter1).  
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Finally, it should be pointed out the concentrations tested in vitro may not apply to the 
situation in vivo, as It is not clear how the body metabolism process affects the absorption 
and fate of ginseng and ginseng products in vivo.  
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6.9 Future Directions 
It is important to carry out further studies on ginseng. Based on the results of the present 
study, the following research work can be carried out in the future: 
 Test the effects of ginseng, ginseng formulas and ginsenosides in smoke-induced 
COPD animal model in vivo. 
 Extend the in vitro study to primary human cells and tissues 
 Employ gene modification technique to study the role of particular proteins, e.g. 
CREB on actions of ginseng 
 Conduct further studies on interactions between NF-κB and cAMP pathways on 
regulation of cellular cytokine productions in vitro and in vivo 
 Conduct clinical studies to evaluate the efficacy and safety of ginseng and effective 
ginseng formula on managing COPD. 
 Using Mass spectrum and HPLC to find activation compound of Ginseng and 
GHMFs. 
 And more control experiments need to be down by using GHFs(Ginseng and 
HunagQi Extraction), GMFs(Ginseng and Maidong Extraction)and HMFs(Ginseng 
free, only HuangQi and Maidong extraction), to narrow down the activate 
compounds. 
 To identify and the active some molecular compound as NFkB inhibitor or 















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Appendix 1 : RIPA Buffer 
For 250mL stock, to be stored at 4ºC: 
 65mM Tris = 1975mg 
 150mM NaCl = 2250mg 
 Add dd H2O to ~180ml, stir until clear and pH to 7.4 with HCl 
 5mM EDTA = 12.5ml of a 100mM stock 
 1% NP-40 = 2.5ml of a 100% stock 
 0.5% Na-deoxycholate = 12.5ml of a 10% stock 
 0.1% SDS = 2.5ml of a 10% stock 
 10% glycerol = 25ml of a 100% stock 
On the day of use, to a total of 50ml of RIPA buffer, add the following protease and 
phosphatase inhibitors: 
 1μg/ml aprotinin = 24µl of a 2.1mg/ml stock (inhibits trypsin and related 
proteolytic enzymes) 
 1μg/ml leupeptin = 5µl of a 10mg/ml stock (inhibit cysteine, serine and threonine 
peptidases) 
 10mM NaF = 2.5ml of a 200mM stock (inhibits serine and threonine 
phosphorylation) 
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 1mM Na3VO4 = 250µl of a 200mM stock (inhibits tyrosine phosphorylation) 
 1mM PMSF = 250µl of a 200mM stock (dissolved in 100% ethanol) (serine 
protease inhibitor) 








Appendix 2: Bradford Protein Concentration Assay 
 Dilute the extracts in d-H2O 
 Make up standards using Bovine Serum Albumen (BSA) at 3, 2, 1.5, 1, 0.75, 0.5, 
0.25 mg/ml. 
 Dilute the Biorad protein dye reagent 1:4 with d-H2O and load this solution in a flat 
bottom 96 wells plate (200µl/well). 
 Add 10ul standard or protein sample in each well. Perform all samples in duplicate. 
 Include a room template for 30 minutes. 




Appendix 3: The preparation of 10% Gel 
 Thoroughly clean glass plates with detergent, wash with tap water, rinse with 
distilled water several times, and air dry.  
 Assemble gel unit in the casting mode according to the instructions.  
 Check for potential leaks by pipetting some distilled water into the assembled unit. 
Then drain away the water by inverting the unit.  
 Prepare the separating gel  
o Acrylamidebi-acrylamide(30%) : 8ml 
o 3M Tris-Hcl, PH8.8: 3 ml 
o Dd H2O: 12.56ml 
o 10% SDS: 240μl 
o 10% APS: 200μl 
o TEMED: 12μl 
 Immediately pipette the separating gel mixture into the assembled unit up to level 
that is ~3 cm from the top.  
 Load 1 ml isopropanol onto the surface of the acrylamide gel solution. The  
isopropanol layer will make the surface of the gel very even. After 20 minutes, a 
sharp gel-water interface can be visible after the gel has polymerized.  
 Drain away theisopropanol layer by gently tilting the casting unit and rinse with dd 
H2O, and dry it.  
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 Prepare the stacking gel 
o Acrylamidebi-acrylamide: 1ml 
o 2M Tris-Hcl, PH6.8: 500μl 
o Dd H2O: 6.4ml 
o 10% SDS: 80μl 
o 10% APS: 200μl 
o TEMED: 4μl 
 Pipette the stacking get mixture and insert the comb into the unit according to the 
instructions.  
 Allow the gel to polymerize and sit for 20 minutes.  
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Appendix 4: The formulations of various buffers in Western blot 
1. Running Buffer 
           10x Running buffer, for 1L 
 Glycine – 144g 
 Tris Base – 30g 
 Add distilled H20 to 900ml 
 pH to 8.9 
 Add 50ml of 10% SDS solution 
 Add H2O to 1L 
 
2. Transfer Buffer 
            1x Transfer Buffer, for 1L 
 100 ml 10 x stock 
 200 ml(20%) methanol 
 Add dd H2O to 1L 
 
3.  TBS-T 
            TBS-T (10X) pH: 7.5  
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 Tris base: 24.2 g  
 Sodium Chloride (NaCl): 80.0 g  
 Tween-20: 10 ml  
 Add dd H2O to 1L 
 Stripping Buffer 
 62.5ml 1MTris-HCl, pH 6.7 
 100ml 20% SDS 
 837.5ml d- H2O 
           On the day of use add 700ul 2-mercaptoethanol per 100ml  
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Appendix 5: NF-κB reporter assay 
 Seed 2.5x 105 macrophage-like U937 cells per well of a 24-well plate in 500μl of 
an appropriate culture medium containing serum and antibiotics. 
 Incubate the cells under normal growth conditions (typically 37°C and 5% CO2) for 
24 hours. 
 Wash cells in the plate once with Dulbecco’s PBS without calcium and 
magnesium. 
 Refresh medium with 500ul Opti-MEM® containing  0.6 μg NF-κB promoter-
firefly/Renilla luciferase (40/1) /Negative control/positive control   (QIAGEN Pty. 
Ltd.)  and 1.5ul  attractene transfection reagent (QIAGEN Pty. Ltd.)  each well  
 Dilute 0.6 μg DNA in 493 μl Dilute 0.6 μg DNA in 60 μl culture medium without 
serum. Add 1.5 μl of Attractene Transfection Reagent to the diluted DNA and mix 
by vortexing. 
 Incubate the samples for 10-15 minutes at room temperature (15-25°C) to allow the 
formation of transfection complexes. 
 Add the complexes drop-wise onto the cells. Gently swirl the plate to ensure 
uniform distribution of the transfection complexes. 
 After 18 hrs incubation, refresh the cell with normal culture medium for another 
6hrs 
 Refresh the medium with treatment drug. 
 After 2hrs pre-incubation, treat 1μg/ml LPS for 6hrs. 
 After the treatment, the cells were rinsed with cold PBS and lysed with reporter 
lysis buffer (Promega) 100ul/well. Place the culture plates on a rocking platform or 
orbital shaker with gentle rocking. Rock the culture plates at room temperature for 
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15 minutes. The lysate was centrifuged at 15,000 × g for 5 min at 4°C, and the 
supernatant was harvested.  Transfer the lysate to a tube or vial for further handling 
and storage. 
 Both firefly and Renilla luciferase levels were measured in a luminometer using the 
Dual-Glo® Luciferase Reporter Assay System (Promega Australia). 
 Predispense 100μl of Luciferase Assay Reagent II (LAR II) into each well. 
Carefully transfer up to 20μl of cell lysate into the well containing LAR II; mix by 
pipetting 2 or 3 times. Do not vortex. Place the plate in the luminometer and initiate 
reading. Program the luminometer to perform a 2-seconds premeasurementdelay, 
followed by a 10-second measurement period for each reporter assay. 
 Add100μl of Stop & GloR Reagent into each well and vortex briefly to mix. 
Replace the sample in the luminometer, and initiate reading. 
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Appendix 6: The protocol of cAMP assay 
1. Buffer Preparation 
 EIA Buffer Preparation 
Dilute the contents of one vial of EIA Buffer Concentrate (10x) with 90 ml 
of Ultra-pure water. Be certain to rinse the vial to remove any salts that may 
have precipitated. 
 Wash Buffer Preparation 
Dilute the Wash Buffer Concentrate (400x) to a total volume of 2 L with 
Ultra-pure water and add 1 ml Polysorbate 20. 
 Note 
Water used to prepare all reagents and buffers must be deionised and free of 
trace organic contaminants. 
Store all diluted buffers at 4°C; they will be stable for about two months. 
2. Preparation of Assay –Specific Reagents 
 cAMP AChE Tracer 
Dilute 100 dtn cAMP AChE Tracer with 6 ml EIA Buffer. 
 cAMP EIA Antiserume 
Dilute 100 dtn cAMP EIA Antiserume with 6 ml EIA Buffer. 
 Note 
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Store the reconstituted cAMP EIA Antiserume at 4C; they will be stable at 
least four weeks. 
3. Sample Preparation 
 Aspirate medium from 24 well-plate 
 Add 55 ul of 0.1 M HCL for every well of surface area. 
 Incubate at room temperature for 20 minutes. 
 Scrape cells off the surface with a cell scraper. 
 Dissociate the mixture by pipetting up and down until the suspension is 
homogeneous, and transfer to 1 ml centrifuge tube. 
 Centrifuge at 1000*g for 10 minutes. 
 Decant the supernatant into a new tube. 
 The preparation of cAMP standards 
 Reconstitute the cAMP EIA standard with 1 ml of EIA buffer. The 
concentration of this solution will be 7,500 pmol/ml. Store this solution at 
4C; it will be stable for approximately six weeks. 
 To prepare the standard for use in EIA 
Obtain eight clean 1ml tubes and number them 1through 8. Aliquot  900 μl 
EIA buffer to tube 1 and 600 μl EIA buffer to tubes 2-8. Transfer 100 μl of 
the bulk standard (7500pmol/ml) to tube 1 and mix thoroughly. The 
concentration of this standard, the first point on the standard curve, is 750 
pmol/ml. Serially dilute the standard by removing 300 μl from tube 1 and 
placing in tube2; mix thoroughly. Next, remove 300 μl from tube 2 and 
place it into tube 3; mix thoroughly. Repeat this process for tube 4-8. The 
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concentrations of these standards are 750 pmol/ml,250 pmol/ml,83.3 
pmol/ml,27.8 pmol/ml, 9.3 pmol/ml, 3.1 pmol/ml,1.0 pmol/ml and 0.3 
pmol/ml separately. These dilupted standards should not be store for more 
than 24 hours.  
4. Performing the assay 
 Add 50 μl EIA buffer to Maximum binding(B0 ) each well. 
 Add 50ul standard sample in standard well (1-8) and 50 μl sample in 
common well. 
 Add 50ul cAMP AChE Tracer to each well. 
 Add 50 μl cAMP EIA Antiserum to each well. 
 Cover each plate with platicfil, and incubate 18 hours at 4C 
 Reconstitute Ellman’s Reagent immediately before use. 
 Dilute 100 dtn vial Ellman’s Reagent with 20 ml of Ultra-pure water. 
 Empty the wells and rinse five times with wash buffer. 
 Add 200 μl of Ellman’s reagent to each well. 
 Cover the plate with plastic film. Optimum development is obtained by 
using an orbital shaker equipped with a large, flat cover to allow the plate to 
develop in the dark for 120 mins. 
 Wipe the bottom of the plate with a clean tissue to remove fingerprints, dirt, 
etc. 
 Remove the plate cover being careful to keep Ellman’s reagent from 
splashing on the cover. 
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 Read the plate at 420 nm. 
5. Calculations 
 Average the absorbance readings from all data. 
 Calculate the B/B0 (sample or standard bound/maximum bound) for the 
remaining wells. 
 Plot the standard curve 
 Plot %B/B0 for standards 1-8 versus cAMP concentration using linear(y) 
and log(x) axes and perform a 4-parameter logistic fit. Plot the data as logit 
(B/B0) versus log concentrations and perform a linear regression fit. 
 Determine the sample concentration 
 Determine the concentration of each sample using the equation obtained 
from the standard curve plot. 
 
